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Chapter 1
Cardiovascular disease
Cardiovascular disease (CVD) is a class of diseases that involve the heart, blood vessels 
or both. Despite great advances in diagnosis and therapy over the past decades, CVD 
remains the leading cause of death in the developed countries 1, 2. Globalization of Western 
life-style is associated with a sharp increase of cardiovascular related deaths in various 
emerging economies. Coronary and congenital heart disease, deep venous thrombosis, 
aortic aneurism, stroke and atherosclerosis are the most common types of CVD. Classical 
risk factors like high blood pressure, unhealthy diet, physical inactivity, tobacco use and 
harmful use of alcohol contribute to the development of CVD 3.
Atherosclerosis is a progressive chronic inflammatory disease in which atherosclerotic lesions 
cause obstructions of large or medium sized arteries and is considered to be major cause 
of CVD (Figure 1B) 4. Atherogenesis in humans commences around 20 years of age. 
Endothelial cell dysfunction causes leakage of cholesterol and low density lipoproteins 
(LDL) into the subendothelial layer (tunica intima) of the blood vessel 5. This leakage 
occurs predominantly at sites with disrupted blood flow as a result of bifurcations or 
curvatures in the arteries 6. Inflammation, cell death, vascular remodeling, thrombus 
formation and calcification contribute to progression of atherogenesis 2, 7. Over time, 
advanced atherosclerotic lesions develop which most often remain asymptomatic 8. 
However, progression over many years may develop vulnerable lesions prone to rupture, 
that consist of a large necrotic core and a thin fibrous cap 9. Depending on the location of 
the lesion, rupture and subsequent coagulation may lead to complete or partial vascular 
occlusion, causing an ischemic event. 
Ischemia is basically a shortage of oxygen and glucose needed for cellular metabolism 
most often caused by (partial) occlusion of an artery. On the contrary, reperfusion is the 
restoration of blood flow to ischemic tissue 10. Depending on the location of the occlusion, 
an ischemic event may lead to ischemic heart disease (Figure 1A), ischemic colitis (colon) 
or ischemic stroke (brain) 11.  Restoring blood flow after ischemia is essential for tissue 
functionality, but initiates a second phase of injury called reperfusion injury. Reperfusion 
injury shares many characteristics with normal inflammation, in which neutrophils are 
the most prevalent leukocyte within the first 24 hours 12, 13. Activated neutrophils release 
reactive oxygen species (ROS), proinflammatory cytokines and chemokines, activate 
the endothelium and results in the recruitment and activation of additional neutrophils. 
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Moreover, activation of neutrophils can lead to NETosis, in which neutrophils excrete 
neutrophil extracullar traps (NETs) consisting of DNA and histones 14. 
Figure 1 – Human heart with obstructed left anterior descending coronary artery (LAD) (A). LAD 
obstruction by blood cloth originating from remote artery (B). Image obtained from the National 
Institute of Health (NIH, Public Domain).
Annexins
Annexins are calcium dependent phospholipid binding proteins that belong to an 
evolutionary well conserved multigene family, with members of the family expressed 
throughout animal and plant kingdoms 15. Vertebrates express 13 different annexins 
termed annexin A1 to A13. Roughly 30 years ago proteins like synexin 16, lipocortin 17 and 
calpectin 18 were discovered. After intensive protein analysis, cDNA sequencing and gene 
cloning they turned out to share similar gene structure, sequence features and biochemical 
properties. In order to solve any confusion in terminology, the common name annexin was 
introduced 15. This name is derived from the Greek annex meaning “bring/hold together” 
and was first used by Geisow in 1987, the term describes the principal property of most 
annexins 19. Structurally, annexins are characterized by a C-terminal convex “tail” and an 
N-terminal concave “head” (Figure 2) 20. The C-terminus is tightly conserved throughout 
evolution and comprises four annexin repeats (eight in case of annexin A6) of 70 amino 
acids. These repeats contain a highly conserved α-helical protein core domain and harbors 
the calcium-regulated membrane binding pockets 21. The N-terminal domain consists of 
40 or fewer residues and is responsible for its specific function 15.
A B
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Figure 2 – Representation of ribbon structure of annexin A1 in the presence and absence of Ca2+. The 
N-terminus (yellow) integrates into repeat 3 in the absence of Ca2+ and is exposed on the surface 
in the presence of Ca2+.
Annexin A1 (anxA1) was discovered and characterized by its ability to suppress phospolipase 
A2 induced eicosanoid generation and was initially termed lipocortin 22.  Since its discovery, 
anxA1 has shown to be capable of modulating a number of biological processes. However, 
anxA1 is most well-known for its anti-inflammatory property 23. It took some time 
before the cellular modus operandi of anxA1 was elucidated. The discovery that derivatives 
of buthyloxycarbonyl (Boc) blocked the anti-migratory effects of anxA1 on human 
neutrophils and in addition affected the calcium flux and L-selectin shedding was a major 
breakthrough. It demonstrated that the receptor for formylated peptides (FPR) was the 
target of anxA1 24. Both full-length anxA1 and the N-terminal derived peptide (Ac2-26) 
are able to interact with FPR-2, which is present on all leukocytes 21, 25-28. This interaction 
inhibits neutrophil recruitment and increases phagocytosis by bridging apoptotic cells 
and phagocytes 23, 29, 30. Generation of the anxA1 knock-out mouse has led to a greater 
understanding of the roles played by endogenous anxA1 31. In general, inflammation is 
exacerbated and prolonged if anxA1 is absent 32. In humans, dysregulation of anxA1 is 
associated with progressive Crohns disease 33, asthma 34 and invasiveness of tumors 35. 
Pharmacological treatment of inflammation using anxA1 and its N-terminal peptide has 
been studied in animal models of neutrophil-dependent edema 36, ischemia-reperfusion 
injury 37, 38 and acute peritonitis 39, however, until now not in atherosclerosis. Treatment 
of ischemia-reperfusion injury with anxA1 showed a reduction of damage and neutrophil 
influx 37, however did not show whether this reduction enhanced cardiac function. 
Annexin A5 (anxA5) was initially discovered as a vascular anticoagulant and termed 
accordingly 40. The anticoagulant property of anxA5 originates from its ability to inhibit 
prothrombinase activity 41. After discovering similarity in structure and the presence 
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of  four annexin repeats it was termed annexin A5 42. Since attaching a fluorescent- or 
radiolabel does not influence its ability to bind phosphatidylserine (PS), anxA5 is widely 
employed as molecular imaging agent to visualize apoptotic cells 43, 44. This PS-binding 
enables treatment with anxA5 and results in suppression of inflammation 45 and inhibition 
of atherosclerotic plaque development in mice 46. Exogenous anxA5 reduced inflammation 
by acting on activated endothelium 45 and target pro-inflammatory mediators 47, 48. Recent 
associations of anxA5 in processes like autophagy 49, microcalcification 50 and phagocytosis 
51 suggests a role for endogenous anxA5 in atherosclerosis and ischemia-reperfusion injury. 
In order to gain more insight into this role, the anxA5 knock-out mouse was generated. 
Deficiency of anxA5 is related to increased placental coagulation and subsequent fetus loss 
52, however, the anxA5 deficient mice do not appear to have a clear aberrant phenotype. 
Even though these deficient mice show altered bone development 53, anxA5 appears 
not to be essential 54, 55. The only known human disease associated with anxA5 is in 
the antiphospholipid syndrome (APS), in which antibodies directed against anxA5 are 
thought to cause hypercoagulability 56.
Future perspectives
Cardiovascular disease will remain amongst the primary causes of death in the developed 
countries for years to come. There is an increasing need for new imaging and treatment 
modalities. Atherosclerosis and ischemia-reperfusion injury have certain similarities that 
bare novel targets for diagnosis and treatment. Both ROS formation and release of NETs 
are detrimental to disease outcome but open novel treatment oppertunities. Cells that 
experience stress lose their phospholipid asymmetry and expose PS on the exoplasmic 
leaflet of their plasma membrane 57.  Targeting PS with annexin A5 has proven to be a 
strategy for non-invasive detection of plaque instability 43, 58.  Annexins may serve as novel 
theranostic, where the ability to target apoptotic or inflammatory cells with a labeled protein 
should be the strategy. This approach is not restricted to cardiovascular disease alone, but 
has the potential to be expanded to other diseases that involve inflammation or stressed 
cells inter alia cancer, rheumatoid arthritis (RA) or inflammatory bowel disease (IBD). 
14
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Outline of the thesis
This thesis aims to investigate roles of annexin A1 and annexin A5 in cardiovascular disease, 
more specifically in atherosclerosis and after ischemia-reperfusion injury. The general 
introductory chapter 1 gives a brief synopsis of cardiovascular diseases and elaborates 
on atherosclerosis and ischemia-reperfusion injury. Furthermore, this chapter introduces 
annexins in general and focuses on annexin A1 and annexin A5 in some more detail. 
Chapter 2 reviews the molecular imaging possibilities of vulnerable atherosclerotic lesions. 
Clinical and preclinical strategies are discussed separately. Targets aimed at inflammation, 
cell death, vascular remodeling, thrombus formation and calcification are considered. 
In addition, there is a short editorial about the socio-economic impact of molecular 
imaging. Chapter 3 confers about the role of endogenous annexin A5 in atherosclerosis. 
Therefore a new knock-out mouse was generated, the annexin A5 knock-out mouse was 
back-crossed with the apoE knock-out mouse that is prone to develop atherosclerosis. 
The role of annexin A5 in efferocytosis and migration of cells, and the expression of the 
protein in atherosclerotic lesions is discussed. Chapter 4 focuses on the effect of exogenous 
annexin A1 on atherosclerosis. Production of full-length functional protein was confirmed 
by measuring both physical and biological properties. The route of administration was 
determined by assessing biodistribution and blood clearance of intravenous and intra 
peritoneal injected annexin A1. The therapeutic potential of annexin A1 was further 
expanded in chapter 5. In this chapter treatment of reperfusion injury after an ischemic 
event was evaluated. Additionaly, a derivative of heparin that lacks anticoagulant activity 
was used to target NETs. Histological analysis and functionality tests are combined to 
determine treatment efficacy. Structural analysis of annexin A1 is the main theme of 
chapter 6. Annexin A1 was uniformly labeled using stable isotopes of hydrogen, carbon 
and nitrogen, which enables structural analysis by nuclear magnetic resonance (NMR). 
The general discussion of chapter 7 describes the most important findings of this thesis 
and discusses these in perspective with current literature. The thesis culminates with a 
summary,  valorization, curriculum vitea, publication list and the acknowledgements as 
addendum.
15
C
ha
pt
er
 1
General introduction
References
1. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N 
Engl J Med. 2011;364:1746-1760.
2. Kusters DH, Tegtmeier J, Schurgers LJ, Reutelingsperger CP. Molecular imaging to identify the 
vulnerable plaque--from basic research to clinical practice. Mol Imaging Biol. 2012;14:523-533.
3. Mozaffarian D, Wilson PW, Kannel WB. Beyond established and novel risk factors: lifestyle risk 
factors for cardiovascular disease. Circulation. 2008;117:3031-3038.
4. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-126.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 
2005;352:1685-1695.
6. Nigro P, Abe J, Berk BC. Flow shear stress and atherosclerosis: a matter of site specificity. Antioxid 
Redox Signal. 2011;15:1405-1414.
7. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Oie E, Aukrust P. Atherosclerotic plaque 
stability--what determines the fate of a plaque? Prog Cardiovasc Dis. 2008;51:183-194.
8. Burke AP, Farb A, Kolodgie FD, Narula J, Virmani R. Atherosclerotic plaque morphology and coronary 
thrombi. J Nucl Cardiol. 2002;9:95-103.
9. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a 
comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb 
Vasc Biol. 2000;20:1262-1275.
10. Powers SK, Murlasits Z, Wu M, Kavazis AN. Ischemia-reperfusion-induced cardiac injury: a brief 
review. Med Sci Sports Exerc. 2007;39:1529-1536.
11. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 
2011;17:1410-1422.
12. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion 
injury. Cardiovasc Res. 1999;43:860-878.
13. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation--the two 
keystones of ischemia/reperfusion injury. Int J Cardiol. 2002;86:41-59.
14. Goldmann O, Medina E. The expanding world of extracellular traps: not only neutrophils but much 
more. Front Immunol. 2012;3:420.
15. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331-371.
16. Creutz CE, Pazoles CJ, Pollard HB. Identification and purification of an adrenal medullary protein 
(synexin) that causes calcium-dependent aggregation of isolated chromaffin granules. J Biol Chem. 
1978;253:2858-2866.
17. Flower RJ. Background and discovery of lipocortins. Agents Actions. 1986;17:255-262.
18. Glenney JR, Jr., Tack B, Powell MA. Calpactins: two distinct Ca++-regulated phospholipid- and 
actin-binding proteins isolated from lung and placenta. J Cell Biol. 1987;104:503-511.
19. Geisow MJ, Walker JH, Boustead C, Taylor W. Annexins--new family of Ca2+-regulated-phospholipid 
binding protein. Biosci Rep. 1987;7:289-298.
20. Rescher U, Gerke V. Annexins--unique membrane binding proteins with diverse functions. J Cell Sci. 
2004;117:2631-2639.
21. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev 
Mol Cell Biol. 2005;6:449-461.
22. Gavins FN, Hickey MJ. Annexin A1 and the regulation of innate and adaptive immunity. Front 
Immunol. 2012;3:354.
23. Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. 
Nat Rev Immunol. 2009;9:62-70.
16
Chapter 1
24. Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates 
neutrophil extravasation by interacting with the FPR. Mol Cell. 2000;5:831-840.
25. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of 
multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta. 1994;1197:63-93.
26. Perretti M. The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol Sci. 2003;24:574-579.
27. Rosengarth A, Luecke H. A calcium-driven conformational switch of the N-terminal and core domains 
of annexin A1. J Mol Biol. 2003;326:1317-1325.
28. Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ. Annexin A1 interaction with the FPR2/
ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem. 
2012;287:24690-24697.
29. Arur S, Uche UE, Rezaul K, Fong M, Scranton V, Cowan AE, Mohler W, Han DK. Annexin I is an 
endogenous ligand that mediates apoptotic cell engulfment. Dev Cell. 2003;4:587-598.
30. Blume KE, Soeroes S, Waibel M, Keppeler H, Wesselborg S, Herrmann M, Schulze-Osthoff K, 
Lauber K. Cell surface externalization of annexin A1 as a failsafe mechanism preventing inflammatory 
responses during secondary necrosis. J Immunol. 2009;183:8138-8147.
31. Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ, Gavins FN, Perretti M, 
Morris JF, Buckingham JC, Flower RJ. Aberrant inflammation and resistance to glucocorticoids in 
annexin 1-/- mouse. FASEB J. 2003;17:253-255.
32. Chatterjee BE, Yona S, Rosignoli G, Young RE, Nourshargh S, Flower RJ, Perretti M. Annexin 
1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. 
J Leukoc Biol. 2005;78:639-646.
33. Sena A, Grishina I, Thai A, Goulart L, Macal M, Fenton A, Li J, Prindiville T, Oliani SM, Dandekar 
S, Sankaran-Walters S. Dysregulation of anti-inflammatory annexin A1 expression in progressive 
Crohns Disease. PLoS One. 2013;8:e76969.
34. Eke Gungor H, Tahan F, Gokahmetoglu S, Saraymen B. Decreased levels of lipoxin A4 and annexin 
A1 in wheezy infants. Int Arch Allergy Immunol. 2014;163:193-197.
35. Cheng TY, Wu MS, Lin JT, Lin MT, Shun CT, Huang HY, Hua KT, Kuo ML. Annexin A1 is associated 
with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide 
receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway. Cancer. 
2012;118:5757-5767.
36. Perretti M, Ahluwalia A, Harris JG, Goulding NJ, Flower RJ. Lipocortin-1 fragments inhibit neutrophil 
accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-
CD11b monoclonal antibody. J Immunol. 1993;151:4306-4314.
37. D’Amico M, Di Filippo C, La M, Solito E, McLean PG, Flower RJ, Oliani SM, Perretti M. Lipocortin 
1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J. 
2000;14:1867-1869.
38. Dalli J, Consalvo AP, Ray V, Di Filippo C, D’Amico M, Mehta N, Perretti M. Proresolving and tissue-
protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide 
receptor 2/lipoxin A4 receptor. J Immunol. 2013;190:6478-6487.
39. Perretti M, Getting SJ, Solito E, Murphy PM, Gao JL. Involvement of the receptor for formylated peptides 
in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol. 2001;158:1969-1973.
40. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant 
from arteries of human umbilical cord. Eur J Biochem. 1985;151:625-629.
41. Andree HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM, Willems 
GM. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem. 
1992;267:17907-17912.
17
C
ha
pt
er
 1
General introduction
42. Huber R, Romisch J, Paques EP. The crystal and molecular structure of human annexin V, an 
anticoagulant protein that binds to calcium and membranes. EMBO J. 1990;9:3867-3874.
43. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, Heidendal GA, 
Reutelingsperger CP. Past, present, and future of annexin A5: from protein discovery to clinical 
applications. J Nucl Med. 2005;46:2035-2050.
44. De Saint-Hubert M, Bauwens M, Deckers N, Drummen M, Douma K, Granton P, Hendrikx G, 
Kusters D, Bucerius J, Reutelingsperger CP, Mottaghy FM. In Vivo Molecular Imaging of Apoptosisand 
Necrosis in Atherosclerotic PlaquesUsing MicroSPECT-CT and MicroPET-CT Imaging. Mol Imaging 
Biol. 2013.
45. Ewing MM, de Vries MR, Nordzell M, Pettersson K, de Boer HC, van Zonneveld AJ, Frostegard J, 
Jukema JW, Quax PH. Annexin A5 therapy attenuates vascular inflammation and remodeling and 
improves endothelial function in mice. Arterioscler Thromb Vasc Biol. 2011;31:95-101.
46. Ewing MM, Karper JC, Sampietro ML, de Vries MR, Pettersson K, Jukema JW, Quax PH. Annexin 
A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion 
in mice. Atherosclerosis. 2012;221:333-340.
47. Domeij H, Hua X, Su J, Backlund A, Yan Z, Frostegard AG, Haeggstrom JZ, Modeer T, Frostegard J. 
Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. Prostaglandins 
Other Lipid Mediat. 2013;106:72-78.
48. Wan M, Hua X, Su J, Thiagarajan D, Frostegard AG, Haeggstrom JZ, Frostegard J. Oxidized but not 
native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. Atherosclerosis. 
2014;235:592-598.
49. Ghislat G, Aguado C, Knecht E. Annexin A5 stimulates autophagy and inhibits endocytosis. J Cell 
Sci. 2012;125:92-107.
50. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, Libby P, Shanahan CM, Croce 
K, Aikawa E. Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification 
in atherosclerotic plaques. Circ Res. 2013;113:72-77.
51. Yoshida S, Minematsu N, Chubachi S, Nakamura H, Miyazaki M, Tsuduki K, Takahashi S, Miyasho 
T, Iwabuchi T, Takamiya R, Tateno H, Mouded M, Shapiro SD, Asano K, Betsuyaku T. Annexin 
V decreases PS-mediated macrophage efferocytosis and deteriorates elastase-induced pulmonary 
emphysema in mice. Am J Physiol Lung Cell Mol Physiol. 2012;303:L852-860.
52. Ueki H, Mizushina T, Laoharatchatathanin T, Terashima R, Nishimura Y, Rieanrakwong D, Yonezawa 
T, Kurusu S, Hasegawa Y, Brachvogel B, Poschl E, Kawaminami M. Loss of maternal annexin A5 
increases the likelihood of placental platelet thrombosis and foetal loss. Sci Rep. 2012;2:827.
53. Brachvogel B, Welzel H, Moch H, von der Mark K, Hofmann C, Poschl E. Sequential expression 
of annexin A5 in the vasculature and skeletal elements during mouse development. Mech Dev. 
2001;109:389-393.
54. Brachvogel B, Dikschas J, Moch H, Welzel H, von der Mark K, Hofmann C, Poschl E. Annexin A5 
is not essential for skeletal development. Mol Cell Biol. 2003;23:2907-2913.
55. Belluoccio D, Grskovic I, Niehoff A, Schlotzer-Schrehardt U, Rosenbaum S, Etich J, Frie C, Pausch 
F, Moss SE, Poschl E, Bateman JF, Brachvogel B. Deficiency of annexins A5 and A6 induces complex 
changes in the transcriptome of growth plate cartilage but does not inhibit the induction of mineralization. 
J Bone Miner Res. 2010;25:141-153.
56. Singh NK, Yadav DP, Gupta A, Singh U, Godara M. Role of anti-annexin A5 in pathogenesis of 
hypercoagulable state in patients with antiphospholipid syndrome. Int J Rheum Dis. 2013;16:325-330.
57. Schutters K, Reutelingsperger CPM. Phosphatidylserine targeting for diagnosis and treatment of 
human diseases. Apoptosis. 2010;15:1072-1082.
18
Chapter 1
58. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, Narula J. 
Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with 
carotid-artery atherosclerosis. N Engl J Med. 2004;350:1472-1473.
Chapter 2
Molecular imaging to identify the vulnerable 
plaque - From basic research to 
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DHM Kusters, J Tegtmeier, LJ Schurgers and CPM Reutelingsperger
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Abstract
Cardiovascular disease (CVD) is still the leading cause of death in the Western World. 
Adverse outcomes of CVD include stroke, myocardial infarction and heart failure. 
Atherosclerosis is considered to be the major cause of CVD and is estimated to cause 
half of all deaths in developed countries. Atherosclerotic lesions of the vessel wall may 
obstruct blood flow mechanically through stenosis, but rupture of atherosclerotic plaques 
causing formation of occlusive thrombi is far more prevalent. Unfortunately, conventional 
diagnostic tools fail to assess whether a plaque is vulnerable to rupture. Research over the 
past decades identified the biological processes that are implicated in the course towards 
plaque rupture, like cell death and inflammation. Knowledge about plaque biology 
propelled the development of imaging techniques that target biologic processes in order to 
predict the vulnerable plaque. This review discusses novel and existing molecular imaging 
targets and addresses advantages and disadvantages of these targets and respective imaging 
techniques in respect of clinical application and socio-economic impact.
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Molecular imaging of atherosclerosis
Introduction
Despite great advances in diagnosis and therapy over the past decades, cardiovascular 
disease (CVD) remains the leading cause of death in developed countries 1. Globalization 
of Western life-style is associated with a sharp increase in cardiovascular-related deaths 
in various emerging economies. Atherosclerosis is considered to be major cause of CVD 
2. Atherosclerosis is a systemic inflammatory disease of arteries with focal manifestations 
of heterogeneous nature that develop over long periods of time 3, 4. The complete process 
of atherogenesis is described to great extent by Ross 2, and will therefore not be subject 
of this review. Briefly, atherosclerosis is characterized by lesions of the intimal vessel wall 
that develop progressively. The immune and haemostatic system are key players in the 
progression towards an advanced lesion 5. The major complication of atherosclerosis is 
formation of an occlusive thrombus after rupture of a plaque 3, 6.
In order to identify high risk patients prone to develop cardiovascular events, risk profiling 
such as the Framingham risk score is applied 7. This score is based on information gathered 
by epidemiological studies and estimates the risk to develop acute myocardial infarction 
over a period of 10 years. Although this helps to visualize the risk of individual patients 
it only offers a rough estimation of a possible event over a long time frame. Moreover, 
even for high-risk patients, it is currently impossible to discriminate between stable 
and unstable plaques, and thus to identify patients in need for immediate intervention. 
Different characteristics of atherosclerotic plaques can be taken into account to assess the 
severity of the disease. Contrary to common beliefs, plaque size itself does not determine 
plaque vulnerability. In fact, it has been shown that most atherosclerotic plaques that 
undergo abrupt rupture showed only negligible levels of vessel stenosis and these patients 
are most often asymptomatic 8, 9. 
Several diagnostic approaches have been employed to identify the patient at high risk 
for acute arterial events in the presymptomatic phase. One such approach comprises 
the quantitative measurement of circulating biomarkers. Despite great advances in 
understanding atherogenic processes on the molecular level, circulating biomarkers 
are still of limited value 10. Other approaches comprise imaging techniques to visualize 
anatomy of atherosclerotic plaques including computed tomography (CT), intravascular 
ultrasound (IVUS), optical coherence tomography (OCT) and magnetic resonance 
imaging (MRI). As stipulated above these techniques fail to identify the vulnerable 
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plaque because no unambiguous association exists between plaque morphology and 
stability. Therefore, recently focus has shifted towards molecular imaging in an attempt 
to identify the unstable plaque 11, 12. Several biological characteristics in humans have 
been associated with an unstable plaque phenotype e.g. pro-inflammatory status 13-15, 
large (oxidized) lipid content 16, thin fibrous cap 17, 18, presence of platelets/intra-plaque 
thrombi or hemorrhage 19, low number of (viable) vascular smooth muscle cells, high 
content of activated matrix metalloproteases (MMPs) 20-25, neovascularization 26, (micro)
calcification 27, 28, high shear  29, large necrotic core 16, high levels of apoptosis 30 and 
impaired efferocytosis 31-35. All these biological characteristics can be exploited for non-
invasive molecular imaging of atherosclerosis in order to visualize the vulnerable plaque. 
This review focuses on existing and novel targets to image atherosclerosis non-invasively, 
and addresses which targets could possibly be translated from preclinic to clinic in order 
to filter out patients at risk for acute atherothrombotic events (Figure 1). 
Molecular imaging of inflammation
Preclinical
The reader is referred to a recent review for details of inflammation and macrophages in 
atherosclerosis 36. Cells participating in the inflammatory process use glucose as main 
energy source. An analogue of glucose, 2-deoxy-2-37fluoro-D-glucose (18FDG), can be used 
to visualize these cells using Positron Emission Tomography (PET) 38. Although not the 
primary aim, it was first noted in cancer studies that also arterial walls showed uptake of 
18FDG and that this uptake was higher in older patients and patients with cardiovascular 
risk factors 39. It was confirmed by several other studies that 18FDG is taken up by the 
vessel wall, and that this uptake correlates with atherosclerosis 40-42. Uptake of 18FDG 
was higher in more advanced and unstable plaques and correlated with macrophages 
content inside the plaque 43, 44. 
Macrophages can also be targeted with antibodies against e.g. LOX-1, PBR (peripheral 
benzodiazepine receptor) or lactadherin (mfg-E8) 15. LOX-1 has been suggested as 
an interesting target since it is upregulated in response to high levels of oxLDL, pro-
inflammatory cytokines, or mechanical stress 45, 46. For imaging purposes, a LOX-1 
antibody was conjugated with 99mTechnetium (99mTc), which can be visualized by Single 
Photon Emission Computed Tomography (SPECT). The efficacy of this antibody was 
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first demonstrated in a rabbit model of atherosclerosis and evaluated by histological 
analysis 47. Li et al. confirmed that this antibody reliably targets macrophages in vivo in 
ApoE-/- mice and LDLR-/-(LOX1-/-) mice 48.  The PBR (also known as translocator protein, 
TSPO) is minimally expressed in non-inflamed tissue and highly expressed on activated 
macrophages, and is therefore exploited as molecular imaging target 49.   
The most frequently used contrast agents for molecular imaging of macrophages in 
atherosclerotic plaques are (lipid-coated ultra) small superparamagnetic iron-oxide particles 
(LUSPIO/SPIO) or antibody coated micelles 50-53. SPIOs are spontaneously engulfed by 
macrophages of animals and humans. Focal accumulation of SPIOs causes a signal decrease 
that can be detected by MRI. It has been shown that this decrease correlates with the level 
of intra-plaque inflammation 54. These nanoparticles can also be conjugated to specific 
ligands targeting macrophages with high sensitivity and selectivity 50. Monocrystalline 
iron oxide nanoparticles (MION) or cross-linked iron oxide nanoparticles (CLIO) have 
been coupled to a variety of unstable plaque-specific ligands targeting, adhesion molecules, 
lipoproteins, proteases and macrophages and offers the possibility to add fluorescent dyes 
for imaging in vivo and in vitro 11, 55-58. 
Another target for imaging of inflammation is P-selectin, which is expressed on activated 
endothelial cells and platelets. This molecule mediates tethering and rolling of leukocytes 
prior to migration into the plaque and is associated with increased plaque instability 59. 
A recently described nuclear tracer (99mTc-fucoidan) can be used to successfully image 
P-selectin overexpression in arterial thrombosis and endothelial cell activation after 
ischemia 60. Using different imaging probes, the feasibility of P-selectin imaging in 
atherosclerotic settings has already been shown 61, 62. Another adhesion molecule, vascular 
cell adhesion molecule 1 (VCAM-1), is also exploited as potential imaging target. In a 
recent publication it is shown that a VCAM-1 targeted USPIO derivative (R832) shows 
specific plaque uptake in ApoE-/- mice, visualized by MRI within 30 minutes 63. Specific 
uptake was confirmed by ex vivo histology. However, after 30 minutes also non-specific 
uptake was observed, which was probably caused by the enhanced permeability and 
retention (EPR) effect in the plaque. The authors show a possibility to identify features 
of unstable plaque phenotypes in these mice, which could potentially be translated to 
the clinic 63. Besides adhesion molecules, activated endothelial cells also highly express 
the integrin αv β3. Targeting this integrin has been done by a low molecular weight 
peptidomimetic of arginine-glycin-asparctic acid peptide (mimRGD) conjugated to 
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gadolinium-diethylenetriaminepentaacetate (Gd-DTPA) 64. Specific integrin binding and 
imaging of aortic plaques was confirmed by competition experiments and subsequent 
histological analysis. Increased uptake of the contrast agent is directly correlated with an 
enlarged neovascular network and thus plaque instability. 
Clinical
Imaging of vascular inflammation by 18FDG uptake with PET has been performed 
in several clinical trials which have recently been reviewed by Rudd et al. 65. Menezes 
et al. performed a prospective study to determine the optimal time to image vascular 
inflammation using 18FDG PET/CT amongst 17 asymptomatic patients undergoing 
routine surveillance for atherosclerotic abdominal aortic aneurysms 66. There was no 
significant difference in Signal to Noise Ratio (SNR), despite a significant difference 
between aortic wall and lumen uptake in time 66. More recently 18FDG PET and CT 
angiography were performed in 21 patients undergoing endarterectomy in order to 
investigate plaque vulnerability. A positive correlation between plaque 18FDG uptake 
and CD68/VEGF positivity was found. Furthermore an inverse relationship between 
18FDG plaque uptake and plaque percentage calcium composition on CT was observed 
67. Meyers et al. conducted a multicenter clinical trial to evaluate arterial 18FDG uptake 
in peripheral artery disease. The researchers included 21 patients and measured 18FDG 
uptake in carotid, aortic and femoral artery before atherectomy, and compared this uptake 
to immunohistochemical CD68 positivity. However, no significant correlation between 
lesion SNR and CD68 level was found 68.
A recent clinical trial (dal-PLAQUE) that evaluates the efficacy and safety of dalcetrapib, 
assigned 64 patients to dalcetrapib or placebo for 24 months. Total vessel area was 
determined by MRI and found to be reduced in patients given dalcetrapib. However, 
PET/CT showed no evidence of increased or decreased vascular inflammation 69, 70. 
Most of these clinical trials provide in vivo evidence that increased plaque metabolism is 
associated with increased biomarkers of inflammation. However the greater part fails to 
show a correlation between 18FDG uptake and plaque vulnerability, particularly in the 
coronary arteries. Imaging of coronary arteries is complicated because of the movement 
of the heart and the small size. Moreover, the myocardium has a high background uptake 
of 18FDG which compromises the SNR. Dietary measures can suppress the background 
uptake of 18FDG by the myocardium to some extent 71.
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Figure 1 – Molecular imaging targets for the detection of  the vulnerable atherosclerotic plaque. The process of  
atherogenesis is shown with preclinical (A) and clinical (B) molecular imaging targets. Some targets 
have proven their potential in animal models but have not been validated in clinical trials. VCAM, 
vascular cell adhesion molecule 1; MMP, matrix metalloprotease; PBR, peripheral benzodiazepine 
receptor; Mφ, macrophage; SPIO, super paramagnetic iron oxide particle; PS, phosphatidylserine; 
ED-B, fibronectin extra-domain B.
A
B
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PET imaging of the peripheral benzodiazepine receptor (PBR) has also been performed. 
Although animal studies have yielded several promising tracers for PBR imaging (e.g. 11C-
PK11195, 11C-DAA1106, 11C-PBR28, 11C-DPA713, 11C-CLINME and 18F-FEDAA1106), 
hitherto only 11C-PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinoline-carboxamide) has been investigated in clinical studies 72. Recently 11CPK11195 
has been used in two small-scale clinical trials. Pugliese et al. imaged 6 patients with 
systemic inflammatory disorders and clinical suspicion of active vasculitis compared to 
9 controls. Focal 11C-PK11195 uptake in the arterial wall of all symptomatic patients 
was noticed compared to no detectable uptake in the control group 73. Gaemperli et 
al. imaged 32 patients with carotid stenosis (9 symptomatic / 23 asymptomatic) and 
compared 11C-PK11195 uptake into carotid plaques 74. Both research groups concluded 
that 11C-PK11195 PET allows non-invasive detection and quantification of intra-plaque 
inflammation in patients. Moreover, the combination of 11C-PK11195 PET with contrast-
enhanced CT provides an integrated assessment of plaque structure, composition and 
biological activity, and allows the distinction between recently symptomatic vulnerable 
plaques and asymptomatic plaques with a high positive predictive value. Whether 11C-
PK11195 is a Molecular Imaging agent to identify vulnerable plaque, also in coronary 
arteries, needs to be assessed by more clinical trials.
Molecular imaging of cell death 
Preclinical
Apoptosis of macrophages and smooth muscle cells is associated with plaque instability, 
since this leads to a growing necrotic core, inflammation, the release of proteases and 
subsequently thinning of the fibrous cap 17, 31. Apoptosis can be imaged using either 
intracellular or membrane bound targets. 
During apoptosis caspases are activated that degrade intracellular proteins and DNA 
in an orderly manner. Caspases are expressed as inactive zymogens in healthy cells, but 
cleave to their active form in response to apoptotic signals. This property makes targeting 
of activated caspases attractive. An inhibitor of caspase-3 and -7, radiolabeled isatin-5-
sulfonamide (18F-ICTM-11) and several of its analogues, have been evaluated as imaging 
agent of apoptosis in vitro 75, in vivo 76, in a rat model of liver cell apoptosis 77 and in 
tumor bearing mice 78. All studies provide great evidence of the potential to use activated 
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caspase specific imaging agents to find culprit lesions. However, thus far this has not been 
tested in animal models of atherosclerosis. 
Another hallmark of apoptosis is, externalization of phosphatidylserine (PS), which is 
normally predominantly confined to the inner leaflet of the plasma membrane 79. The 
protein annexin A5 (anxA5) has been shown to bind PS with nanomolar affinity. This 
discovery has led to the use of PS as target for molecular imaging of apoptosis in vitro and 
in vivo in myocardial infarction 80, cancer 81, 82 and atherosclerosis 43. For this purpose, anxA5 
was conjugated to radiotracers for nuclear imaging and fluorescent probes for histological 
analysis 83-85. Pioneering studies of molecular imaging of apoptosis were performed with 
technetium-labeled anxA5 (99mTc-anxA5) and SPECT. One of the first approaches was 
to target apoptotic macrophages in animal models of atherosclerosis 43, 51, 86, 87. To verify 
the results of molecular imaging, histological analysis of the atherosclerotic plaques was 
performed. Atherosclerotic lesions showed increased uptake of 99mTc-AnxA5 compared 
to control animals. Furthermore a gradient of 99mTc-anxA5 uptake was observed which 
correlated to the grade of the atherosclerotic lesion. This level of 99mTc-anxA5 uptake 
could directly be linked to the level of macrophage infiltration 87. Those in vivo results 
confirmed that 99mTc-anxA5 can target apoptosis in living animals and that uptake 
correlates with the severity of atherosclerosis 43, 87. An alternative to anxA5 to target 
PS is lactadherin (mfg-E8). Falborg et al. compared the biodistribution of lactadherin 
and anxA5, both conjugated to 99mTc-labeled hydrazinonicotinamide (99mTc-HYNIC). 
Regarding biodistribution and blood clearance lactadherin is comparable to anxA5. 
However, anxA5 showed higher uptake in the kidneys, whereas lactadherin showed higher 
uptake in the liver 88. Another alternative for detection of cell death is the C2A domain 
of synaptotagmin-I which also binds PS 89. The C2A domain has been labeled with 
paramagnetic and radionuclide labels and used to detect apoptosis in vivo successfully. 
However, a proper quantification of conjugated label could not be performed, and affinity 
for PS decreased after labeling 90. A recent study compared a mutated form of C2A and 
anxA5 in their ability to quantitatively image cell death 91. The mutant described was 
fluorescently labeled and showed lower binding to viable cells than a similarly labeled 
anxA5, thus increasing its specificity. This could partly be explained by a slightly lower 
affinity for PS, which might be important when radionuclide derivatives of this protein 
will be used to detect cell death in vivo 91. Confirmation of its ability to detect apoptosis 
in atherosclerotic plaques still has to be performed.
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Clinical
The first small scale clinical trial to image apoptosis with labelled anxA5 was done in 
4 patients with either recent or remote history of a transient ischemic attack (TIA) 92. 
These patients were scheduled for carotid endarterectomy (CEA), and imaging was done 
before removal of the carotid lesions. The patients with a recent TIA showed lucid uptake 
of 99mTc-AnxA5, whereas those with a remote TIA did not show any significant uptake. 
After CEA, plaque analysis from patients with recent TIA showed that unstable plaques 
stained anxA5 positive. In contrast, lesions of patients with remote TIA which had a stable 
phenotype, showed almost no anxA5 uptake. The researchers conclude that 99mTc-anxA5 
imaging could help to identify unstable plaques in patients with carotid atherosclerosis 
92. Unfortunately, this clinical study involved only a very small number of patients, thus 
more and larger clinical cohort studies are needed to confirm these promising results. 
Although very promising, all other imaging tracers mentioned above for the imaging of 
cell death, have not been tested in a clinical trial thus far. 
Molecular imaging of remodeling 
Preclinical
As response to partial occlusion of a vessel, constrictive or expansive vascular remodeling 
can occur 93. Vascular remodeling is associated with increasing plaque vulnerability and 
consists of several distinct processes. Two major processes are angiogenesis and hypertrophic 
compensation of the vessel 94.
Key players and potential imaging target of vascular remodeling are vascular smooth 
muscle cells (VSMCs). In general, VSMCs can exhibit two phenotypes, contractile 
or synthetic 95. Synthetic VSMCs are predominantly present in the intima, are more 
prone to calcify and become apoptotic, and therefore seen as detrimental 96. Several 
groups targeted vascular remodeling in atherosclerosis with a labeled antibody (Z2D3) 
specific against synthetic VSMCs. They verified binding ex vivo in human atherosclerotic 
endarterectomy specimens 97, in vivo by SPECT in a rabbit model 98, 99, a rat model 100 and 
by scintillation gamma counting in a swine model 101, 102. All studies show the possibility 
to selectively image synthetic VSMCs to great extent in animals, but this still has to be 
established in clinical trials.
29
C
ha
pt
er
 2
Molecular imaging of atherosclerosis
Hypertrophic compensation is associated with the activation of several proteases (e.g. 
matrix metallo proteases (MMPs) or cathepsin G). Besides their role in vascular remodeling 
and inflammation, these proteases have significant detrimental effects on cap thickness 
and therefore plaque stability 20-22, 24. Activated MMPs form an interesting target to 
identify unstable lesions, and have extensively been investigated using an antibody against 
activated MMPs (P947). This antibody was recently tested and validated in several in 
vivo studies 23, 25, 55, 103. Lancelot et al. show excellent delinearization of the plaque with 
strong signal intensity enhancement using non-invasive MRI. However, a limitation of 
imaging with P947 is that it does not discriminate between different activated MMPs 
and Johnson et al. found that MMP-3 and 9 could even exert a beneficial effect on 
plaque phenotype 22. Another strategy for imaging of activated MMP’s is using MMP2/9 
specific substrate. Deguchi et al. show that labeling of a small substrate peptide with a 
near infra-red probe enables specific non-invasive optical molecular imaging of activated 
MMP2/9 in atherosclerotic plaques 104. As an alternative for MMP imaging, Narula et 
al. used a 99mTc-labeled broad-spectrum MMP inhibitor and demonstrated feasibility of 
noninvasive detection of activated MMPs in atherosclerotic lesions 105.
Another process in vascular remodeling is angiogenesis. Plaque and vasa vasorum 
neovascularization are associated with decreased plaque stability and offers several potential 
imaging targets that have been investigated; integrin αvβ3 
26, 106, 107,  fibronectin extra-
domain B (ED-B) 108 and vascular endothelial growth factor receptor (VEGFr). Winter 
et al. showed that in vivo imaging of neovascularization of atherosclerotic plaques using 
MRI targeting αvβ3 is feasible and might provide a method for defining the burden 
and evolution of atherosclerosis 26. Matter et al. showed that targeting of fibronectin 
with a labeled human recombinant antibody (125I-SIP108), could selectively visualize 
atherosclerotic plaques in ApoE-/--mice with a high SNR and very high specificity 108. 
Thus far no molecular imaging studies targeting VEGFr in atherosclerosis have been 
performed, nevertheless molecular imaging of VEGFr in cancer has been investigated 
and validated extensively 109, 110. 
Taken together these preclinical studies indicate high potential for non-invasive molecular 
imaging of vascular remodeling, even though none of above mentioned probes has made 
it to clinical studies yet (table 1).
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Process Target Agent Imaging 
Modality
Phase (ref )
Inflammation Macrophages 18FDG PET or PET/CT Clinical 40-44, 66-70
11C-PK11195 PET Clinical 72-74
99mTc-anti-
LOX-1
SPECT Preclinical 47, 48
Nanoparticles MRI Preclinical 52, 54
P-Selectin 99mTc-fucoiden SPECT/MRI Preclinical 60-62
Apoptosis VSMC, 
Macrophages
99mTc-anxA5 SPECT Clinical 43, 84-86, 92
Vascular 
remoddeling
VSMC Z2D3 SPECT Preclinical 97-102
MMP P947 MRI Preclinical 23, 25, 
55, 103
Integrin αvα3 Nanoparticles MRI Preclinical 
26
ED-B L19 SPECT Preclinical 108
Table 1: Molecular imaging targets for the vulnerable plaque
Molecular imaging of thrombosis
Preclinical
The haemostatic system is an important modulator of atherosclerosis and plays a key role 
in plaque rupture and subsequent thrombus formation 111. Therefore, partakers of the 
coagulation cascade might be an interesting target for molecular imaging to identify the 
vulnerable plaque 112. Inflamed endothelium and cells participating in the development 
of the necrotic core show high levels of fibrin and thrombin expression. Abundance 
of fibrin on the surface or within atherosclerotic plaques has thus been associated with 
vulnerable plaques 113, 114. The fibrin-targeted-contrast-agent (FTCA) uses gadolinium 
contrast and can be visualized by MRI. Besides its various applications in animal studies, 
FTCA has also been used in a clinical trial to detect thrombi in the heart and blood 
vessels 115-118. A recent study showed that FTCA can be successfully applied to image 
endothelial and intraplaque fibrin in a mouse model of atherosclerosis 119. Despite the 
ubiquitous distribution of fibrin, FTCA in atherosclerotic plaques could be visualized 
with a good SNR. FTCA uptake and signal enhancement was strongest in culprit lesions, 
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as confirmed by immunohistochemistry. This is in concordance with recent findings 
from autopsy studies that indicate that advanced lesions express high levels of fibrin 113. 
Additionally, it was found that fibrin is a key component of plaque erosion 114, 120 and can 
be applied to image eroding plaques which can cause thrombosis without plaque rupture 
119. Although less common in general, plaque erosion is estimated to cause up to 25% 
of coronary thrombosis leading to MI and is especially important in women 121. Even 
though molecular imaging of thrombosis has not yet been applied in clinical studies of 
atherosclerosis, it still represents a promising target. Given that fibrin is associated with 
two important characteristics of vulnerable plaques and FTCA has been successfully used 
to detect thrombi in the heart and blood vessels of patients. Therefore, the future clinical 
use of thrombosis imaging to identify vulnerable plaques is highly probable. 
Molecular imaging of (micro)calcification
Preclinical
Calcification has long been associated with the process of atherosclerosis and acute 
cardiovascular events 120. Although large calcifications inside the plaque have been shown 
to promote plaque stability 122, spotty calcifications – especially inside the fibrous cap – are 
suggested to cause plaque rupture and thrombotic events 28, 123. It is postulated that those 
micro-calcifications, which are undetectable by conventional imaging, increase the local 
stress inside the thin fibrous cap by 2-fold and thus increase the likelihood of rupture 
28. It is assumed that calcification is a product of osteogenic action by osteocytic- and 
chondrocytic-like cells inside the plaque. The work of Aikawa and colleagues provided 
substantial insights in the course of micro-calcification and possibilities to visualize 
this process 124. In a mouse model of atherosclerosis they showed that macrophage 
infiltration in early atherosclerotic plaques precedes calcification. Later, those events 
occur in temporal and spatial overlap. Conventional histological and CT imaging failed 
to visualize early micro-calcifications. Using intravital fluorescence microscopy with a 
nanoparticle-based contrast agent to visualize macrophages and a bisphosphonate-bases 
agent to detect calcifications, the authors were able to properly detect inflammation 
and micro-calcifications in early atherosclerotic plaques. Due to the time at which these 
micro-calcifications take place and their implications in destabilizing the plaque, molecular 
imaging would be able to detect rupture-prone plaques at a very early stage. Asymptomatic 
high-risk patients would benefit from this application. Additionally, molecular imaging 
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of micro-calcification provides an opportunity to monitor and evaluate the early success 
of therapeutic interventions. 
Clinical
The association of vascular 18FDG uptake and vascular calcification detected by 
contemporaneous CT was investigated. The researchers evaluated PET/CT images of 78 
patients that were referred for tumor staging. These images were analyzed for the presence 
of vascular 18FDG uptake and vascular calcification. They found that vascular calcification 
and vascular metabolic activity rarely (<2%) overlapped. This suggests that these findings 
represent different phases of atherosclerosis 125. These findings were confirmed by Rudd et 
al. who investigated the relationship between inflammation and arterial calcification. The 
researchers imaged inflammation in 41 patients with 18FDG PET/CT and scored calcium 
by CT analysis. Additionally, from 33 of these patients a collection of biomarkers was 
determined. The authors suggested that 18FDG PET imaging can be used as a surrogate 
marker of both atherosclerotic disease activity and drug effectiveness 41.
Calcification status can also be visualized by 18F-sodium fluoride with PET. In a retrospective 
study, arterial 18F-sodium fluoride uptake and calcification was evaluated. When spatial 
correlation between vascular 18F-sodium fluoride uptake and calcification sites were 
analyzed per-lesion, 12% of lesions with marked arterial wall 18F-sodium fluoride uptake 
did not show concordant calcification. This study shows the feasibility of using 18F-sodium 
fluoride for in vivo functional imaging of  atherosclerotic lesions 126. Hitherto, locating 
microcalcification in the vessel wall with 18F-sodium fluoride has not been demonstrated, 
in order to find these minute alterations OCT might be more feasible. 
Socio-economic impact of molecular imaging
As major cause of cardio- and cerebrovascular morbidity and mortality, atherosclerosis 
puts a significant strain on healthcare budgets. The following numbers serve as an 
example of the costs that originate from atherosclerosis and underline the need for new 
diagnostic tools and treatments. The total expenses for stroke in the Netherlands summed 
up to more than 1.6 billion euros in the year 2007, making stroke one of the ten most 
expensive conditions 127. The costs for stroke made up 2,2% of total healthcare costs in 
the Netherlands. A comparable situation is found in Germany (3.4% of total costs) 128. 
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Acute coronary syndromes (mostly unstable angina and acute MI) are also within the 
top ten of the most expensive diseases in the Netherlands. The total expenses in 2007 
summed up to 1.807 billion euros 127. In other European countries like the UK, France, 
Germany, Italy and Spain costs range from 1 to 3 billion euros yearly 129. These values 
represent between 1% and 3% of total healthcare costs in those countries. In the US, 
total annual costs for CVD and stroke are estimated at 297.7 billion dollar, accounting 
for 16% of total healthcare expenditures in 2008 130. 
These numbers demonstrate the enormous expenses for the healthcare system. Therefore 
any improvement in the diagnosis of atherosclerosis, and thus prevention of its adverse 
outcomes, would lower financial burden significantly. 
Support for this approach comes from the SHAPE Guideline by Naghavi and colleagues 131. 
In an extensive work the SHAPE task force proposed protocols to identify the vulnerable 
patient with a high risk of MI or stroke. The report underlines the shortcomings of 
current risk stratification as the Framingham Risk Score and the System Coronary Risk 
Evaluation (SCORE). These tools assign most people to a group with intermediate risk 
for adverse outcomes. The power to predict an acute event is especially low in this group; 
yet the incidence of MI is the highest. To improve risk profiling the authors propose two 
non-invasive tests namely carotid intima-media thickness (CIMT) and coronary artery 
calcification (CACS) to be applied to the population at risk. Based on initial screening 
with CIMT or CACS patients are categorized and treated if necessary. Large studies 
demonstrated predictive power and cost-effectiveness of this approach. All current non-
molecular imaging modalities are able to find vascular stenosis but fail to discriminate 
reliably between vulnerable and stable lesions in patients 132. Newer imaging techniques 
can increase the accuracy of this risk stratification. In this regard, molecular imaging of 
the vulnerable plaque offers great potential. Once established, molecular imaging can 
be added to the SHAPE Guideline to strengthen the power of diagnostics in preventive 
cardiology. Another beneficial aspect is that molecular imaging uses probes specific for 
targets on (unstable) atherosclerotic plaques, which could potentially be used as theranostic. 
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Conclusion and Future Perspectives 
Molecular imaging of atherosclerosis bears potential as a powerful diagnostic tool to 
screen and select patients prone to develop CVD morbidity and mortality and, hence, to 
contribute to a personalized and more cost-effective treatment of atherosclerotic disease. 
This review has highlighted molecular imaging targets that have been studied in vitro 
and in vivo in experimental animal models of atherosclerosis and that have potential 
to be translated to clinical practice. Most promising targets are found in the process of 
apoptosis, vascular remodelling and inflammation (Figure 1, Table 1). Additionally, we 
suggest that efferocytosis of apoptotic cells might be added as an interesting molecular 
imaging target, since impairment of efferocytosis is associated with an increase of necrotic 
core and consequently with an increased vulnerability 31, 32, 34, 133, 134. Ligands specific for 
non-invasive imaging of efferocytosis still need to be explored; potential targets might 
be C1q, MfgE-8, LRP-1 and Gas6. 
Translation of molecular imaging ligands from preclinical research to clinical practice 
faces important scientific as well as financial challenges to be overcome. Although animal 
models can reflect human vulnerable plaque phenotype, results of preclinical research 
cannot simply be extrapolated to the human situation, since spontaneous rupture of a 
plaque without manipulation so far has not been observed in animal models. In addition, 
molecular imaging remains relatively expensive and time-consuming, both of which limit 
large clinical studies to validate targets and ligands. 
Further scientific research into pathobiology of the vulnerable plaque, and technological 
development of imaging equipment that increases sensitivity and specificity are required 
if we wish to uphold the promise of molecular imaging to reduce health care costs. 
Successful translation of targets and ligands to clinical molecular imaging of the vulnerable 
plaque may also offer novel therapeutic avenues to treat the vulnerable plaque employing 
strategies such as targeted drug delivery.
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Abstract
Background and purpose - Efferocytosis, the process by which apoptotic cells are engulfed 
by phagocytes, plays a crucial role in atherosclerosis. Exogenous annexin A5 (anxA5) binds 
apoptotic cells and inhibits efferocytosis. Here we investigate the role of endogenous 
anxA5 in efferocytosis and development of atherosclerosis.
Experimental approach - ApoE-/-/anxA5-/- double knock-out  (DKO) and ApoE-/- mice 
were fed normal chow diet and sacrificed at 14, 20 and 26 weeks of age. Plaque size and 
phenotype were analyzed. In vivo efferocytosis by resident peritoneal macrophages was 
measured. Bone marrow derived macrophages were used to measure migration.
Key results - DKO mice were slightly lower in body weight and had increased levels of 
circulating triglycerides and total cholesterol. Levels of circulating Ly6Chigh monocytes were 
higher in DKO mice. DKO mice of 26 weeks had smaller plaques with less apoptotic cells. 
In contrast to ApoE-/- mice there was no large necrotic core development in DKO mice. 
DKO macrophages expressed higher efferocytotic activity. No difference in migration 
was observed between DKO and ApoE-/- macrophages.
Conclusion and implications - Endogenous anxA5 inhibits efferocytosis and promotes 
atherosclerosis. Targeted inhibition of anxA5 may be a therapeutic avenue to attenuate 
plaque progression
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Introduction
Atherosclerosis is the major cause of cardiovascular disease, of which adverse outcomes 
include stroke, myocardial infarction and heart failure 1-3. Atherosclerosis is a chronic 
inflammatory disease of the arterial vessel wall in which macrophages play a crucial role 
4, 5. Macrophages are the most important phagocyte in atherosclerotic lesions and can 
limit formation of a necrotic core through phagocytosis of apoptotic cells (this process is 
termed efferocytosis) which otherwise would become secondary necrotic 6, 7. Efferocytosis 
is preceded by tethering and tickling of macrophage receptors by so-called “eat me” 
signals on the surface of the apoptotic cell 8. The negatively charged aminophospholipid 
phosphatidylserine (PS) is an important “eat me” signal that is ubiquitously expressed 
by apoptotic cells regardless of cell type and cell death trigger 9, 10. 
Annexin A5 (anxA5) is a member of the multigene annexin family 11 that binds cell surface 
expressed PS with high affinity 12. Human recombinant anxA5 (hr-anxA5) is employed as 
Molecular Imaging agent to visualize the unstable atherosclerotic plaque (Chapter 2), the 
PS content of which increases with increasing vulnerability 13, 14. In addition, hr-anxA5 
acts pharmacodynamically by suppressing inflammation 15 and inhibiting atherosclerosis 
in the ApoE-/- mouse model 16. Hr-anxA5 reduces inflammation by acting on activated 
endothelium 15 and targeting pro-inflammatory mediators 17, 18. Interestingly, hr-anxA5 
inhibits efferocytosis in vitro by binding PS of the apoptotic cell 19, 20 and the macrophage 21.
In contrast to the wealth of published data on hr-anxA5 and its interaction with 
atherosclerosis, the (patho)physiological role of endogenous anxA5 in atherosclerosis is 
unknown. Therefore we have generated anxA5-/-/ApoE-/- double knock-out mice (DKO) 
and studied atherogenesis in DKO mice on chow diet compared to ApoE-/- mice. Mice 
were put on normal chow diet to induce minor atherogenic pressure. We demonstrate 
that anxA5 deficiency increases efferocytosis by macrophages and consequently reduce 
progression of atherosclerotic plaque development.
Methods
Animal welfare and ethical statement – All animal experiments have been conducted 
under a protocol approved by the ethics committee for animal experiments of Maastricht 
University (DEC 2010-152) and comply with ARRIVE (Animal Research: Reporting 
In Vivo Experiments) guidelines and followed the European Union Directive (2010/63/
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EU). All procedures used were performed as humane as possible. A total of 160 animals 
were used in the experiments described here. Mice were kept at a constant temperature 
(21°C) and a regular light (06:30–19:30h) and dark (19:30–06:30h) cycle, with normal 
chow diet and water provided ad libitum.
Mouse strain – The anxA5-/- C57/Bl6/J mice have been generated by Brachvogel et al. 
as described previously 22. These mice were back-crossed for at least 5 generations with 
ApoE-/-Bl6.129P2-ApoEtm1Unc/J mice before inclusion into the experiment. Complete 
knock-out of anxA5 was confirmed by genotyping and western blotting with a specific 
rabbit-α-anxA5 antibody. AnxA5 heterozygous ApoE knock-out mice were used for 
crossbreeding; AnxA5-WT/apoE-/- (ApoE-/-) and anxA5-/-/ApoE-/- (DKO) male littermates 
of indicated ages were used for experiments. ApoE-/- and DKO were co-housed during 
the entire experiment.
Genotyping – Genotyping of mice was performed by PCR detecting the wild type allele 
with primers Exon4-dw (5‘-GAAGCAATGCTCAGCGCCGGA-3’) and Intron4-up 
(5‘-CTGTACTCTATCACTATCACTGACTGTTTAATC-3’) and the mutated allele with 
primers Exon3-dw (5‘-CGAGAGGCACTGTGACTGACTTCCCTGGAT-3’) and LacZ-
up (5‘-GCCAGTTTGAGGGGACGACGACAG-3‘) as described previously 22. Genotyping 
for ApoE was performed using primers: ApoE-up (5‘-CATAGTGTCCTCCATCAGTGC-3’) 
and ApoE-low (5‘-GCCTAGCCGAGGGAGAGCCG-3’).
Atherosclerosis experiments – Mice were fed normal chow diet for 14, 20 or 26 weeks before 
sacrifice. Blood was collected in 3.2% sodium citrate by vena cava puncture. Residual cells 
were removed by perfusion with 10ml binding buffer (BB, containing 40mM HEPES, 
150mM NaCl, 5mM KCl, 1mM MgCl2 and 2.5mM CaCl2) supplemented with 100μM 
sodium nitroprusside via the left ventricle. The aortic arch and main branch points 
(brachiocephalic, carotid and subclavian artery) were dissected and either fixed in 1% 
paraformaldehyde (PFA) in BB o/n and paraffin embedded (5μm sections), or directly 
frozen in TissueTek O.C.T. Compound for cryosectioning (7μm sections). 
Endogenous thrombin potential – ETP was determined in plasma containing 3.3μM 
corn trypsin inhibitor (CTI) using 7pM of tissue factor, 60μM of phospholipids 
(20%PS/60%PC/20%PE) and 8.2mM Ca2+ as discribed previously 23.
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Cholesterol and triglyceride measurements – Total plasma cholesterol and triglycerides 
were determined according to manufacturer’s protocol (Precimat glycerol and GPO-PAP, 
Boehringer-Manheim).
Flow cytometry analysis of blood and bone marrow – Blood was collected via vena cava 
puncture in 3.2% sodium citrate. After erythrocyte lysis, blood cell composition was 
determined using anti-bodies against CD11b (BD Biosciences), Ly6G (BD Biosciences), 
Ly6C (Miltenyi Biotec), CD3e (eBioscience), B220 (BD Biosciences), NK1.1 (eBioscience), 
CD4 (BD Biosciences) and CD8a (eBioscience). Bone marrow composition was determined 
using antibodies against B220, CD3e, NK1.1, CD11b, Ly6G, Ly6C and CD115 
(eBioscience). Flow cytometry was analyzed using FACSDiva Software (V6.1.3), gate 
settings for blood analysis are shown in Supplemental Figure 1. Values are expressed as 
percentage of viable cells.  
Histology – Plaque sizes were determined using standard Hematoxylin and Eosin (H&E) 
staining on every fifth section and analyzing total aortic plaque burden with ImageJ Software 
(V1.45). Total plaque area was determined for the entire arch and major branchpoints. 
Sizes of every two consecutive sections are averaged, multiplied by 20μm (the distance in 
between) and summed up to obtain total plaque burden. Plaque progression was scored 
on the following parameters: neutrophil and macrophage content, apoptosis and necrosis, 
cap thickness and calcification status as is summarized in Supplemental Tables 1 and 
2. Additional plaque features were determined using a Sirius red staining for collagen, 
terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) for apoptosis 
and immunohistochemistry using antibodies against MAC-3 (BD Biosciences, clone 
M3/84) for all macrophages, iNOS (Abcam, AB3523) for M1-polarized macrophages and 
α-SMa (Abcam) for vascular smooth muscle cells. Size and cross-linking of the collagen 
fibers is determined by the color distribution of polarized light as described previously 24. 
AnxA5 promoter activity was determined by β-galactosidase (lacZ) staining of cryostat 
sections as described previously 25. 
Cells – Primary bone marrow derived monocytes were isolated as described before 26. At 
least 6 femurs and 6 tibias were dissected, rinsed with 70% ethanol and flushed with 
RPMI1640. Bone marrow plugs were collected, and disrupted by passing through a 19 
gauge needle twice. Cell suspension was filtered using a 70μm cell strainer, and collected 
by centrifugation (400g, 5 min). Cells were resuspended and differentiated for 8 days in 
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RPMI1640 containing 10mM HEPES, 10% heat inactivated FBS (Gibco-BRL), 15% 
L929 conditioned medium and 100U.ml-1 penicillin (Gibco-BRL) and 100μg.ml-1 
streptomycin (Gibco-BRL). Macrophages were polarized using vehicle, 100U.ml-1 IFN-γ, 
20ng.ml-1 IL-4 and 10ng.ml-1 IL-10 (all Peprotech, UK) to obtain M0, M1, M2a and M2c 
macrophages respectively. Migration of bone marrow derived macrophages was assessed 
in a label free Real-Time Cell Analysis platform on CIM plates of the xCELLigence 
(Roche) according to manufacturer’s protocol. 
Jurkat cells were cultured in RPMI1640 containing 10% heat inactivated FBS (Gibco-
BRL), 100U.ml-1 penicillin (Gibco-BRL) and 100μg.ml-1 streptomycin (Gibco-BRL).
In vivo phagocytosis – In vivo phagocytosis was adapted from Taylor et al. 27. In short, Jurkat 
cells were labeled with 2.5μM CFSE, resuspended to 2.106 cells.ml-1 and irradiated for 
10 minutes with UV-B (290-320nm). After 3 hours of incubation, about 80% of cells 
were apoptotic (Supplemental Figure 2) as determined by flow cytometry 28. 10.106 cells 
were injected intraperitoneally in temperature controlled, isoflurane anesthetized, paired 
ApoE-/- and DKO mice. Phagocytosis was allowed for 30 minutes before collection of 
cells by peritoneal lavage with ice cold PBS. After isolation, Fc-receptors were blocked 
(CD16/32, eBioSceince) and macrophages were stained with F4/80 (F4/80-APC, ITK 
diagnostics) and analyzed by flow cytometry. 
Statistical analysis – All values are shown as mean ± SEM. Statistical significance between 
two groups was checked for normal distribution using the Shapiro-Wilk normality test 
and tested on significance by unpaired (or paired if stated) student’s t-test using Graphpad 
Prism 5.0 software. A two tailed value of p<0.05 was considered statistically significant. 
P-values are indicated in the table and figures by asterisks representing: *p<0.05, **p<0.005, 
***p<0.001
Results
Comparison of baseline characteristics of DKO and ApoE-/- 
In order to study the role of endogenous anxA5 in atherogenesis, anxA5-/-/ApoE-/- double 
knock-out mice (DKO) were generated. First we compared DKO and ApoE-/- mice for 
a selection of parameters. Body weights did not differ significantly between DKO and 
ApoE-/- (Table 1). Blood triglycerides and total cholesterol were significantly higher in 
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20 and 26 weeks old DKO mice (Table 1). AnxA5-deficiency did not cause a change 
in coagulability of blood plasma as determined by the endogenous thrombin potential 
(ETP) (Table 1). Total body section did not reveal any organ abnormalities or other 
differences between both strains as assessed by an animal pathologist. Analyses of circulating 
leukocyte populations revealed that 26 weeks old DKO mice had a circulating leukocyte 
profile with a significantly lower fraction of B-cells (p=0.047) (Table 2 and supplemental 
Figure 1). Within the monocyte population there was a shift towards pro-inflammatory 
Ly6Chigh monocytes (p=0.018) (Table 2). Analyses of bone marrow leukocytes showed 
no differences between DKO and ApoE-/- (Table 2).
AnxA5 deficiency slows down atherogenesis
At 14 weeks of age neither ApoE-/- nor DKO mice showed lesion formation in the arch, 
whereas both developed single cell adhesion (SCA) in the brachiocephalic artery (BCA) 
indicating initiation of plaque formation (Figure 1A). At 20 weeks of age ApoE-/- and 
DKO showed SCA and intimal xanthoma (IX) formation in aortic arch. BCA lesion 
development progressed towards intermediate lesions (IL) and advanced lesions (AL) 
(Figure 1B). At 26 weeks both strains had developed plaques in aortic arch and BCA. 
Plaques of DKO mice were smaller and less advanced compared to plaques of ApoE-/- mice 
(Figure 1C). Quantification showed a significant reduction of plaque size in DKO at 26 
weeks of age in the arch (Figure 2A) and BCA (Figure 2B). While both strains have IL 
and AL in the BCA, the progression of the lesion development in the arch of DKO mice 
was delayed (Figure 2C). Only 2 out 13 DKO mice developed a plaque with a necrotic 
core in the arch after 26 weeks, while in ApoE-/- mice this was 10 out of 12  (Figure 2D). 
No difference in necrotic core development was observed in BCA (Figure 2D).
Cellularity of the plaques was equal between both strains at 20 and 26 weeks of age 
and predominantly consisted of macrophages and VSMC (Figure 3 A-D). Cell death as 
determined by TUNEL-staining was less in plaques of DKO mice as compared to plaques 
of ApoE-/- mice at 26 weeks of age (Figure 3E, F). AnxA5 deficiency affected neither total 
collagen content nor cross-linking of collagen fibers at 26 weeks (Figure 2G-J).
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14 weeks 20 weeks 26 weeks
DKO ApoE-/- DKO ApoE-/- DKO ApoE-/-
Weight (g) 26±3 27±2 27±2 28±2 28±2 31±2
Lipids (nM)
Cholesterol n.d. n.d. 13±3 12±4 14±4*** 11±3
Triglycerides n.d. n.d. 1.5±0.6* 1.1±0.4 1.6±0.6* 1.1±0.6
Coagulation
ETP (nM.min) 556±124 680±34 713±189 651±153 523±72 706±243
Peak height (nM) 137±15 123±13 149±22 162±19 129±29 141±8
Table 1 Baseline characteristics of ApoE-/- and DKO mouse strains.
Table 2 Flow cytometric analysis of blood and bone marrow at 26 weeks of age
Parameter Subpopulation DKO (n=16) ApoE-/- (n=17) P
Blood
Leukocytes (109.L-1) 6.8±0.7 5.7±1.8 n.s.
Erythrocytes (1012.L-1) 7.9±0.2 8.1±0.3 n.s.
Hemoglobin (mM) 7.2±0.2 7.6±0.6 n.s.
Hematoctit (%) 40.0±7.0 40.1±15.2 n.s.
B-cells (%viable) 26.6±15.0* 37.6±15.6 0.047
NK-cells (%viable) 3.1±1.4 4.1±1.4 n.s.
Granulocytes (%viable) 41.2±21.4 28.4±16.5 n.s.
Monocytes (%viable) 12.4±5.8 9.5±5.2 n.s.
Ly6Chigh  (%parent) 63.5±25.5* 45.9±14.9 0.018
Ly6Cmed (%parent) 5.4±0.5 7.7±1.7 n.s.
Ly6Cneg (%parent) 30.9±26.5 41.5±20.7 n.s.
T-cells (%viable) 12.0±5.8 15.5±5.7 n.s.
CD4+ (%parent) 55.8±27.4 41.4±13.7 n.s.
CD8+ (%parent) 40.0±19.7 54.3±22.2 n.s.
Bonemarrow
B-cell (%viable) 13.4±8.5 13.5±4.3 n.s.
NK-cell (%viable) 0.4±0.2 0.6±0.2 n.s.
Granulocytes (%viable) 36.7±9.7 33.8±8.4 n.s.
Monocytes (%viable) 6.6±2.5 7.1±3.5 n.s.
Ly6Chigh (%parent) 40.9±32.6 45.5±37.4 n.s.
Ly6Cmed (%parent) 20.9±7.9 42.2±17.0 n.s.
Ly6Cneg (%parent) 45.2±30.8 14.1±10.2 n.s.
T-cells(%viable) 2.3±1.1 2.0±0.6 n.s.
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Figure 1 - Hematoxylin and eosin stained aortic arches.  Representative images of  H&E stained sections 
of  (A) 14 weeks (B) 20 weeks and (C) 26 weeks old apoE-/- and DKO mice fed normal chow 
diet. Showing initial plaque development starts in the BCA and is followed by development in 
the arch. 40 x magnification, scale bar 500μm. n ≥ 10/group.
A
C
DKO 500μm ApoE-/- 500μm
DKO
B
500μm ApoE-/- 500μm
DKO 500μm ApoE-/- 500μm
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Figure 2 - AnxA5 deficiency slows down atherogenesis. At 14 weeks of age there is only single 
cell adhesion; measurable plaque development starts from 20 weeks of age. (A) Plaque size was 
measured in the aortic arch, DKO show decreased plaque development at 26 weeks. (B) Plaque 
size was measured in the brachiocephalic artery (BCA), DKO show decreased plaque development 
at 26 weeks. (C) Plaque phenotype was scored at 26 weeks of age, DKO has decreased progression 
towards advanced lesions in the arch and equal plaque development in the BCA. (D) Necrotic 
core size and number were measured at 26 weeks. DKO had only a necrotic core in 2/13 (15%) 
of cases in the arch and 11/13 (85%) in the BCA, while the ApoE-/- had developed a necrotic 
core in 10/12 (83%) in the arch and 12/12 (100%) in the BCA. When mice developed a necrotic 
core, the size was equal. Values are represented as mean +/- SEM, n≥12/group. SCA = single cell 
adhesion; IX = intimal xanthoma; IL = intermediate lesion; AL = advanced lesion.
ANXA5 gene promoter activity is increased in macrophages around the necrotic core
In order to study ANXA5 gene promoter activity in atherosclerotic plaques we performed 
a LacZ staining for β-galactosidase on cryosections of 26 weeks DKO aortas. The 
atherosclerotic plaque contained cells that stained blue, reflecting ANXA5 gene promoter 
activity (Figure 4A, B). Cells around the core stained intense blue whereas cells in the 
shoulders of the plaque had a faint blue staining. Blue cells were predominantly MAC-3 
positive macrophages, indicating that MAC-3 positive macrophages can regulate ANXA5 
gene promoter activity locally (Figure 4C, D). Staining of the M1 macrophage specific 
marker iNOS, shows an evenly distribution of M1 macrophages in the shoulder and 
around the necrotic core (Figure 4E). There was no difference in total M1 macrophage 
content between ApoE-/- and DKO (data not shown). In order to investigate whether 
ANXA5 gene promoter activity is regulated by polarization of macrophages, bone marrow 
derived macrophages were differentiated towards M0, M1 and M2 phenotype. Figure 
4F demonstrates that differentiation per se did not affect anxA5 mRNA levels. However, 
stimulation with LPS caused an upregulation of anxA5 mRNA expression only in M1 
macrophages.
A B C D
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Figure 3 - AnxA5 deficiency results in more stable lesion development. All sections shown are representative 
images of  26 wks old fed normal chow diet ApoE-/- and DKO mice. (A,B) MAC-3 staining (brown) 
for total macrophage content, MAC3 macrophage positive area is equal between ApoE-/- and 
DKO, quantified as percentage of  MAC3+ area of  total intima (40x, scale bar 500μm). (C,D) 
αSMA staining (red) for total vascular smooth muscle cells shows no difference between apoE-/- 
and DKO, quantified as percentage of  αSMA+ area of  total intimal area (40x, scale bar 500μm). 
(E,F) TUNEL staining for apoptosis (green) and DAPI staining for nucleus (blue), show less 
apoptotic cells in DKO at 26 weeks of  age, quantified as percentage of  TUNEL+ cells of  total 
number of  intimal cells (200x, scale bar 100μm). (G,H) Picrosirius Red staining for total collagen 
content in bright-field shows higher collagen content at 20 weeks of  age in DKO (200x, scale 
bar 100μm). (I,J) Picrosirius Red staining visualized by polarized light for collagen birefringence, 
shows no difference in age or cross-linking between apoE-/- and DKO (200x, scale bar 100μm). 
All quantifications are represented as mean ± SEM, n≥12.
500μm 500μm
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DKO macrophages exhibit increased efferocytosis in vivo
Resident peritoneal macrophages were exposed to fluorescently labeled apoptotic Jurkat 
cells in vivo. Flow cytometry analysis of collected peritoneal macrophages revealed 
that DKO macrophages phagocytosed apoptotic cells significantly better than ApoE-
/- macrophages (Figure 5 A-C). Since peritoneal macrophages egress from peritoneum 
after efferocytosis we excluded that the observed enhanced efferocytosis results from 
impairment in migration as a result of anxA5 deficiency. DKO and ApoE-/- macrophages 
display similar migratory activity with a tendency that DKO macrophages migrate better 
than ApoE-/- macrophages (Figure 5 D).
200μm 200μm50μm
200μm 100μm
A B C
D E F
Figure 4 - ANXA5 gene promoter activity is increased in macrophages around the necrotic core. (A,B) LacZ 
staining for β-galactosidase activity as a measure of  ANXA5 gene promoter activity of  BCA plaque 
shows increased activity around the core (100x and 400x, scale bar 200μm and 50μm respectively). 
(C) MAC-3/LacZ staining of  BCA plaque for macrophages and anxA5 promoter activity, shows 
that the core and shoulders of  the plaque contain MAC-3 positive macrophages (100x, scale bar 
200μm) (D) LacZ staining of  consecutive section shows that not all MAC-3+ macrophages of  
figure 4C stained equally blue positive (100x, scale bar represents 200μm). (E) iNOS staining for 
M1 polarized macrophages indicates that M1 macrophages are evenly distributed throughout 
the lesion. (F) qPCR analysis of  polarized macrophages, corrected for GAPDH expression and 
normalized to M0 without LPS stimulation, shows that polarization by itself  does not affect anxA5 
promoter activity, but activation with LPS causes an upregulation of  anxA5 in the M1 polarized 
macrophages only. Values are presented as mean ± SEM, n=4 mice measured in triplicate.
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Figure 5 – DKO macrophages exhibit increased efferocytosis in vivo. (A,B) Representative dot plot of 
the uptake of CFSE-labeled apoptotic Jurkat cells by residential peritoneal macrophages of DKO 
and ApoE-/- mice. Upper right corner of the FL-1/FL-4 image represent double positive cells for 
CFSE (apoptotic cells) and F4/80-APC (macrophages). Parameters are set using unlabeled and single 
labeled control conditions. (C) Quantification of in vivo phagocytosis shows increased phagocytosis 
by DKO (n=8 mice/group, analysis was performed using paired t-test). (D) Migration of bone 
marrow derived macrophages in a label free Real-Time Cell Analysis platform (xCELLigence), 
indicates that the migratory ability between DKO and apoE-/- is equal, with a tendency of higher 
migration by DKO macrophages.
Discussion
In this paper we investigated the role of anxA5 in atherosclerosis by anxA5 knockout on 
an ApoE-/- background. AnxA5 is broadly known as imaging tool to visualize apoptosis 
in vitro 29, and in vivo in animal models 30 and patients 13. Imaging studies revealed that 
anxA5 accumulates in atherosclerotic plaques and that extent of its accumulation reflects 
plaque vulnerability 14, 31-33. Recently it was also shown that exogenously administered 
hr-anxA5 reduces plaque inflammation and shifts plaques towards a more stable 
phenotype 16 (Burgmaier et al. J Cell Mol Med 2014 accepted for publication). The 
pharmacodynamics of hr-anxA5 were explained by its ability to reduce pro-inflammatory 
effects of phosphatidylserine, lysophosphatidylcholine, oxidated LDL and oxidated 
cardiolipin 12, 17, 18. 
We were interested whether endogenous anxA5 would serve a similar protective function 
in atherosclerosis. Knocking out anxA5 was associated with a significant increase in plasma 
triglycerides, total cholesterol and a shift towards circulating Ly-6Chigh monocytes. There 
was a tendency towards an increase of circulating granulocytes. All these factors have 
previously been associated with increased atherogenic pressure 34-38 and therefore, would 
suggest an aggravation of atherosclerosis in the DKO mice. Surprisingly, our study shows 
that anxA5 deficiency results in inhibition of atherogenesis in mice on normal chow diet. 
Differences in plaque burden became significant at the age of 26 weeks. DKO had smaller 
and less advanced plaques both in aortic arch and BCA. The effect of anxA5-deficiency 
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on atherogenesis was more pronounced in the arch. The speed of plaque development was 
slower in the arch suggesting that anxA5-deficiency causes subtle differences in processes 
underlying plaque formation. After 26 weeks plaques of the arch of DKO mice had a 
lower frequency of cell death and were almost devoid of a necrotic core. This indicates that 
either fewer cells execute apoptosis and progress towards secondary necrosis, or apoptotic 
cells are more efficiently removed by efferocytosis in DKO plaques. 
It has been shown before that increased apoptotic and necrotic cell accumulation leads to 
increased plaque development 39-41. Apoptosis is an important process with dual impact 
on atherogenesis, as it impedes development of early plaques and accelerates progression 
of late plaques 42. Our findings that anxA5 deficiency does not accelerate early plaque 
development, suggests that apoptosis is not affected. Therefore we reasoned that depletion 
of anxA5 affects efficiency of efferocytosis by plaque macrophages. Our in vivo experiments 
indeed show that anxA5 deficiency improves efferocytosis by macrophages. Others showed 
that anxA5 deficiency increased engulfment of necrotic cells by peritoneal macrophages 
43. How endogenous anxA5 suppresses efferocytosis remains to be elucidated. Possibly 
the macrophage externalizes anxA5 44, 45 which subsequently shields PS on the apoptotic 
prey and phagocyte and suppresses efferocytosis 19-21. Alternatively, intracellular anxA5 is 
involved in phagolysosome formation 46. Interestingly we observed that plaque macrophages, 
and especially macrophages located in the core of the plaque where necrotic debris 
coalesces, have increased promoter activity of the ANXA5 gene. Atherosclerotic plaques 
of ApoE-/- mice contain predominantly the classically activated and pro-inflammatory M1 
macrophage 38. The differential regulation of ANXA5 gene promoter activity by plaque 
macrophages was not associated with skewing of polarization towards the alternatively 
activated and anti-inflammatory M2 phenotype. Apparently, the micro-environment of 
macrophages determines ANXA5 gene promoter activity without affecting polarization. 
This notion is supported by our findings that M0, M1 and M2 have comparable ANXA5 
gene promoter activity and that only M1 macrophages respond to LPS by upregulating 
anxA5 mRNA expression. It is tempting to speculate that the plaque core environment 
induces M1 macrophages to upregulate anxA5 expression with subsequently suppression 
of phagocytic activity and necrotic core development.  
In conclusion, our results demonstrate that endogenous anxA5 plays a role in atherogenesis 
and that targeted inhibition of anxA5 may be a therapeutic avenue to attenuate plaque 
progression.
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Supplemental figure 1 – Gate settings for blood analysis. Flow cytometry analysis of blood on 
FACS Canto. First single cells are selected. Viable cells are selected from the single cells and further 
classified using antibodies against CD11b (monocytes+granulocytes), Ly-6G (granulocytes), Ly-
6C (monocytes), CD3e (T-cells), B220 (B-cells), NK1.1 (NK-cells), CD4 (T-helper cell) and 
CD8a (cytotoxic T-cell).
Supplemental figure 2 – the effect of UV-B radiation and incubation time on apoptosis and necrosis 
of Jurkat cells. After 10 minutes of UV-B irradiation and 3 hours incubation, about 75% of 
cells are apoptotic with minor necrosis present. This is the condition we selected for the in vivo 
phagocytosis assay.
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Subject Amount Score
Neutrophils (#) 0
1, 2
≥3
0
1
2
Macrophages (% intima) 0-10
11-20
21-30
≥31
0
1
2
3
Apoptosis (yes/no) negative
positive
0
1
Necrotic core size (% intima) 0
<20
≥20
0
1
2
Cap thickness (cell layers) 0-1
2-3
>3
0
1
2
Calcification (status) absent
osteochondrocytic cells
calcification
0
1
2
Supplemental Table 1 - quantification of plaque progression.
Supplemental Table 2 - Classification of plaque progression score.
Total score Definition Abbreviation
0-3 Intimal Xanthoma IX
4-5 Small Lesion SL
6-7 Intermediate Lesion IL
≥8 Advanced Lesion AL
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Exogenous annexin A1 attenuates athero-
genesis in LDLR-/- mice on 
Western Type Diet
DHM Kusters, ML Chatrou, BAG Willems, M De Saint-Hubert, M Bauwens, E van 
der Vorst, S Bena, EAL Biessen, M Perretti, LJ Schurgers, CPM Reutelingsperger
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Abstract
Objective: To investigate effects of anxA1 administration on atherogenesis in LDLR-/- mice.
Methods: In vivo, biodistribution of human recombinant annexin A1 (hr-anxA1) was 
determined in C57Bl/6J mice after intravenous and intraperitoneal administration. 
For atherosclerosis, Western Type Diet fed LDLR-/- mice were treated 3 times per 
week for a period of 6 weeks. Total plaque burden and phenotype were analyzed using 
immunohistochemistry. In vitro, effects of hr-anxA1 on leukocyte adherence and rolling 
on activated endothelial cells are studied in a flow chamber model.
Results: In vivo, intravenously administered hr-anxA1 had blood clearance with t1/2 <10 
minutes. Intraperitoneal administered hr-anxA1 peaked in circulation 50 minutes post-
injection and had 0.5% of injected dose per gram circulating after 24 hours. Administration 
of hr-anxA1 did not affect initiation of plaque formation (-33%; P=0.21) but significantly 
inhibited progression of plaque size (-50%; P=0.005) and necrotic core size (-76%, 
P=0.015). In vitro, hr-anxA1 inhibited rolling and adherence of neutrophils but not 
monocytes to activated endothelial cells.
Conclusion: Annexin A1 attenuates atherogenesis by reducing plaque inflammation
67
C
ha
pt
er
 4
Annexin A1 treatment of atherosclerosis
Introduction
Atherosclerosis is a systemic chronic inflammatory disease affecting the vascular wall of 
arteries and is the major cause of morbidity and mortality in both developed and developing 
countries. The disease is characterized by confined manifestations of atherosclerotic lesions 
in the arterial vessel wall that may develop into unstable plaques causing adverse outcomes 
over time 1-3. Unstable plaques are characterized by abundant presence of inflammatory 
cells, a large necrotic core and a thin fibrous cap 4. Inflammatory cells are considered key 
players in initiation of- and progression to an unstable plaque 5, 6. Activated neutrophils 
act as important effectors and regulators of inflammation through their ability to produce 
a myriad of effector molecules including cytokines, chemokines and angiogenic factors 7. 
Reducing recruitment of neutrophils to the inflamed arterial vessel wall by neutrophil-
specific antibodies and gene-deletions of chemokines and their receptors, suppresses 
arterial lesion development in mouse models of atherosclerosis 8-10.
Annexin A1 (anxA1) is a member of the multigene annexin family 11 with potent anti-
inflammatory activity 12. The polypeptide chain of anxA1 comprises a C-terminal core 
domain, which is conserved amongst all members of the family and harbors the Ca2+ and 
phospholipid binding sites, and an N-terminal tail that varies between annexin members. 
The N-terminal tail of anxA1 can interact with the receptor for formylated peptides 
(FPR-2/ALXR) 11, 13-16. In the absence of calcium and a phospholipid surface, the tail is 
concealed within the core domain. However, upon membrane binding anxA1 changes 
conformation and exposes its N-terminus at the surface enabling interaction with FPR-2 
15. AnxA1-FPR-2 interaction results in inhibition of neutrophil recruitment to inflamed 
sites 17. Alternatively, proteolysis can cause release of the N-terminal peptide 18, which then 
can interact with FPR-1 and 2 evoking anti-inflammatory activity 19. Pharmacological 
treatment of inflammation using anxA1 and its N-terminal peptide has been studied in 
mouse models of neutrophil-dependent edema 20, cardiac ischemia-reperfusion injury 21, 
22 and acute peritonitis 23, however, hitherto not in atherosclerosis.
In this paper we studied pharmacological effects of human recombinant anxA1 (hr-anxA1) 
on the initiation of atherosclerosis and the progression of established atherosclerotic 
plaques in an LDLR-/- mouse model. We demonstrate that hr-anxA1 has no effect on 
initiation of early plaque development, but significantly attenuates progression of existing 
lesions to unstable plaques.
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Methods
Design, production and purification of human recombinant (hr)-anxA1- cDNA 
coding for hr-anxA1 was amplified by polymerase chain reaction (PCR) using 
primers: 5’-GGTATCGAGGGAAGGGCAATGGTATCAGAATTC-3’ and 
5’-GCTCAGCTAATTAAGCTTTAGTTTCCTCCACAAAGAGC-3’. The primers 
introduced Stu-I and Hind-III restriction sites, required for the ligation into the expression 
vector pQE30Xa (Qiagen). His-tagged hr-anxA1 was produced according to previously 
published protocol for anxA5 24. In short, E. Coli (SG13009[pREP4]) (Novagen) were 
fermented in Luria-Bertani broth (LB) medium supplemented with Ampicillin (50ug/ml, 
Roche), Kanamycin (30ug/ml, Gibco) and 0.5% glycerol. At OD450 of >6, over-expression 
of the protein was initiated by addition of 5mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG, Eurogentec). Proteins were purified by immobilized metal affinity chromatography 
(IMAC) using nickel. Purity and homogeneity were assessed by silver-stained SDS-PAGE, 
western blotting and MALDI-TOF/TOF analysis.
Endotoxin determination - Endotoxin was determined with the Endosafe-PTS (Charles-
River) according to manufacturer’s protocol. Purified protein preparations containing <1 
unit/ml endotoxin were used for experiments. 
Ellipsometry - PS-binding property of purified hr-anxA1 was determined by ellipsometry using 
a bilayer of 20 mole% dioleoyl-phosphatidylserine / 80 mole% dioleoyl-phosphatidylcholine 
(20 mole% DOPS/80 mole% DOPC; Avanti Polar Lipids, Alabaster, AL, USA) as 
described previously 25.
Cell culture – Primary bone marrow derived monocytes were isolated as described before 
26. Mice are anesthetized with 5% isoflurane before sacrifice by cervical dislocation. Cells 
were grown for 8 days in RPMI 1640 containing 10mM Hepes, 10% heat inactivated fetal 
bovine serum (FBS, Gibco-BRL), 15% L-cell conditioned medium, 100U/ml Penicillin 
(Gibco-BRL) and 100 μg/ml Streptomycin (Gibco-BRL). The human monocytic cell line 
THP-1 (ATCC, Manassas, USA), was cultured in RPMI 1640 without color indicator 
(Gibco-BRL, Invitrogen, USA) supplemented with 2 mM glutamine (Gibco-BRL, 
Invitrogen), 10% heat-inactivated FBS, 100 units/ml penicillin and 100μg/ml streptomycin. 
Polymorphonuclear leukocytes (PMN) were isolated from blood collected into 3.2% 
sodium citrate, diluted 1:1 in RPMI 1640 (Sigma-Aldrich) before separation through 
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a double-density gradient as described previously 19. Confluent human umbilical vein 
endothelial cells (HUVEC, PromoCell, C12203) were grown to a monolayer in a μ-slide 
(Ibidi, 80666, Germany) before flow experiments. 
Calcium mobilization and flow-chamber assay – Receptor binding studies were performed 
on FPR-2 transfected HEK293 cells as described previously 27. Leukocyte rolling and 
adhesion flow chamber experiments were performed as described previously 19. Each flow 
experiment consisted in total of a 10 second recording at 1 frame per 0.3 second. Cells 
of all 32 frames were counted: adhering cells were stationary in all frames, while rolling 
cells were defined as all interacting non-stationary cells. 
In vitro internalization of hr-anxA1 - Binding and internalization of fluorescently labeled 
hr-anxA1 by apoptotic Jurkat cells was visualized with confocal laser scanning microscopy 
(CLSM) as described previously 28 and by flow cytometry.
Animals - The investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institute of Health (NIH Publication NO. 85-
23, revised 2011). All animal studies were conducted under a protocol approved by the 
ethics committee for animal experiments of Maastricht University. For pharmacological 
treatment with hr-anxA1, 12 weeks old LDLR-/- mice were fed a Western type diet (WTD, 
0.15% cholesterol) (AB diets 4021.13) for 6 weeks (group I, n=12) or 12 weeks (group 
P, n=12). Group I received either 1 mg/kg hr-anxA1 or PBS (control) 3 times per week 
via intraperitoneal (IP) injection starting at day 0 for 6 weeks. Group P received either 1 
mg/kg hr-anxA1 or PBS 3 times per week via IP injection starting 6 weeks after initiation 
of WTD for 6 weeks. Mice were treated with 0.1 mg/kg Buprenorphine (Temgesic) 
subcutaneously and anesthetized with 5% isoflurane, before sacrifice by vena cava puncture. 
Aortic arches with all major branch points were dissected, fixed in 1% PFA o/n, paraffin 
embedded and sectioned at 4μm thickness. Total plaque area was determined for the entire 
arch and the brachiocephalic, carotid and subclavian arteries using standard hematoxylin/
eosin (H&E) staining on every fifth section, and analyzed with ImageJ Software (v1.45). 
Plaque progression was scored on the following parameters: neutrophil and macrophage 
content, apoptosis and necrosis, cap thickness and calcification status as is summarized 
in supplemental Tables 1 and 2.
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Nuclear imaging, biodistribution and blood clearance – Purified His-tagged hr-anxA1 was 
radiolabeled with technetium-99m (99mTc(CO)3-His-anxA1) using the IsoLink tricarbonyl 
labeling method (Covidien, Petten, The Netherlands) as described previously for His-
anxA5 29. Nuclear imaging, blood clearance and biodistribution were performed using 
12 weeks old LDLR-/- mice (Charles-River). Biodistribution and blood clearance of IP 
and intravenous (IV) injection of 100 MBq 99mTc(CO)3-His-anxA1 were determined. To 
exclude any dietary effect on the biodistribution or blood clearance, the mice were put on 
WTD 2 weeks prior to the experiment. Total body single photon emission tomography 
(SPECT) imaging was performed 45 minutes post-injection as previously described 30.
Flow cytometric analysis of blood and bone marrow – Single cell suspensions were prepared 
and stained with anti-CD3, -CD4, -CD8a, -CD11b, -CD115, -Ly6C, -Ly6G, -B220, 
-NK1.1, or isotype control IgG. Antibodies conjugated to FITC, PE, APC, Cy7, eFluo450, 
or PerCP (all BD Biosciences) were used and cells were analyzed using a FACS-Canto II 
and FACSDiva Software (V6.1.3, BD Biosciences). 
Anti-hr-anxA1 antibody formation – Blood was collected in 3.2% sodium citrate, plasma 
was collected by 5 minutes centrifugation at 10.000 g. A 96-well plate was coated with 5 
μg/ml hr-anxA1 in 0.1M carbonate buffer (pH 9.5) o/n, washed with PBS and blocked 
with 3% non-fat dry milk in phosphate buffered saline (PBS). Ten times diluted plasma 
was added and incubated 1h at 37°C, rabbit-α-human anxA1 antibody was used as positive 
control. HRP-labeled rat-α-mouse-IgG (Dako, P0161) was added and incubated 1h at 
37°C. Chromogenic substrate tetramethyl benzidine (TMB) was measured at 450nm.   
Endogenous thrombin potential (ETP) – ETP was determined in plasma containing 
3.3μM corn trypsin inhibitor (CTI) using 7pM of tissue factor, 60 μM of phospholipids 
(20%PS/60%PC/20%PE), 420μM fluorogenic substrate and 8.2mM Ca2+  as described 
previously 31. 
Immunohistochemistry – Immunohistochemistry was performed using antibodies against 
MAC-3 (BD Biosciences, clone M3/84, 553322) for all macrophages, iNOS (Abcam, 
AB3523) for M1-polarized and Ym1 (kind gift from professor Christoph Binder, Vienna, 
Austria) and CD206 (ITK diagnostics, 141702) for M2-polarized macrophages.
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Statistical analysis – All data is presented as mean ± SEM. Normality was tested using the 
Shapiro-Wilk normality test with GraphPad Prism 5.0 software. Statistical significance 
between two groups was tested by unpaired two tailed student’s t-test. A value of P<0.05 
was considered statistically significant. P-values are indicated in the tables and figures by 
asterisks as follows *P<0.05, **P<0.005, ***P<0.001.
Results
Physical and biological characterization of hr-anxA1
The N-terminal tail mediates anti-inflammatory activities of anxA1 and contains protease-
sensitive sites 27. We used the expression vector pQE30Xa that introduced a His-tag 
upstream of the N-terminal tail, which was cleaved off after purification by FXa. In 
order to verify that our procedure yielded full length recombinant product, purified hr-
anxA1 was subjected to structural analyses including MALDI TOF/TOF (Supplemental 
Figure 1A), silver stained SDS-PAGE and Western blotting (Supplemental Figure 1B) 
and tryptic digestion. These analyses confirmed the production and purification of 
full-length hr-anxA1 with a purity of >95%. Hr-anxA1 was stable for at least 1 year if 
stored in HEPES/NaCl pH7.4 at 4°C.  Biological functionality of the N-terminal tail 
and Ca2+-dependent PS-binding of the C-terminal core were intact as assessed by the 
calcium flux induced in FPR-2 transfected HEK-293 cells and ellipsometry respectively 
(Figure 1A, B and supplemental Figure 2A-C). Furthermore, hr-anxA1 was internalized 
by Jurkat cells in the early phase of apoptosis in an PS-binding and FPR-dependent 
manner. This was demonstrated with FPR-inhibitors cyclosporine H (CsH) and WRW4 
using flow cytometry (Figure 1C) and confocal microsopy (Figure 1D) and underscored 
by absence of internalization if hr-anxA1 lacks its N-terminus (Supplemental Figure 3). 
AnxA5 internalization, which depends on PS-binding and trimerization 32, 33 was affected 
by neither inhibitor (Figure 1C). Finally, hr-anxA1 significantly inhibited rolling and 
adhesion of polymorphonuclear cells (50% and 63%, respectively) over a monolayer of 
TNFα-activated HUVECs (Figure 1E) while it had no effect on rolling and adhesion of 
THP-1 monocytes (Figure 1G). 
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Figure 1 – Physical and biological characterization of hr-anxA1. Hr-anxA1 induced concentration 
dependent calcium flux in FPR-2 transfected HEK-293 cells, 1μM ionomycin is taken as reference 
value (100%) (A). Ellipsometry analysis shows calcium dependent binding of 1µg/ml purified 
annexin to a 20/80 mol% PS/PC bilayer (B). Internalization of fluorescent annexin by apoptotic 
Jurkat cells in presence and absence of inhibitors of FPR-1 (cyclosporin H, 1μM) and FPR-2/3 
(WRW, 10μM) as analyzed by flow cytometry (C). Mean fluorescence intensity (MFI) is normalized 
to MFI of annexin internalization on ice. Hr-anxA1 internalization (green) as visualized by 
fluorescent confocal laser scanning microscopy (CLSM) (D). Nuclei are stained with DAPI (blue) 
and PS-expression is stained with anxA5-AF568 (red). PS negative cells (indicated by arrow) did 
not internalize hr-anxA1. Pretreatment of PMN with 10nM rh-anxA1 inhibited both rolling and 
adhesion of PMN on a TNF-α activated HUVEC monolayer (G). One frame out of 32 is shown 
of a flow chamber model with rolling and adhering fluorescent THP-1 monocytes, flowing over 
TNF-α activated HUVEC monolayer. Flowing and adhering THP-1 monocytes are indicated 
by white and red arrows respectively (F). Pretreatment of THP-1 cells with 10nM hr-anxA1 has 
effect on neither rolling nor adhesion of THP-1 cells (G). All values are represented as mean ± 
SEM of 3 independent experiments.
Determination of in vivo administration route of hr-anxA1 
In order to establish the preferred route of administration, biodistribution and blood 
clearance were determined for intravenously (IV) and intraperitoneally (IP) administered 
technetium labeled anxA1 (99mTc(CO)3-His-anxA1). 
99mTc(CO)3-His-anxA1 had 
radiochemical purity of approximately 90% and eluted as a single peak on RP-HPLC 
(Supplemental Figure 4A). IV administered 99mTc(CO)3-His-anxA1 was cleared by the 
kidneys, liver and lungs. IP administered 99mTc(CO)3-His-anxA1 was gradually released 
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into the blood circulation, peaked at 50 min post injection and then gradually decreased 
through clearance by the kidneys and liver (Supplemental Figure 4B-D) with t1/2 of 
approximately 6 hours. About 0.5% of injected dose per gram (ID/g) anxA1 remained 
in the circulation 24 hours post injection. On basis of pharmacokinetics we decided to 
administer hr-anxA1 three times per week IP as treatment.
Administration of hr-anxA1 does not alter baseline characteristics of LDLR-/- mice
Treatment of LDLR-/- mice on WTD with hr-anxA1 had no effect on body weight, 
circulating cholesterol and triglyceride levels and procoagulant activity of blood plasma 
(Table 1). Sustained treatment did not cause generation of antibodies against hr-anxA1 
(data not shown). Heart rate and blood pressure were not affected by anxA1 administration.
Table 1 - Baseline characteristics of control and hr-anxA1 treated mice.
Initial plaques (I) Existing plaques (P)
Ctrl AnxA1 Ctrl AnxA1
Age (weeks) 18.0 ±0.5 18.0 ±0.5 24.0 ±0.5 24.0 ±0.5
Weight (g) 26.2 ±1.9 25.8 ±1.6 29.2 ±2.4 27.9 ±1.5
Cholesterol (mM) 25.2 ±2.9 24.6 ±3.9 28.3 ±2.7 26.9 ±2.9
Triglycerides (mM) 3.3 ±0.6 3.2 ±0.8 3.3 ±0.6 3.6 ±0.5
Coagulation
ETP (nM.min) 1376.1 ±104.0 1312.3 ±46.3 1342.2 ±78 1325.4 ±59.8
Peak Height (nM) 185.3 ±6.7 190.8 ±11.0 180.1 ±7.3 188.6 ±8.9
Hr-anxA1 has no significant effect on early plaque development
Administration of hr-anxA1, starting with initiation WTD, failed to effect plaque 
initiation (total plaque size 0.024±0.019 mm3 versus 0.016±0.010 mm3, control versus 
hr-anxA1, -33%, P=0.21). Analysis of plaque development at different anatomical sites 
did not reveal site-specific effects of hr-anxA1 on plaque size (Figure 2A, B). Vehicle and 
hr-anxA1 treated animals both showed intimal xanthoma (IX) formation and small foam 
cell lesions (SL) (Figure 2C) with infiltrated macrophages in comparable proportion, 
suggesting that hr-anxA1 affects neither onset of IX formation nor their transition into 
SL in LDLR-/- mice under atherogenic pressure. 70% to 80% of the endothelium of the 
aortic arch was activated as evidenced by ICAM-1 expression. Treatment with hr-anxA1 
had no significant effect on ICAM-1 expression (Figure 2D, E).
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Figure 2 - Hr-anxA1 has no significant effect on early plaque development. 12 weeks old mice were 
fed WTD during 6 weeks. Hr-anxA1 treatment started at the initiation of WTD. Representative 
H&E staining of aortic arches after 6 weeks of treatment (A). Treatment with hr-anxA1 significantly 
reduced total plaque burden in the arch and subclavian artery (SA) but not in brachiocephalic 
(BCA) and left common carotid artery (CA) (B). Individual plaque progression was scored on 
following parameters: neutrophil and macrophage content, apoptosis and necrosis, cap thickness 
and calcification status (see Supplemental Tables 1 and 2). Hr-anxA1 treatment had no effect on 
early plaque progression (C). Hr-anxA1 treatment had no effect on endothelial ICAM-1 expression 
(D, E). IX: intimal xanthoma; SL: small lesion; IL: intermediate lesion; AL: advanced lesion. All 
values are represented as mean ±SEM, n=12 per group. Panel A: 40x magnification, scale bar 
represents 500μm. Panel D: 200x magnification, scale bar represents 100μm.
Hr-anxA1 attenuates progression into advanced plaques 
Hr-anxA1 treatment of mice with established plaques caused a significant inhibition 
of total plaque growth (0.131±0.080 mm3 versus 0.065±0.031 mm3, control versus 
hr-anxA1, -50%, P=0.005), which was most pronounced in the arch and subclavian 
artery (Figure 3A, B). Necrotic core development was suppressed by hr-anxA1 treatment 
(Figure 3C). As a measure of plaque size we determined plaque volume and plaque 
surface area at maximal stenosis. These two parameters showed a very high correlation 
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(R2=0.84) (Supplemental Figure 5), indicating that a single 2-dimensional measurement 
at maximal stenosis is sufficient for plaque size determination. All lesions of control and 
hr-anxA1 treated mice contained comparable amount of infiltrating macrophages and 
smooth muscle cells as further evaluated by MAC-3 (Figure 3D, E) and αSMa (Figure 
3F, G) staining, respectively. Furthermore there was no difference in endothelial ICAM-1 
expression (Figure 3H, I). Individual plaque progression was further scored as described 
by Supplemental Tables 1 and 2. This classification showed that hr-anxA1 treated mice 
predominantly developed IX and SL, while the control treated mice predominantly had 
already intermediate lesion (IL) and advanced lesion (AL) development (Figure 3J). In 
addition, blood analysis revealed significant increase in proportion of granulocytes of 
circulating leukocytes, while bone marrow showed no differences in leukocyte composition 
between control and hr-anxA1 treated mice (Table 2).
Table 2 - Flow cytometric analysis of blood and bone marrow.
Parameter Subpopulation ctrl (n=7) hr-anxA1 (n=6) P
Blood (% of viable) (% of parent)
B-cells 46.9 ±9.5 33.8 ±15.8 n.s.
NK-cells 4.1 ±0.4 4.0 ±0.3 n.s.
Granulocytes 18.2 ±7.1 35.0 ±18.8* 0.039
Monocytes 9.9 ±4.5 10.6 ±2.5 n.s.
Ly6Cneg/low 22.1 ±4.2 18.5 ±10.0 n.s.
Ly6Cmedium 10.7 ±2.0 9.7 ±1.8 n.s.
Ly6Chigh 67.2 ±5.6 71.8 ±8.3 n.s.
T-cells 14.2 ±1.8 12.1 ±4.9 n.s.
CD4+ 41.9 ±1.6 45.3 ±6.4 n.s.
CD8+ 58.1 ±1.6 54.7 ±6.4 n.s.
Bone marrow n.s.
B-cells 17.8 ±1.4 19.6 ±5.2 n.s.
NK-cells 1.1 ±0.2 1.0 ±0.2 n.s.
Granulocytes 36.7 ±2.0 30.2 ±9.1 n.s.
Monocytes 14.8 ±1.5 14.3 ±2.0 n.s.
Ly6Cneg/low 10.6 ±2.5 9.9 ±2.8 n.s.
Ly6Cmedium 51.1 ±6.2 46.2 ±9.4 n.s.
Ly6Chigh 38.2 ±7.8 43.8 ±10.6 n.s.
T-cells 0.5 ±0.2 0.7 ±0.3 n.s.
Undefined 25.6 ±1.8 30.1 ±5.0 n.s.
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Figure 3 – Hr-anxA1 attenuates progression into advanced plaques. 12 weeks old mice were fed 
WTD 6 weeks before start of treatment with hr-anxA1. Representative H&E staining of aortic 
arches (A). Treatment with hr-anxA1 significantly reduced total plaque burden in the arch and 
subclavian artery (SA) but not in the brachiocephalic (BCA) and left carotid artery (CA) (B). 
Total necrotic core size was smaller after treatment (C). Macrophage (D, E) and smooth muscle 
cell (F, G) content and endothelial ICAM-1 expression (H, I) were not changed by treatment. 
Individual plaque progression was scored on following parameters: neutrophil and macrophage 
content, apoptosis and necrosis, cap thickness and calcification status (see Supplemental Tables 1 
and 2). Hr-anxA1 treatment caused inhibition of plaque progression (J). IX: intimal xanthoma; 
SL: small lesion; IL: intermediate lesion; AL: advanced lesion. All values are represented as mean 
±SEM, n=12 per group. Panel A: 40x magnification, scale bar represents 500μm; Panel D,F: 100x 
magnification, scale bar represents 200μm; Panel H: 200x magnification, scale bar represents 100μm.
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Hr-anxA1 does not affect macrophage polarization in atherosclerotic plaque
Recently we demonstrated that endogenous anxA1 contributes to resolution of chronic 
inflammation in a mouse model of nonalcoholic steatohepatitis (NASH) through stimulation 
of IL-10 production and down-modulation of M1 polarization 34. Therefore we studied 
whether hr-anxA1 could influence polarization of macrophages in the atherosclerotic 
plaque. Quantification of M1 polarization marker iNOS (Figure 4A, B) showed no 
differences between control and anxA1 treated plaques. Staining was diffuse throughout 
the entire lesion, whereas the non-immune immunoglobulin staining was negative (data 
not shown). We did not detect any marker of M2 polarization in the atherosclerotic 
lesions of both groups using antibodies against Ym1 (Figure 4C, D) and CD206 (data not 
shown). This indicates that the lesions are predominantly occupied by M1 macrophages. 
Treatment of bone marrow-derived macrophages (BMDM) with hr-anxA1 in vitro did 
neither affect IL-12 and TNF-α mRNA expression nor NO production as compared to 
control (see Supplemental Figure 6). IL-10 mRNA expression was below detection limit 
in hr-anxA1 teated and untreated BMDM.
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Figure 4 – Rh-anxA1 does not affect macrophage polarization in atherosclerotic plaque. Representative 
staining for M1 macrophage specific marker iNOS. Black arrows indicate fully commited M1 
macrophages, white arrows indicate iNOS negative macrophages (A). Quantification of iNOS-
staining indicates no difference between control and anxA1 treated animals (B). Representative 
staining of M2 specific marker Ym1. Both control and rh-anxA1 treated mice were negative 
for Ym1 (C). Staining of Ym1 positive cells in the spleen indicating functionality of anti-Ym1 
antibody (D). Panel A: 200x magnification, scale bar represents 100μm; panel D: 40x and 400x 
magnification, scale bar represent 500μm and 50μm respectively.
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Discussion
AnxA1 has anti-inflammatory and pro-resolving properties causing dampening of 
inflammation in several animal models of acute and chronic inflammation 34-36. We 
hypothesized that exogenously administered anxA1 would reduce atherogenesis. In order 
to explore pharmacodynamics of anxA1 on atherogenesis we produced recombinant 
human anxA1 (hr-anxA1) and thoroughly inspected integrity and functional properties 
of the N-terminal tail and C-terminal core. Both are essential to the anti-inflammatory 
properties of anxA1, since this requires both interaction with FPR-2 and binding to PS, 
respectively 22. Hr-anxA1 possessed both functional properties with sufficient shelf-stability 
to perform series of in vivo experiments. Secondly, pharmacokinetics and biodistribution 
of hr-anxA1 were determined to select the preferred route of administration. Intravenous 
administered hr-anxA1 was cleared rapidly from circulation with t1/2 of <10 min. This 
rapid pharmacokinetic is comparable with half-life reported for anxA5, another member 
of the annexin family 37. Biodistribution showed accumulation of hr-anxA1 in kidneys 
but also in liver and lungs. Currently we have no explanation for the latter phenomenon 
but this could indicate clearance via the reticula-endothelial system. Pharmacokinetics 
and biodistribution of intraperitoneal administered hr-anxA1 revealed release of hr-anxA1 
into circulation during a longer period of time with a peak at 50 min post administration. 
Here, clearance from circulation occurred predominantly by kidneys. Based on the 
pharmacokinetics we decided to administer hr-anxA1 by IP injection, 3 times per week 
as treatment regimen. 
In our experiments hr-anxA1 did not affect the formation of intimal xanthoma lesions 
or the transition to small lesions, but treatment significantly attenuated the transition 
from small lesions to intermediate and advanced lesions. This was most pronounced in 
the inner curvature of the arch and in the subclavian artery. Neutrophils are considered 
as the primary target of anxA1 for its anti-inflammatory action 12 and neutrophils can 
modulate initiation and progression of atherosclerosis 38, 39. ICAM-1 is a strong regulator 
of neutrophil adhesion and transmigration 40. Endothelial ICAM-1 expression was not 
altered by anxA1 in our experiments. AnxA1 inhibits adhesion of neutrophils to endothelial 
cells 19, 41 and diminishes their transmigration across the endothelium 42 by engaging via 
its N-terminal tail with the FPR-2/AXLR 14, 43. Concordant with a previous report 42 we 
observed that hr-anxA1 induced a relative increase of circulating granulocytes, which 
is an indication for hr-anxA1 induced neutrophil demargination and inactivation. A 
similar effect has been reported for treatment with glucocorticoids 44, of which anxA1 is 
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considered to be a down-stream effector 12. Interestingly, our in vivo results show that hr-
anxA1 treatment did not affect intimal xanthoma and small lesion formation but afforded 
substantial inhibitory effects on progression of small lesions towards advanced lesions. 
Recent observations showed that hyperactivation and life prolongation of neutrophils 
through knocking out CXCR4 affect progression rather than initiation of atherosclerosis 
39. Together our findings strongly indicate that the neutrophil is likely to be the main 
target for inhibition afforded by hr-anxA1 on experimental atherosclerosis.
Hr-anxA1 may attenuate atherosclerosis also by acting on the plaque macrophage. 
We reported recently that anxA1 can polarize liver macrophages towards the anti-
inflammatory M2 phenotype 34. Macrophage polarization is an important contributor 
to atherogenesis 45, 46. M2 polarized macrophages diminish plaque inflammation and 
inhibit plaque progression 47. However, we found no evidence of macrophage skewing 
in the atherosclerotic lesions of our mice. We cannot exclude hr-anxA1 might modulate 
macrophage functions. Indeed, hr-anxA1 may also affect removal of apoptotic cells by 
enhancing efferocytosis by macrophages. Apoptosis and efferocytosis determine rate of 
plaque progression and plaque phenotype 48, 49. Hr-anxA1 is known to act as opsonin 
for apoptotic cells and in this way it stimulates efferocytosis 22, 50, 51, and subsequently 
reduces release of pro-inflammatory cytokines IL-6 and TNF-α 52. Atherosclerotic plaques 
that were treated with hr-anxA1 had smaller necrotic cores, suggestive of a stimulated 
efferocytotic machinery within the plaque. 
We conclude that established atherosclerosis can be treated with hr-anxA1 in a murine model 
of atherosclerosis. These findings may open novel avenues to treat chronic inflammatory 
diseases such as atherosclerosis.
80
Chapter 4
References
1. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary 
lesions. J Interv Cardiol. 2002;15:439-446.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Kusters DH, Tegtmeier J, Schurgers LJ, Reutelingsperger CP. Molecular imaging to identify the 
vulnerable plaque--from basic research to clinical practice. Mol Imaging Biol. 2012;14:523-533.
4. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the 
pathologists’ view. Eur Heart J. 2013;34:719-728.
5. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
6. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med. 
2013;210:1283-1299.
7. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation 
of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519-531.
8. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered 
neutrophilia promotes early atherosclerosis. Circulation. 2010;122:1837-1845.
9. de Jager SC, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, van Santbrink PJ, van Berkel TJ, Kuiper 
J, Biessen EA. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by 
affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol. 2013;33:e75-83.
10. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober 
A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C. Protective role of 
CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 
2008;102:209-217.
11. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev 
Mol Cell Biol. 2005;6:449-461.
12. Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. 
Nat Rev Immunol. 2009;9:62-70.
13. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of 
multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta. 1994;1197:63-93.
14. Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ. Annexin A1 interaction with the FPR2/
ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem. 
2012;287:24690-24697.
15. Rosengarth A, Luecke H. A calcium-driven conformational switch of the N-terminal and core domains 
of annexin A1. J Mol Biol. 2003;326:1317-1325.
16. Perretti M. The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol Sci. 2003;24:574-579.
17. Babbin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, Perretti M, Nusrat A. Annexin I regulates SKCO-
15 cell invasion by signaling through formyl peptide receptors. J Biol Chem. 2006;281:19588-19599.
18. Vong L, D’Acquisto F, Pederzoli-Ribeil M, Lavagno L, Flower RJ, Witko-Sarsat V, Perretti M. Annexin 
1 cleavage in activated neutrophils: a pivotal role for proteinase 3. J Biol Chem. 2007;282:29998-30004.
19. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide 
inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. 
Blood. 2006;107:2123-2130.
20. Perretti M, Ahluwalia A, Harris JG, Goulding NJ, Flower RJ. Lipocortin-1 fragments inhibit neutrophil 
accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-
CD11b monoclonal antibody. J Immunol. 1993;151:4306-4314.
81
C
ha
pt
er
 4
Annexin A1 treatment of atherosclerosis
21. D’Amico M, Di Filippo C, La M, Solito E, McLean PG, Flower RJ, Oliani SM, Perretti M. Lipocortin 
1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J. 
2000;14:1867-1869.
22. Dalli J, Consalvo AP, Ray V, Di Filippo C, D’Amico M, Mehta N, Perretti M. Proresolving and tissue-
protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide 
receptor 2/lipoxin A4 receptor. J Immunol. 2013;190:6478-6487.
23. Perretti M, Getting SJ, Solito E, Murphy PM, Gao JL. Involvement of the receptor for formylated peptides 
in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol. 2001;158:1969-1973.
24. Schutters K, Kusters DH, Chatrou ML, Montero-Melendez T, Donners M, Deckers NM, Krysko DV, 
Vandenabeele P, Perretti M, Schurgers LJ, Reutelingsperger CP. Cell surface-expressed phosphatidylserine 
as therapeutic target to enhance phagocytosis of apoptotic cells. Cell Death Differ. 2013;20:49-56.
25. Cuypers PA, Corsel JW, Janssen MP, Kop JM, Hermens WT, Hemker HC. The adsorption of prothrombin 
to phosphatidylserine multilayers quantitated by ellipsometry. J Biol Chem. 1983;258:2426-2431.
26. Davies JQ, Gordon S. Isolation and culture of murine macrophages. Methods Mol Biol. 2005;290:91-103.
27. Pederzoli-Ribeil M, Maione F, Cooper D, Al-Kashi A, Dalli J, Perretti M, D’Acquisto F. Design 
and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the 
microvasculature. Blood. 2010;116:4288-4296.
28. van Genderen H, Kenis H, Lux P, Ungeth L, Maassen C, Deckers N, Narula J, Hofstra L, Reutelingsperger 
C. In vitro measurement of cell death with the annexin A5 affinity assay. Nat Protoc. 2006;1:363-367.
29. De Saint-Hubert M, Mottaghy FM, Vunckx K, Nuyts J, Fonge H, Prinsen K, Stroobants S, Mortelmans 
L, Deckers N, Hofstra L, Reutelingsperger CP, Verbruggen A, Rattat D. Site-specific labeling of 
‘second generation’ annexin V with 99mTc(CO)3 for improved imaging of apoptosis in vivo. Bioorg 
Med Chem. 2010;18:1356-1363.
30. De Saint-Hubert M, Bauwens M, Deckers N, Drummen M, Douma K, Granton P, Hendrikx G, 
Kusters D, Bucerius J, Reutelingsperger CP, Mottaghy FM. In Vivo Molecular Imaging of Apoptosisand 
Necrosis in Atherosclerotic PlaquesUsing MicroSPECT-CT and MicroPET-CT Imaging. Mol Imaging 
Biol. 2013.
31. Tchaikovski SN, BJ VANV, Rosing J, Tans G. Development of a calibrated automated thrombography 
based thrombin generation test in mouse plasma. J Thromb Haemost. 2007;5:2079-2086.
32. Kenis H, van Genderen H, Bennaghmouch A, Rinia HA, Frederik P, Narula J, Hofstra L, Reutelingsperger 
CP. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol 
Chem. 2004;279:52623-52629.
33. Ungethum L, Kenis H, Nicolaes GA, Autin L, Stoilova-McPhie S, Reutelingsperger CP. Engineered 
annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting 
strategies. J Biol Chem. 2011;286:1903-1910.
34. Locatelli I, Sutti S, Jindal A, Vacchiano M, Bozzola C, Reutelingsperger C, Kusters D, Bena S, Parola 
M, Paternostro C, Bugianesi E, McArthur S, Albano E, Perretti M. Endogenous annexin A1 IS a 
novel protective determinant in nonalcoholic steatohepatitis (NASH). Hepatology. 2014.
35. Girol AP, Mimura KK, Drewes CC, Bolonheis SM, Solito E, Farsky SH, Gil CD, Oliani SM. Anti-
inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of 
ocular inflammation in vivo and in vitro. J Immunol. 2013;190:5689-5701.
36. Leoni G, Alam A, Neumann PA, Lambeth JD, Cheng G, McCoy J, Hilgarth RS, Kundu K, Murthy 
N, Kusters D, Reutelingsperger C, Perretti M, Parkos CA, Neish AS, Nusrat A. Annexin A1, formyl 
peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest. 2013;123:443-454.
82
Chapter 4
37. Vangestel C, Peeters M, Oltenfreiter R, D’Asseler Y, Staelens S, Van Steenkiste M, Philippe J, Kusters D, 
Reutelingsperger C, Van Damme N, Van de Wiele C. In vitro and in vivo evaluation of [99mTc]-labeled 
tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing 
cells. Nucl Med Biol. 2010;37:965-975.
38. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012;110:875-888.
39. Bot I, Daissormont IT, Zernecke A, van Puijvelde GH, Kramp B, de Jager SC, Sluimer JC, Manca 
M, Herias V, Westra MM, Bot M, van Santbrink PJ, van Berkel TJ, Su L, Skjelland M, Gullestad 
L, Kuiper J, Halvorsen B, Aukrust P, Koenen RR, Weber C, Biessen EA. CXCR4 blockade induces 
atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol. 2014;74C:44-52.
40. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil 
adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood. 
2005;106:584-592.
41. Vago JP, Nogueira CR, Tavares LP, Soriani FM, Lopes F, Russo RC, Pinho V, Teixeira MM, Sousa LP. 
Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing 
neutrophil apoptosis. J Leukoc Biol. 2012;92:249-258.
42. Lim LH, Solito E, Russo-Marie F, Flower RJ, Perretti M. Promoting detachment of neutrophils 
adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1. Proc Natl 
Acad Sci U S A. 1998;95:14535-14539.
43. Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates 
neutrophil extravasation by interacting with the FPR. Mol Cell. 2000;5:831-840.
44. Nakagawa M, Terashima T, D’Yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced 
granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. 
Circulation. 1998;98:2307-2313.
45. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: 
from mice to humans. Immunity. 2013;38:1092-1104.
46. Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, Daemen MJ, 
Lutgens E, de Winther MP. Distribution of macrophage polarization markers in human atherosclerosis. 
Atherosclerosis. 2012;225:461-468.
47. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, Wagner O, Stangl 
H, Soehnlein O, Binder CJ. Interleukin-13 protects from atherosclerosis and modulates plaque 
composition by skewing the macrophage phenotype. EMBO Mol Med. 2012;4:1072-1086.
48. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the 
importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264.
49. Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic 
plaque progression. Circ Res. 2010;106:58-67.
50. Scannell M, Flanagan MB, deStefani A, Wynne KJ, Cagney G, Godson C, Maderna P. Annexin-1 and 
peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils 
by macrophages. J Immunol. 2007;178:4595-4605.
51. Blume KE, Soeroes S, Keppeler H, Stevanovic S, Kretschmer D, Rautenberg M, Wesselborg S, Lauber 
K. Cleavage of annexin A1 by ADAM10 during secondary necrosis generates a monocytic “find-me” 
signal. J Immunol. 2012;188:135-145.
52. Yang YH, Aeberli D, Dacumos A, Xue JR, Morand EF. Annexin-1 regulates macrophage IL-6 and 
TNF via glucocorticoid-induced leucine zipper. J Immunol. 2009;183:1435-1445.
83
C
ha
pt
er
 4
Annexin A1 treatment of atherosclerosis
Supplemental Figures and Tables
Supplemental Figure 1 – Production and purification of hr-anxA1. MALDI-TOF/TOF analysis 
shows a molecular weight of 38.5kDa for purified hr-anxA1, which is in concordance with the 
theoretical molecular weight of full-length anxA1 (A). Bis-protonated hr-anxA1 and hr-anxA1 dimers 
are represented on the spectrum as peaks of 19.2kDa and 77.2kDa respectively. Representative 
image of 50ng purified hr-anxA1 (1) and His-anxA1 (2) on silver-stained SDS-PAGE for total 
protein (B) and Western blotting with an α-anxA1-antibody (C) (n ≥ 5 purifications) M = broad 
range protein marker.
Supplemental Figure 2 – Ellipsometry analysis of phospholipid binding properties. Ca2+-dependent 
binding curves of 1 µg/ml hr-anxA1 and 1 µg/ml anxA5 binding to 5/95 (A), 10/90 (B) and 
20/80 mol% PS/PC bilayer (C) as measured by ellipsometry.
A B C
M 1 2 M 1 2
A B C
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Supplemental figure 3 – MALDI-TOF/TOF analysis of truncated hr-anxA1. Mass spectrometry 
analysis of truncated hr-anxA1 shows a molecular weight of 35.8kDa, which means truncation 
occurred between Thr23 en Val24.
Supplemental Figure 4 - Determination of in vivo administration route of hr-anxA1. HPLC 
analysis of radio-labeled His-anxA1 (99mTc(CO)3-His-anxA1) shows a radiochemical purity of 
>95% and specific retention time of approximately 18 minutes (A). SPECT image 45 minutes 
after intraperitoneal (IP) and intravenous (IV) injection of 99mTc(CO)3-His-anxA1 (B). White 
arrows indicate site of injection, red arrows indicate kidneys and green arrows indicate lungs. 
Rapid renal clearance and uptake in the lungs was observed in the IV injected mice, whereas IP 
injection mice show peritoneal localization. Time courses of blood levels of 99mTc(CO)3-His-
anxA1 were determined by γ-counting (C). Biodistribution was determined by weighing and 
γ-counting of organs dissected 3 (D) and 24 hours (E) post-injection. All values are represented 
as mean ±SEM (n=6 per group).
A B
C D E
IP IVcranial cranial
caudal caudal
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Supplemental Figure 5 – Correlation of 2 and 3 dimensional plaque sizes. Plaque volumes were 
determined and correlated with plaque areas of the section having the largest plaque area.
Supplemental Figure 6 – Response of bone marrow derived macrophages to anxA1. IL-12 and 
TNF-α release are not affected by  1 or 10μg/ml anxA1 (A). Nitric oxide release is not altered by 
anxA1 stimulation.
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Subject Amount Score
Neutrophils (#) 0
1, 2
≥3
0
1
2
Macrophages (% intima) 0-10
11-20
21-30
≥31
0
1
2
3
Apoptosis (yes/no) negative
positive
0
1
Necrotic core size (% intima) 0
<20
≥20
0
1
2
Cap thickness (cell layers) 0-1
2-3
>3
0
1
2
Calcification (status) absent
osteochondrocytic cells
calcification
0
1
2
Supplemental Table 1 - quantification of plaque progression.
Supplemental Table 2 - Classification of plaque progression score.
Total score Definition Abbreviation
0-3 Intimal Xanthoma IX
4-5 Small Lesion SL
6-7 Intermediate Lesion IL
≥8 Advanced Lesion AL
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Annexin A1 ameliorates infarct size and LV 
systolic function following myocardial 
ischemia/reperfusion injury
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Abstract
Background - Neutrophils play a detrimental role in myocardial ischemia/reperfusion (I/R) 
injury. Citrullinated histones released by activated neutrophils are cytotoxic. Annexin 
A1 (anxA1) inhibits neutrophil recruitment and function. Low-anticoagulant heparin 
(AADH) neutralizes cytotoxic activity of histones.
Aim – The aim is to determine effects of administration of anxA1 and AADH on the 
extent of ischemic area and cardiac function after 24 hours of reperfusion.
Methods - 12 weeks old C57Bl.6J mice were subjected to 30 minutes ischemia by left 
anterior descending artery occlusion followed by 24 hours of reperfusion. Mice were 
treated with 1mg/kg annexin A1 or 18mg/kg AADH 30 minutes before onset of ischemia 
and directly at start of reperfusion.
Results - Treatment with anxA1 and AADH significantly reduced infarcted area as 
compared to vehicle. Neither anxA1 nor AADH reduced influx of neutrophils into 
the area at risk after 24 hours of reperfusion. However, anxA1 administration caused a 
significant reduction in loss of ventricular contractility. AADH had no effect on I/R-
affected ventricular contractility.
Conclusion - Both anxA1 and AADH reduce the infarcted area after ischemia-reperfusion, 
however only anxA1 improves ventricular contractility. 
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Introduction
Restoring myocardial reperfusion after an ischemic attack is considered essential for 
cardiac functionality, but initiates a second phase of myocardial injury termed reperfusion 
injury 1. The initial ischemia, followed by reperfusion (IR) induces a complex cascade of 
events that ultimately leads to cardiomyocyte apoptosis and necrosis. Reperfusion injuries 
share many characteristics with the normal inflammatory response, where neutrophils 
are the most prevalent leukocyte the first day after injury. The impact neutrophils have in 
reperfusion injury became apparent over time 1-3. Complete or partial neutrophil depletion 
in animals undergoing IR resulted in a marked decrease in infarct size, demonstrating 
that a significant amount of myocardial injury is neutrophil dependent 4. Neutrophils 
release reactive oxygen species, proinflammatory cytokines and chemokines activating 
the endothelium, resulting in recruitment and activation of additional neutrophils. Upon 
activation, neutrophils have the possibility to excrete neutrophil extracellular traps (NETs) 
in a specialized form of cell death named NETosis 5. NETs consist of a complex network 
that contains DNA and proteins like histones and neutrophil elastase 6, 7. Histones in 
particular exhibit cytotoxic activity towards host cells 8. 
Annexin A1 (anxA1), is a member of the multigene annexin family 9 with potent anti-
inflammatory activity 10. The N-terminal tail of anxA1 can interact with the receptor 
for formylated peptides present on all leukocytes (FPR-2/ALXR) 9, 11-14. AnxA1-FPR-2 
interaction results primarily in inhibition of neutrophil recruitment to inflamed sites 
15, but also affects neutrophil survival 16-18 and clearance 19. Administration of anxA1 to 
rats undergoing I/R has shown to reduce infarction size 20. However, its effect on the 
important clinical marker of post ischemic heart function has so far not been studied. 
Antithrombin affinity depleted heparin (AADH), is a strong negatively charged 
polysaccharide with the ability to neutralize positively charged histones. Using this 
ability, AADH prevents histone-mediated cytotoxicity thus improving overall survival 
in a murine sepsis model 6. 
In this paper we study the potential of anxA1 and AADH to inhibit neutrophil cytotoxicity 
after ischemia-reperfusion. We study the effect of treatment at 24 hours of reperfusion 
and show that anxA1 and AADH treatment reduce infarct size. In addition, anxA1 was 
able to reduce the loss of ventricular contractile force. Both anxA1 and AADH treatment 
did not affect neutrophil infiltration at 24 hours of reperfusion, which suggests that the 
cardioprotective effect of both treatments occurred earlier or was neutrophil independent.
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Materials and methods
Animals – Male 12 week old out bred C57bl6/J mice were purchased from Charles 
River (Someren, the Netherlands). All animal experiments were conducted according 
to a protocol approved by the ethics committee for animal experiments of Maastricht 
University. (After surgery, animals were housed individually with unlimited access to 
food and water).
Ischemia-reperfusion – Ischemia Reperfusion injury was performed as described previously 22. 
In short, mice received subcutaneous analgesia 0.1mg/kg buprenorphine HCl (Temgesic) 
before being anesthetized with 4% isoflurane. After intubation and mechanical ventilation 
(tidal volume of 250μl and 210 breaths/min anesthesia was maintained with 2% isoflurane. 
First a canula was placed into the vena jugularis for injection of PBS, 1mg/kg anxA1 or 
18mg/kg AADH. Then, an incision was made in the left fourth intercostal space 2mm 
from the sternum. Ligature of the left anterior descending (LAD) coronary artery at the 
inferior edge of the left atrium was performed using a 6-0 prolene suture (Surgipro, Chicago, 
USA). A small piece of polyethylene tube (PE-10) was used to secure the ligature without 
damaging the artery. After 30 minutes of ischemia the tube was removed and reperfusion 
occurred. Reperfusion was confirmed by visible restoration of color to the ischemic tissue. 
After surgery, the chest was closed and respiration was returned to normal. Mice received 
another dose of analgesia (0.1mg/kg) buprenorphine before sacrifice the next day.
Area at risk and infarct size assessment - To assess area at risk (AAR) and infarcted area (IA) 
in an in vivo I/R model, mice were anesthetized and sacrificed after 24 hours of reperfusion. 
The left anterior coronary artery was re-occluded and Evan’s blue dye (2%; Sigma) was 
injected into the vena cava inferior to delineate the AAR. The heart was rapidly excised, 
directly rinsed in 0.9% NaCl and atria were removed. Hearts were frozen for 10 minutes 
and sectioned into 1 mm transverse sections from the apex to the base (10-12 slices/heart). 
The sections were incubated with preheated 2% triphenyltetrazolium chloride (TTC) 
in phosphate buffer (pH 7.4) for 10 min at 37 °C. Sections were photographed with a 
digital microscope eyepiece camera (Dino-lite, Naarden, The Netherlands) to distinguish 
the area not at risk (AnAR) in blue, stained ischemic viable tissue in red, and unstained 
necrotic tissue in white 21. Planimetry was performed using Image J software (v1.45). AAR 
was expressed as percentage of total heart size; IA was expressed as percentage of AAR.
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Left ventricular function – Left ventricular function was evaluated 24h after reperfusion as 
described before 22. In short, mice were anaesthetized with 2.5 mg/g body weight urethane 
(Sigma). A high-fidelity catheter tip micromanometer (Mikro-tip 1.4F; SPR-671, Millar 
Instruments, USA) was inserted through the right carotid artery into the left ventricular 
cavity. Ventricular pressure was measured and sampled at a rate of 2 kHz. Maximal 
positive pressure development (+dP/dt) and heart rate were determined on a beat-to-
beat basis and 1 s averages were stored. The heart was then stimulated with increasing 
concentration of dobutamine (Sigma) administered intravenously into the jugular vein 
using a microinjection pump (model 200 Series, KdScientific, USA). Maximal values 
of +dP/dt were recorded and the changes of +dP/dt values from baseline were calculated. 
At the end of the experiment heart was excised and embedded in OCT compound for 
histochemical staining. 
Echocardiography - Cardiac function and heart dimensions were evaluated by two-
dimensional echocardiography using a Visual Sonics Vevo 2100 Ultrasound (Visual 
Sonics, Canada) with MicroScan-400 probe (18-38MHz) under isoflurane anesthesia. 
B-mode echocardiograms were captured to measure anterior and posterior wall thicknesses 
at end diastole and end systole. Left ventricular (LV) internal diameter (LVID) was 
measured as the largest anteroposterior diameter in either diastole (LVIDd) or systole 
(LVIDs). A single observer blinded to mouse groups performed echocardiography and 
data analysis. Fractional shortening was calculated by: FS(%) = ((LVIDd − LVIDs)/
LVIDd)×100. Ejection fraction was calculated by: EF = EDV-ESV/EDV where ESV is 
end systolic volume and EDV is end diastolic volume. LV mass was calculated by use of 
an uncorrected cube assumption as LVmass = ((LVIDd + LVPWd + IVSd)3-(LVIDd)3)
x1000, as described previously 23. 
Immunohistochemistry - Hearts were frozen in OCT and cut serially in 7μm sections 200μm 
from the occlusion locus towards the apex (8 series of 20 sections). Between each series 
100μm was removed. Immunohistochemic staining for neutrophils (rat-α-mouse Ly6G, 
1:250 clone RB6-8C5, Abcam) and citrullinated histone H3 (H3Cit)(Abcam, ab5103) 
was performed. Quantification was done with ImageJ (v1.45) on 3 fields within the area 
at risk at 40x magnification. Neutrophils were expressed as number of infiltrating cells 
per mm2 and H3Cit as positive % of the area at risk.
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Antithrombin affinity depleted heparin – Antithrombin affinity depleted heparin (AADH) 
was prepared as described previously 6. 
Endogenous thrombin potential – ETP was determined of citrated plasma using 7pM of 
tissue factor (TF), 60μM of phospholipids (20%PS/60%PC/20%PE) and 8.2mM Ca2+, 
supplemented with 3.3μM corn trypsin inhibitor (CTI) to inhibit thrombin formation 
from contact activation (FXIIa) 24.
Results
AnxA1 and AADH reduce IR injury
Age and body weight of control and experimental groups were comparable (Table 1). 
Administration of anxA1 and AADH did not cause significant changes in blood coagulability 
as determined by the endogenous thrombin potential (Table 1). After twenty-four hours 
of reperfusion the area at risk (AAR) of the left ventricle was comparable for all groups, 
indicating no significant variation in positioning of the ligature around the LAD (Figure 
1A-C). Infarcted area (IA) within the AAR was significantly smaller for anxA1 (36.4%) 
and AADH (28%) treatment compared to vehicle treated controls (Figure 1D).
Table 1 – baseline characteristics
Category control (n=12) anxA1 (n=12) AADH (n=12) P
baseline characteristics
Age (weeks) 12 ±0.5 12 ±0.5 12 ±0.5 n.s.
Body weight (g) 25.5 ±0.1 26.1 ±1.7 26.0 ±1.2 n.s.
Coagulation
ETP (nM.min) 415.9 ±49.7 394.7 ±69.7 389.1 ±106.0 n.s.
AnxA1 but not AADH reduces loss of left ventricular contractility 
Echocardiography showed that neither treatment affected physical parameters of the 
beating heart (Table 2). At unstressed conditions heart rate was lower in the AADH 
treated group (Figure 1E). Even though there is no difference in ejection fraction at 
baseline, dobutamine stimulation showed that ventricular contractility was significantly 
better after anxA1 treatment compared to the control (Figure 1F). Systolic pressure and 
lusitropy were comparable between the three groups (Figure 1G, H).
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Figure 1 – Effects of anxA1 and AADH on infarct size and ventricular function after 24 hours of 
reperfusion. Mice were submitted to 30 min of ischemia and 24 hours of reperfusion. At the start 
of reperfusion mice were either treated with vehicle (ctrl), anxA1 or AADH. Macroscopic view of 
the ischemia/reperfusion injured heart 24h after reperfusion (A). The heart was perfused with 2% 
Evans Blue (blue) and stained with triphenyltetrazolium chloride (TTC, red). LV, left ventricle; 
C, left ventricular cavity; RV, right ventricle. Color coded representation of the heart of panel A 
showing the area not at risk (AnAR, blue), the area at risk (AAR, red) and the infarcted area (IA, 
white) within the AAR (B). Left ventricular cavity (C, black) and adipose tissue (AT, grey) complete 
the heart. Enumeration of color-coded area was employed to measure AAR as % of total heart 
area (C) and IA as % of AAR (D). After 24 hours of reperfusion heart rate (E), contractility (F), 
systolic pressure (G) and lusitropy (H) were measured as function of administration of increasing 
amounts of dobutamine. n=7 per group; ns, non-significant; * p <0.05; ** p <0.01.
AnAR
AAR
IA
C
AT
A B C D
E F G H
C
RVLV
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Tabel 2 – echocardiographic parameters of unconscious animals after 24 hours  of 
reperfusion.
Category Name ctrl (n=6) anxA1(n=6) AADH (n=8) P
Long axis derived parameters
End diastolic volume (μl) EDV 72.5±8.6 73.7±7.4 71.2±17.0 n.s.
End systolic volume (μl) ESV 42.9±14.5 45.4±2.8 46.9±20.1 n.s.
Ejaction fraction (%) EF 41.0±15.0 38.0±5.0 37.0±14.0 n.s.
Short axis derived parameters
Diastolic dimensions (mm) LVIDd 4.1±0.3 4.3±0.4 4.2±0.3 n.s.
PWTd 0.7±0.1 0.9±0.3 0.7±0.1 n.s.
AWTd 0.8±0.1 0.8±0.1 0.7±0.1 n.s.
Systolic dimensions (mm) LVIDs 3.3±0.3 3.5±0.5 3.3±0.7 n.s.
PWTs 1.1±0.2 1,2±0.4 1.0±0.2 n.s.
AWTs 1.1±0.1 1.0±0.2 1.0±0.2 n.s.
Left ventricle mass (mg) LVmass 108.7±3.7 109.6±10.0 109.2±21.4 n.s.
Fractional shortening (%) FS 21.0±7.0 19.0±6.0 23.0±11.0 n.s.
AnxA1 and AADH do not affect neutrophil infiltration at 24 hours of reperfusion 
AnxA1 and AADH treatment had no effects on infiltration of CD45+ leukocytes (Figure 
2A, B) or ly6Ghigh neutrophils in the AAR after 24 hours of reperfusion (Figure 2C, D). 
Neutrophils executing NETosis are known to citrullinate histone H3. H3Cit-positive 
staining colocalized with neutrophil positive regions in the AAR (Figure 2E). AnxA1 and 
AADH treatment had no effects on the amount of H3Cit-positivity in the AAR (Figure 
2F). Interestingly, we found H3Cit-positive/Ly6G-negative microvasculature in the AnAR 
that were present in all groups (Figure 2G). Plasma nucleosome levels as determined with 
measurement of histone/DNA concentration were not significantly different between 
the groups (Figure 2H).
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Figure 2 – Effects of anxA1 and AADH on neutrophil infiltration and H3 citrullination after 24 
hours of reperfusion. Mice were submitted to 30 min of ischemia and 24 hours of reperfusion. At 
start of reperfusion mice were either untreated (ctrl) or treated with anxA1 and AADH. After 
24 hours of reperfusion hearts were excised, sectioned and immunohistochemically stained with 
anti-CD45 (A, B), anti-Ly6G antibody (C, D) and anti-H3Cit antibody (E, F). Panel G shows 
a representative image of an H3Cit-positive/Ly6G-negative micro vessel in the AnAR. Plasma 
nucleosomes were quantified to assess free histone and DNA content in plasma (H). Panels A, C 
and E show representative images. Scale bar upper panels A, C and E 500 µm, scale bar of lower 
panels A, C, E and G 100 µm. n=6 per group, n.s. is non-significant.
Discussion
Annexin A1 (anxA1) has anti-inflammatory and pro-resolving properties causing dampening 
of inflammation in several animal models of acute and chronic inflammation 25-27. Low-
anticoagulant heparin (AADH) has been shown to prevent histone-mediated cytotoxicity 
and improve overall survival in sepsis 6. We hypothesized that treatment with anxA1 and 
AADH can reduce ischemia-reperfusion injury by inhibiting neutrophil infiltration and 
neutrophil extracellular trap (NET) formation. Indeed, the results of the current study 
show that anxA1 and AADH both reduce infarcted area. Interestingly, we found that in 
addition to reducing infarct size, anxA1 alone improves functional outcome.
500μm
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100μm
100μm
100μm
100μm
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Although beneficial to limit ischemic damage, reperfusion itself causes myocardial injury 
and a large body of evidence suggests a predominant role for neutrophils 1, 28-30. Ischemic 
damage leads to influx of neutrophils and formation of granulation tissue, deposition of 
collagen-based matrix, complement activation and free radical generation, followed by 
a complex cytokine cascade and upregulation of chemokines 31. This causes endothelial 
dysfunction, microvascular collapse and blood flow defects resulting in apoptosis and 
myocardial infarction which lead to further deterioration of the damaged heart 3. Strategies 
aimed at total removal of neutrophils from perfusing blood in humans, reduce the 
amount of cardiac edema formation and total damage 32, 33. Neutrophil influx and ROS 
formation are directly correlated in infarcted hearts 34 and attempts to inhibit neutrophil 
recruitment or activity appeared very successful in reducing damage 34-36, but its impact 
on heart function remains to be elucidated. 
Previously it has been shown that treatment with full-length anxA1 or anxA1 mimetic 
peptide (Ac2-26) leads to a dose-dependent decrease of leukocyte influx in a rat model of 
ischemia/reperfusion. This resulted in 50% reduction of infarct size at 2 hours of reperfusion 
20, 37. A longer anxA1 mimetic peptide (Ac2-50) resulted in 50-70% reduction of infarct 
size at 2 hours of reperfusion in a mouse model 38. Using full-length protein instead of 
mimetic peptides may increase the potency even further due to higher binding affinity 
to the anxA1 receptor and increased receptor specificity 39. We show that treatment with 
full-length anxA1 reduces infarct size with 35% after 24 hours of reperfusion. We did not 
observe a reduction of neutrophil influx at this point in time and therefore suggest that 
the cardioprotective effect of anxA1 is most likely due to an earlier effect on neutrophil 
infiltration or a direct effect of anxA1 on the survival of cardiomyocytes 40. Qin et al. 
have proposed that the anxA1 mimetic peptide Ac2-26 prevents cardiomyocyte injury by 
enhanced activation of cardioprotective signaling and/or improved intracellular calcium 
re-uptake by the sarcoplasmic reticulum 41. 
In conclusion, we show that full-length anxA1 and AADH have the ability to limit 
myocardial damage 24 hours after reperfusion without reducing neutrophil influx after 
24 hours of reperfusion. Our results also demonstrate that a therapeutic strategy aiming 
at limitting infarct size will not necessarily result in improved cardiac function after 
reperfusion.
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Abstract
Background - AnnexinA1 (anxA1) is a relatively large, anti-inflammatory protein that binds 
formyl peptide receptor 2 (FPR-2) via its N-terminal domain. Although an X-ray crystal 
structure of anxA1 and an NMR structure of Domain I are known, NMR structural and 
dynamic information on full-length anxA1 is lacking.
 
Aim - To investigate structural changes of human recombinant anxA1 in presence and 
absence of calcium and phospholipids by using NMR spectroscopy.
Materials and methods - AnxA1 was recombinantly expressed in normal and deuterated 
M9 minimal media containing 13C-glucose and 15N-ammoniumchloride as sole carbon 
and nitrogen source. Double and triple isotopically labeled proteins were purified using 
IMAC. Purity and homogeneity were assessed by MALDI-TOF/TOF analysis and Western 
blotting. Structural analysis was performed by NMR spectroscopy.  
Results - The N-terminal domain of anxA1 is sensitive to degradation and its conformation 
is strongly dependent on the calcium concentration. Calcium binding to one pocket 
changes the affinity of the other calcium-binding pockets. AnxA1 has three stable, closed 
conformations in the absence of calcium, whereas in the presence of calcium anxA1 has 
one single stable open conformation with the N-terminal domain exposed for interaction. 
In the presence of a phospholipid surface, calcium promotes aggregation of anxA1 that 
leads to co-precipitation of anxA1 with phospholipid vesicles.
Conclusion - The calcium concentration determines the conformation of anxA1 and 
causes substantial changes solely to the N-terminal domain, leaving the other domains 
relatively unaffected. Thus, calcium may be an important regulator of anxA1 function.
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Introduction
Annexin A1 (anxA1) belongs to the annexin superfamily of proteins that share a common 
organizational structure with a highly conserved core domain and a variable N-terminal 
region. The core domain is composed of four annexin repeats, each of which consists 
of five α-helices and the calcium/phospholipid binding pockets 1, 2 (Figure 1A, B). The 
N-terminal domain contains a number of phosphorylation sites 3 and the binding site for 
S100A11 4 and formyl peptide receptor 2 (FPR-2) 5, 6. AnxA1 is particularly well-known 
as a potent anti-inflammatory protein operating on the glucocorticoid axis 7, 8. By binding 
both phosphatidylserine (PS) and FPR-2, anxA1 bridges apoptotic cells to phagocytes 
thereby facilitating phagocytosis 9, 10. In addition, anxA1 can be cleaved and function as 
a local mediator of inflammation 11. The structure of the protein (and consequently the 
availability of cleavage and binding sites) is essential for its function. Structural analysis 
of full-length anxA1 has hitherto only been performed by using X-ray crystallography 
12, which proposed that different conformations of anxA1 possess mechanistic and 
regulatory functions. It has also been suggested that anxA1 undergoes a conformational 
change following calcium-dependent phospholipid binding, thereby exposing a second 
membrane binding site 13, 14 and the N-terminal domain that is normally sequestered 
within the annexin core domains 13, 14. Even though NMR studies on anxA1 have been 
performed previously, only part of the first domain was structurally defined 15, 16. NMR 
studies on the single, isolated subdomains of anxA1 have shown that subdomain D1 
can fold autonomously 16. In contrast, subdomains D2 to D4 are poorly soluble and do 
not fold properly without the presence of neighboring subdomains of the tetradomain 
arrangement. In other words, to gain insight into the biologically relevant structure of 
anxA1 in solution, analysis of the full-length anxA1 is required. To this end, we have 
employed NMR spectroscopy to study the structure and internal dynamics of anxA1, 
along with the effects of calcium and phospholipid binding.
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Figure 1 – Structural properties of anxA1. AnxA1 consists of an N-terminal domain and four 
annexin repeats that each consist of five α-helices and contain the calcium/phospholipid binding 
pockets (A). In the presence of calcium the N-terminal domain becomes available for interaction 
with FPR-2 and electron density is no longer visible with crystallography (B).
Materials and methods
Production of 13C15N-anxA1 and 2H13C15N-anxA1 – For double isotopically labeled 
13C15N-anxA1 milliQ water was used, for triple labeled 2H13C15N-anxA1 milliQ water 
was replaced with 99.9% deuterated water (D2O, CIL Isotopes). Fermentation of cDNA 
transformed E. Coli was performed as described in Chapter 4. SG13009[pREP4] bacteria 
were inoculated in 5ml Luria-Bertani broth (LB) medium supplemented with Ampicilin 
(50ug/ml, Roche) and kanamycin (30ug/ml, Gibco). After 8 hours, the culture was diluted 
1/100 in 50ml LB and grown o/n. The next day, the culture was diluted 1/20 in 50ml M9 
minimal growth medium (M9) supplemented with glucose (6g/L) and 15NH4Cl (2g/L). 
Following 8 hours, the culture was diluted 1/20 to 500ml M9 supplemented with glucose 
(2g/L) and 15NH4Cl (2g/L) and grown again o/n. The next day, the 500ml culture was 
fermented in 3 liter M9 supplemented with 15NH4Cl (2g/L), oxygen saturation and 
glucose were constantly monitored. Induction of protein production was initiated when 
12C-glucose was depleted using 1mM isopropyl-β-D-1-thiogalactopyranoside (IPTG, 
Eurogentec). Directly after induction 2g/L 13C-glucose for double and [U-13C-d7-2H]-
deuterated glucose (CIL Isotopes) for triple labeled anxA1 was added and cultured until 
the glucose was depleted. The bacterial pellet was collected by centrifugation, and the 
proteins were purified by IMAC (GE Healthcare) to homogeneity as determined by 
silver-stained SDS-PAGE and MALDI-TOF/TOF analysis. The His-tag was removed 
from His-anxA1 by Factor Xa-cleavage as also discribed in Chapter 4.
NMR spectroscopy - NMR spectra were recorded on a Bruker Avance III HD 700 MHz 
spectrometer operating at a 1H frequency of 700 MHz and equipped with a triple channel 
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TCI cryoprobe. Stock solutions of expressed and uniformly labeled 13C15N-His-anxA1 (2.8 
mg/ml), 13C15N-anxA1 (1.7 mg/ml) and 2H13C15N-anxA1 (0.2mg/ml) were kept in 50mM 
Tris and 140mM NaCl buffer (pH 7.4) at 4°C. Stock solutions were concentrated using 
ultra-centrifugal filter units with a 10kDa cut-off (Millipore). For assignment purposes, 
13C15N-anxA1 (30mg/ml) and 2H13C15N-anxA1 (12.3 mg/ml) were prepared in 3mm 
NMR tubes (Wilmad) in sample buffer (50mM Tris, 140mM NaCl, 10mM Ca2+, pH 
7.40). The deuterium lock was obtained by adding 5-7% (v/v) of D2O to 152μl sample 
volume and 1μl of 1mM 4,4,dimethyl-4-silapentane-1-sulfonic acid solution (DSS, 
Sigma) was added to the NMR sample to act as internal chemical shift reference for 1H 
of 0ppm to a total volume of 160μl. Removal of Ca2+ ions in the apo-anxA1 control 
NMR samples was achieved by addition of 0.1mM EDTA during ultracentrifugation. 
NMR pulse sequences of acquisition spectra were taken from the standard Bruker pulse 
sequence library. Conventional NMR spectra were recorded with selective suppression of 
water using excitation sculpting techniques. Two dimensional (2D) heteronuclear single 
quantum coherence  (HSQC) 15N-1H, 2D transverse relaxation optimized spectroscopy 
(TROSY) 15N-1H and 2D HSQC constant-time 13C-1H were acquired using sensitivity 
enhancement and gradient pulses. For resonance assignment purposes, backbone triple 
resonance spectra were TROSY variants of the following three-dimensional (3D) pulse 
sequences: HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, HN(CO)CACB. 
Additional NMR spectra were acquired using 3D HCCH-DIPSI, carbon-detected 2D 
C_CON and C_CAN spectra (13C15N samples), 3D TROSY-NOESY, and 3D HN(CO)
CANNH and 3D HNCANNH triple resonance spectra (2H13C15N sample) 17. Typically, 
NMR free induction decays were apodized with cosine square window functions and 
zero-filled once or twice prior to Fourier transformation. The resolution in the indirect 
proton, carbon or nitrogen dimensions of 2D and 3D spectra were normally enhanced by 
applying forward linear prediction up to twice the original digital resolution. Acquisition 
of spectra was performed using the Bruker program Topspin (v3.2), and analysis (peak-
picking and integration) of processed NMR data was done using the program Sparky 
(version 3.114). 
Calcium and sodium titrations - Specificity of calcium binding was investigated by performing 
a calcium titration of a highly concentrated sample of 13C15N-anxA1 (30mg/ml) buffered 
in Tris 50mM (pH 7.4). NMR spectra were acquired at 30 and 140 mM NaCl and 0.5, 
1.2, 2.8 and 10 mM calcium. For titration with sodium up to 500mM Na+, the buffer was 
exchanged with NaCl–free, 50mM K3PO4 (pH 7.4) supplemented with 0.1mM EDTA.
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NMR spectra acquired on anxA1 with small unilamilar vesicles - NMR samples of anxA1 
in small, phospholipid unilaminar vesicles (SUV) were prepared by mixing the protein 
solution with a freshly prepared stock solution of 30mM SUV particles (80% DOPC/20% 
DOPS in Tris 50mM, 140mM NaCl, 0.1mM EDTA). The phospholipid stock solution 
was sonicated for 10 minutes to obtain SUV particles of roughly 20nm in diameter, and 
the pH was adjusted to pH 7.4. All SUV solutions were characterized by collecting and 
analyzing 1H and natural abundance 13C NMR spectra. A concentrated stock solution (9.9 
mg/ml) of 13C15N-labeled apo-anxA1 (12-346) was used with calcium being rigorously 
removed from solution by EDTA chelation and diluted to a final protein concentration 
of 1.6mg/ml protein and 24mM of total phospholipid. Calcium-mediated anxA1-lipid 
complexation was made by adding concentrated CaCl2 (up to 2.5mM Ca
2+) to the apo-
protein-lipid mixture. 
Results
Production of 13C15N-anxA1 and 2H13C15N-anxA1 for NMR analysis
Isotopically enriched anxA1 was produced recombinantly. Bacterial oxygen consumption 
was greatly reduced when 12C-glucose was depleted. At that point, 13C-glucose and 
IPTG were added to induce expression of isotopically-labeled His-tagged anxA1 (His-
anxA1) (supplementary Figure S1). Purity and homogeneity were checked on silver-
stained SDS-PAGE (Figure 2A), Western blotting (Figure 2B) and MALDI-TOF/TOF 
analysis (Figure 2C). Theoretical and empirical molecular weights for double and triple 
isotopically-labeled His-anxA1 and anxA1 were 42.9kDa and 40.5kDa for double-labeled 
protein, and 45.8kDa and 43.3kDa for triple labeled protein, respectively, as determined 
by MALDI-TOF/TOF mass spectrometry. Purity was >95% as determined by silver-
stained SDS-PAGE (supplementary Figure S2). Maximum solubility of anxA1 at room 
temperature was found to be approximately 24mg/ml in Tris/NaCl (pH 7.4).
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Figure 2 – Purification of anxA1 for NMR spectroscopy. Silver stained SDS-PAGE (A), Western 
blotting (B) and MALDI-TOF/TOF analysis (C) of the purification of 2H13C15N-anxA1. Silver-
stained SDS-PAGE indicates purity >95% and MALDI-TOF/TOF analysis confirms theoretical 
molecular weight of 42.3kDa for 2H13C15N-anxA1. M-broad range protein marker; L-bacterial 
lysate; F-flow-through; H-2H13C15N-His-anxA1 peak fraction; A-2H13C15N-anxA1; P-anxA1 
(positive control).
Spontaneous N-terminal truncation of 13C15N-His-anxA1 and 13C15N-anxA1
NMR measurements for complete backbone resonance assignments required about 
three weeks of acquisition time. To assess N-terminal cleavage susceptibility of long-term 
incubations, we performed NMR spectroscopy, mass spectrometry, and gel-electrophoresis. 
All three methodologies demonstrated that the first eleven amino acids were susceptible 
to degradation, whereas Trp-12 remained unaffected. In the 2D 15N-HSQC spectrum, 
the readily identifiable side chain Hε proton of Trp-12 appeared as two well-resolved 
resonances, one corresponding to intact anxA1 and the other to (Δ2-11) truncated 
anxA1(12-346). Based on the ratio between the two peaks, complete conversion would 
take months at 4°C. The formation of truncated anxA1(12-346) was also observed for 
His-anxA1. Silver stained SDS-PAGE and MALDI-TOF/TOF analyses on these NMR 
samples confirmed the loss of amino acids 2-11 (Supplementary Figure S2). 
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AnxA1 has two calcium dependent conformations. 
To assess helix insertion as function of calcium binding, two NMR constructs of anxA1 
were investigated: N-terminally His-anxA1 and full-length anxA1(2-346) (Figure 3A, 
B). Preliminary data on unlabeled protein showed that anxA1 may be kept in various 
buffers to a maximum concentration of 15mg/ml at 37°C. NMR spectra recorded at 
low (1.7mg/ml) and saturated (≥24 mg/ml, partially precipitated) protein concentration 
appeared to be essentially the same. Therefore, most samples used for 3D-NMR backbone 
assignments were recorded using saturated protein solutions. Comparison of the 15N1H 
HSQC spectrum of double- and triple-labeled anxA1 showed comparable spectral patterns 
and similar peak intensities, indicating that all amide deuterons were back-exchanged to 
protons in the folded protein of the triple labeled sample. N-terminal degradation had 
negligible effects on NMR spectra of calcium bound anxA1. Because more backbone 
N-H resonances were observed than expected, we concluded that several conformations 
of apo-anxA1 were present in the sample. Several amide peaks were separated into two 
slightly offset signals exhibiting a constant intensity ratio of estimated 2:1. This ratio 
was not affected by N-terminal cleavage at Trp-12, and appears to be independent of the 
protein concentration and method of isotope labeling.
The NMR spectrum of anxA1 closely resembles the crystal structure
Figure 2A shows the 2D TROSY 15N-1H spectra of triple-labeled, back-exchanged anxA1(2-
346) in the absence (grey cross peaks) and presence (black cross peaks) of calcium. Note 
that these spectra differ considerably. Focusing on Trp-12, it is apparent that there are 
three broad signals in the apo-form (Figures 3B and 4A), yet only a single, sharp peak in 
the calcium bound state (Figures 3B and 4A). Tripling of peaks is also detected in other 
areas of the spectrum, implying the presence of three slowly exchanging states of apo 
anxA1 and one stable, calcium-bound state. In apo-His-anxA1, the Trp-12 Hε-group 
appears as a single resonance at the identical position as that in the calcium bound state 
in anxA1 (Figure 3B), indicating similar structural environments. The calcium-bound 
His-anxA1 and calcium-bound anxA1 yield very similar spectra, indicating analogous 
structures over this shared sequence. In 13C-1H HSQC spectra, there are only minor 
differences between calcium-bound His-anxA1 and calcium-bound anxA1 (Figures 4A 
and 4B). This spectral region mainly contains peaks of hydrophobic amino acid residues 
(Met, Ala, Val, Ile and Leu). With His-anxA1, there are some additional resonances 
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arising from linker residues Met(-21) and Ile(-4). Differences in chemical shifts of some 
of the remaining resonances are consistent with perturbations induced by the linker on 
the N-terminus, which results in a rather large displacement in the position of the Ala-2 
methyl group (see arrow in Figure 5B).
Figure 3 – 15N-1H HSQC spectrum of 13C15N-anxA1 in an overlay of apo-anxA1 (grey) and calcium 
bound anxA1 (black). Overview spectrum (A) and an expanded zoom view (B) of the rectangled 
region in the left spectrum. Backbone amino groups belonging to Asn, Gln or Arg and Nε amides 
of the sidechain can be determined based on chemical shifts alone and are and indicated in the 
plot (A). Of interest are the sharp downfield shifted Nε amino signals of arginines, which are a 
strong indicator for the presence of salt bridges between Arg side-chains and Glu or Asp carboxyl 
groups. The salt bridges are preserved after calcium binding, since the number of peaks remains 
equal and only minute chemical shifts occur.
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Figure 4 – 15N-1H HSQC spectrum of 13C15N-His-anxA1 and 13C15N-anxA1 containing Hε 
Trp-12 at high protein concentrations.  The apo-form of anxA1(2-346) shows three broad 
peaks (grey) of which only one state is promoted in the presence of excess calcium (black peak) 
(A). The His-anxA1 shows one major peak for Hε Trp-12 in the apo form (grey) at the identical 
position of the calcium bound form of anxA1 (black). *The grey peak on the left is assigned to a 
small percentage of truncated apo-anxA1(12-346) (B).
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Figure 5 – 13C-1H HSQC spectra of His-tagged and full-length anxA1. Comparison between 
13C15N-anxA1(2-346) (A) and His-tagged 13C15N-anxA1 (-21-346) (B) in saturated calcium and 
of AnxA1(2-346) in the presence of EDTA (C). Chemical shifts between the apo and the calcium 
bound form of anxA1(2-346) with focus on the methionines (arbitrarily numbered I-VIII) (D).
Sodium causes chemical shift profiles comparable to calcium in the absence of calcium
In the 13C1H HSQC spectrum, chemical shifts of side chain methyl resonances are 
greatly influenced by the binding of calcium. Note the changes in calcium bound anxA1 
(Figure 5A) and His-anxA1 (Figure 5B) compared to the apo state (Figure 5C). It is 
most interesting to focus on the eight well-resolved methionine methyl groups in anxA1 
(Figure 5D). The addition of increasing amounts of calcium or sodium induces chemical 
shift changes in at least three out of these eight methionine resonances (labeled V, VI and 
VII in Figure 6). In absence of calcium and at low sodium salt resonances are split up in 
two components, indicated “a” and “b”, and that merge into a single peak at higher salt 
conditions. AnxA1 in the presence of 140mM NaCl is comparable to anxA1 in 50mM 
K3PO4 and 0.5mM calcium, indicating that NaCl can induce overall structural changes 
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that are normally associated with calcium binding. Met-VII shows the highest affinity 
for calcium with a Kd value below 0.5mM, whereas Met-IV must be distant from the 
calcium binding site because its resonance is not chemically shifted during the titration.
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Figure 6 - 13C-1H HSQC spectrum showing the effect of sodium and calcium on the methionines 
of anxA1. The methyl group of Met-3 is too broad to detect in the absence of calcium, but appears 
and sharpens with increasing calcium concentrations. Met VII (and to lesser extent II and V) 
display two clear signals in the spectra recorded with no added Na+ and low concentration of 
30mM NaCl (denoted ‘a’ and ‘b’). Above 100mM NaCl the two peaks of Met VII signal start to 
merge into a broad peak, confirming the presence of a dynamic conformational switch in the apo 
form induced by calcium binding. The peak of Met VII is most broadened at 0.5mM Ca2+ and 
for that reason the lowest contour level has been set four times lower (indicated in the squared 
box). The peak labeled with a question mark is unassigned for now, but most likely corresponds 
to a methyl group of an Ala in close proximity to one of the calcium binding loops.
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Calcium induced anxA1 phospholipid binding causes temperature dependent precipitation
Although solutions of SUV without protein are very stable, the mixture of cleaved apo 
13C15N anxA1(12-346) and SUV is observed to precipitate slowly at 37°C (Figure 7A). 
On the other hand, the signals from phospholipid also decrease over time (Figure 7B), 
suggesting formation of insoluble complexes between particles of SUV and the protein. 
Precipitation is completely blocked at room temperature (Figure 7C), and addition of 
calcium promotes rapid precipitation under all conditions. Analysis of a conventional 
1D NMR spectrum indicates the loss of at least 80% of the protein (lower panels 
Figure 7A-C), but then the sample remains unchanged for days. Increasing the calcium 
concentration and lowering the incubation temperature yields similar results (Figure 
7C). AnxA1 resonances that remain in the HSQC spectrum are in fact a subset of minor 
peaks already present in the original spectrum (Figure 7D). This fraction of the protein 
is not considered capable of binding DOPS phospholipids in the presence of calcium.
Discussion
Currently, there are no solution structures of native, full-length human anxA1, and most 
of our knowledge about the structure of anxA1 comes from crystallographic studies 
of porcine anxA1 6, 12 or of truncated (Δ1-32) human anxA1 15. Human and porcine 
anxA1 have 89% sequence identity, therefore many of their structural features should be 
conserved. More recently, the high-resolution crystal structure of annexin B22 from the 
malaria parasite Schistosoma mansoni 18 has become available. This structure also has the 
highly conserved annexin folding motif. By analysis of our NMR data, we have been able 
to partially assign backbone and side chain resonances for human anxA1. Based on these 
preliminary results, it appears that in solution anxA1 is a quite dynamic molecule that 
exploits the binding of calcium as a structural switch to modulate its biological function 
and binding to cell membranes. 
Each of the four annexin domain repeats (D1 to D4) can bind up to two calcium ions 6, 
19. This significantly affects the position of the N-terminal tail (2-32) and therefore the 
possibility of the protein to interact with FPR-2. Based on our NMR data, the structures 
of calcium bound His-anxA1 and anxA1 are very comparable. However, residues at the 
N-terminus of apo-anxA1 (Ala-2, Met-3 and Trp-12) exist in multiple conformations, a 
feature that is not found in apo His-anxA1. If the His-tag itself sterically hinders insertion 
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Figure 7 – The effect of calcium dependent lipid binding of anxA1 in solution. The top spectrum 
shows the reference SUV spectrum. Incubation of SUV with apo-anxA1(12-246) is followed for 
18 hours at 37°C (A, B, middle spectrum) and 20°C (C), showing a small loss of protein signal (A) 
and phospholipid signal (B) but not at 20°C (C). Small impurities like chloroform are indicated 
with asterisks. The bottom two spectra show the loss of proton signal immediately after addition 
of calcium at 0 and 18 hours. Arrows indicated downward movement of complete spectrum. 
Overlay of 13C-1H HSQC of 13C15N-AnxA1(12-346) in the absence of calcium (grey) and after 
addition of an excess of calcium (black) at 37°C (D). Addition of calcium caused a removal of 
most native anxA1 resonances. The proton signals of the natural occurring 13C atoms (1.1%) of 
the phospholipids are relatively large and prominently present in the spectra (indicated as ‘SUV’). 
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of the N-terminal tail into the protein, then the N-terminal helix, as hypothesized, should 
be preferentially inserted into the core of the protein in absence of calcium. The non-linear, 
curved nature of chemical shift trends of anxA1 Met-VII and VIII resonances during the 
calcium titration strongly suggests the presence of a multi-state equilibrium that includes 
various intermediate states, each having a different calcium binding affinity. Moreover, 
this suggests the presence of a cooperative process in which calcium binding to one 
binding site influences the affinity of calcium binding to another site. The conformation 
and functionality of anxA1 are highly dependent on the sodium concentration. We 
114
Chapter 6
have demonstrated that anxA1 is only active at a physiological salt concentration. This 
salt-stabilized form should be considered the initial state for the calcium-specific switch, 
although the same state can also be reached at low calcium concentration. The lower 
affinity binding sites have apparent dissociation constants of about 1 to 2mM. Saturation 
of all calcium binding sites occurs at 10mM calcium. Even at 30mg/ml anxA1, calcium 
binding has its saturation point near 20mM calcium. Thus, in absence of lipid, the fully 
calcium-bound state of anxA1 is attained at a calcium:protein molar ratio of about 25:1. 
Furthermore, our NMR data demonstrate that in the absence of calcium or another divalent 
cations, anxA1 interacts only weakly with a lipid bilayer comprised of small, unilaminar 
phospholipid vesicles (SUV). In fact, our NMR spectra of apo-anxA1 in the presence 
and absence of SUV vesicles are virtually indistinguishable, indicating the absence of 
any significant structural changes to the protein in the phospholipid environment. On 
the other hand, we observed a relatively strong association between anxA1 and DOPS-
phospholipids even at low levels of calcium. At higher levels of calcium, however, SUV-
anxA1 complexes precipitate and NMR signals are lost. This supports previous findings 
that anxA1 promotes aggregation of phospholipid vesicles in a calcium-dependent manner 
20. AnxA1-mediated vesicle aggregation, which probably involves homotypic dimerization 
21, is dependent on the presence of its N-terminal tail 22. This phenomenon precludes 
NMR-based structural analysis of the influence of calcium and phospholipids on the 
topology of the N-terminal tail in full-length anxA1.
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Supplemental Figures
Supplemental Figure S1 – Oxygen saturation and glucose consumption of anxA1 fermentation in 
time. Oxygen and glucose consumption were continuously monitored, bacteria completely stopped 
oxygen consumption when glucose was depleted. At this point 13C-glucose was added together 
with IPTG to induce protein production.
Supplemental Figure S2 – Silver-stained SDS-PAGE after NMR analysis. Silver-stained SDS-
PAGE gel (A) enlarged (B) of 50ng protein demonstrates partial degradation 13C15N-anxA1 and 
His-tagged 13C15N-anxA1 after diverse NMR measurements. M) broad range protein marker; 
1) His-tagged 13C15N-anxA1; 2) 13C15N-anxA1; 3) Tris-NaCl-EDTA-NMR 13C15N-anxA1; 4) 
K3PO4-NaCl-EDTA-NMR 
13C15N-anxA1; 5) His-tagged 13C15N-AnxA1 completely truncated
M 1 2 3 4 5 M 1 2 3 4 5
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Cardiovascular disease (CVD) is the leading cause of death in the Western societies 
and accounts for over 17 million deaths world-wide annually 1. Atherosclerosis is the 
predominant underlying pathology for CVD and contributes most to the morbidity and 
mortality 2. Cell death by apoptosis contributes largely to the growth and progression of 
atherosclerotic lesions. One of the first hallmarks of cell death is the externalization of the 
phospholipid phosphatidylserine (PS). Annexins are calcium and phospholipid binding 
proteins that belong to an evolutionary well conserved multigene family, with members 
of the family being expressed throughout animal and plant kingdoms 3. All annexins 
bind calcium dependently and reversibly to negatively charged phospholipids thereby 
regulating membrane-associated processes. This thesis centers around two members of 
the annexin family, annexin A1 and A5. Annexin A1 (anxA1) is involved in intracellular 
vesicle trafficking as well as in regulation of neutrophil activity through binding the 
extracellular domain of members of the formyl peptide receptors (FPR) 4 and is a well-
known anti-inflammatory protein that operates on the glucocorticoid axis. AnxA5 is 
most famous as (molecular) imaging agent to visualize cell surface expressed PS 5. The 
(patho)physiology of anxA5 is less apparent, it is known that anxA5 inhibits the activity 
of prothrombinase 6 and is linked to the antiphospholipid syndrome 7.
This thesis focused on the role of anxA1 and anxA5 in cardiovascular disease. We have 
investigated the role of endogenous anxA5 in atherogenesis (I). Furthermore we have 
studied the effect of exogenous anxA1 on atherosclerosis (II) and ischemia-reperfusion 
injury (III). Additionally, we have investigated the efficacy of low-anticoagulant heparin 
(AADH) on ischemia-reperfusion injury (IV). Finally, we performed a structural NMR 
analysis of anxA1 in order to obtain more insight in the structure-function relationship 
of this protein (V).
The key findings of this thesis are:
(I) Endogenous anxA5 inhibits efferocytosis of apoptotic cells and aggravates plaque 
development (chapter 3).
(II) Exogenous anxA1 reduces plaque progression and increases plaque stability 
(chapter 4).
(III) Exogenous anxA1 reduces ischemia-reperfusion injury and improves cardiac 
function (chapter 5).
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(IV) AADH reduces ischemia-reperfusion injury without improving cardiac function 
(chapter 5).
(V) AnxA1 has a single closed conformation with a concealed N-terminal tail in 
absence of calcium ions; the presence of calcium ions induces a conformational 
change towards two stable open conformations (chapter 6).
Impaired efferocytosis promotes plaque progression.
Histological analysis of advanced atherosclerotic lesions demonstrates the presence of 
large necrotic and acellular regions 8. Even though necrosis is involved, consensus is that 
the vast majority of dying cells in the lesion execute apoptosis 9. This is supported by the 
detection of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) 
and active caspase-3 in atherosclerotic lesions 10. Whereas in histological sections of 
healthy tissues apoptosis is only rarely observed, due to swift clearance mechanisms 
such as efferocytosis 11. Several phases of efferocytosis can be distinguished; attraction of 
phagocytes, recognition, engulfment and post-engulfment responses 12. Cells executing 
apoptosis release soluble attractants or “find me” signals to recruit phagocytes. Examples 
are an ATP gradient and lysophosphatidylcholine (LPC) 13. After attraction, exposure 
of PS on the exoplasmic leaflet of the plasma membrane of apoptotic cells is the most 
prominent “eat me” signal for phagocytes 14. Therefore, cell surface expressed PS is an 
ideal target for molecular imaging of vulnerable atherosclerotic plaques (chapter 2). 
The balance between positive (“eat me”) and negative (“don’t eat me”) signals determine 
whether efferocytosis is initiated or not 11. Exposure of PS on the apoptotic cell as well 
as on the phagocyte is necessary for proper efferocytosis 15. However, PS by itself does 
not suffice for adequate efferocytosis; certain bridging molecules facilitate/opsonize the 
interaction between apoptotic cell and phagocyte 16. Molecules like complement factor 
C1q, anxA1, pentraxin and thrombospondin-1 have been shown to opsonize apoptotic 
cells and facilitate clearance 17, 18. However, the phagocytic function is impaired in 
atherosclerosis, which results in accumulation of extracellular apoptotic debris and high 
numbers of apoptotic cells 19. This impaired phagocytic function is explained by several 
factors. First there is competition of apoptotic cells and oxidized lipids for phagocytes 19, 
20. Furthermore, direct oxidative stress and the uptake of oxidized lipids by macrophages 
leading to foam cell formation, impairs their ability to engulf apoptotic debris 12, 19. 
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Efferocytosis as target in atherosclerosis
The importance of proper efferocytosis is shown by aggravation of atherosclerosis when 
clearance of apoptotic cells is impaired 19. Individual deficiency of opsonins such as 
lactadherin, MERTK or C1q lead to impaired efferocytosis, and thus enhanced accumulation 
of apoptotic cells and subsequent increased necrotic core and plaque development 21-23. 
Therefore, enhancing efferocytosis would be a feasible approach to treat atherosclerosis 
24. This thesis focuses on two less obvious proteins involved in efferocytosis: anxA1 and 
anxA5. Intraperitoneal injection of anxA5 has shown to reduce plaque formation by 
suppressing inflammation. This suppression results from the effect of anxA5 on endothelial 
cells and inhibition of proinflammatory mediators like oxidized cardiolipin and LPC 
25-28. We have shown that anxA5 deficiency results in a significant attenuation of plaque 
formation (chapter 3). Moreover, plaques had features of a more stable phenotype as 
deduced from decreased TUNEL positivity and a smaller necrotic core. In order to 
determine whether this reduced detection of apoptotic cells is a result of anxA5 mediated 
diminished susceptibility to apoptosis or an increased clearance of apoptotic cells, we 
have performed additional experiments. We showed that anxA5 deficiency does not 
result in reduced susceptibility to apoptosis as a result of oxidative stress. In addition, we 
demonstrated that anxA5 deficient peritoneal macrophages display increased phagocytosis 
of apoptotic cells. Frey et al. showed that anxA5 deficient macrophages have increased 
capacity to phagocytose secondary necrotic cells and exhibit an anti-inflammatory 
cytokine profile 29. We hypothesized that this anti-inflammatory response could induce 
a difference in macrophage polarization. Polarization of atherosclerotic macrophages 
towards an anti-inflammatory phenotype is important for the stability of the lesion 
30. However, we could not confirm that macrophage polarization was affected in the 
atherosclerotic lesions between anxA5 deficient and wild-type mice. Interestingly, we did 
find a difference in anxA5 expression of polarized macrophages in vitro. Stimulation of 
M1 polarized macrophages with LPS caused a significant upregulation of anxA5 promoter 
activity. We hypothesize that anxA5 exhibits an intracellular function in the regulation 
or maintenance of macrophage polarization after activation. Our hypothesis is supported 
by the finding that expression of anxA5 is more pronounced in macrophages located in 
the center of the lesions or at the edges of the necrotic core of more advanced lesions. 
Since this location is subjected to high numbers of apoptotic and necrotic cells and thus 
macrophage activation 31 it is temping to speculate that this may influence macrophage 
polarization. However, we did not find a link between anxA5 expression and macrophage 
polarization in the atherosclerotic lesions. 
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Neutrophils as target in atherosclerosis
Standard treatment of atherosclerosis is lowering LDL cholesterol and triglyceride levels and 
reducing blood pressure by statins (HMG-CoA reductase inhibitors) and antihypertensive 
medication, respectively 32, 33. Additional or alternative targets have been subject of intense 
research, examples are myeloperoxidase (MPO) 34 and phospholipase A2 (PLA2) 35, 36. 
Both PLA2 and MPO are profoundly linked to neutrophils. PLA2 activates neutrophils 
and MPO is a major part of the neutrophils granule proteins and causes the generation of 
reactive oxygen species (ROS). The role of neutrophils in atherosclerosis has been subject 
of serious debate for years, particularly because the detection in atherosclerotic lesions 
is minute 37, 38. Nevertheless, there is current scientific consensus that neutrophils are 
involved during all stages of atherosclerotic plaque development 37, 39. AnxA1 is known 
to exert its anti-inflammatory effect predominantly by direct inhibition of neutrophil 
activity 40. Additionally, anxA1 is known to inhibit PLA2 activity 17. AnxA1 exerts direct 
anti-inflammatory functions by binding to the receptor for formylated peptides (FPR) on 
neutrophils and can serve as opsonin by binding PS on the apoptotic cells and bridging 
them to phagocytes 41-43. Both routes of action result in an anti-inflammatory response 
44-46. Because of these anti-inflammatory properties, we treated atherosclerosis prone 
mice with endogenous anxA1 and investigated the effect on atherogenesis (chapter 4). 
We showed that anxA1 treatment reduces total plaque size in LDLR-/- mice. Moreover, 
anxA1 treatment attenuated plaque progression, predominantly in the later stages of 
plaque development. we hypothesized that these effects are caused by a combination of 
enhanced opsonization of apoptotic debris and the direct anti-inflammatory effect of 
anxA1 on neutrophils. Supporting this premise is the significantly smaller necrotic core 
in anxA1 treated animals. In concordance with previous reports, we observed a relative 
increase in circulating granulocytes resulting from prolonged anxA1 treatment, without 
affecting bone marrow composition 42. The increase in circulating neutrophils is most 
likely caused by an influx of neutrophils from the margins of the blood vessel rather than 
reduced apoptosis or increased release from the bone marrow, an effect that has previously 
been observed after corticosteroid treatment 47. 
Neutrophils as target in ischemia-reperfusion injury
Restoring myocardial reperfusion after an ischemic attack is essential for cardiac functionality, 
however may initiate a second phase of myocardial injury called reperfusion injury 48. 
Reperfusion injury is predominantly caused by neutrophil derived reactive oxygen species 
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(ROS), the excretion of proteases and the production of proinflammatory chemokines and 
cytokines 48-51. Neutrophil extracellular traps (NETs) are put forward as major contributors 
of hind-limb reperfusion injury 52. However, their contribution to reperfusion injury of 
the heart is hitherto not proven. NETs are composed of a complex network of DNA and 
proteins such as histones and neutrophil elastase 53. Histones in particular exhibit cytotoxic 
activity towards host cells 54. Because of their strong positive charge, they form an apposite 
target for treatment with a strong negatively charged moiety like antithrombin affinity 
depleted heparin (AADH). We treated mice with anxA1 to target neutrophil infiltration 
and with AADH to neutralize neutrophil derived histones (chapter 5). Since it is known 
that anxA1 and AADH interact with each other 55, 56, the combination of both was not 
performed. The capacity of anxA1 to reduce neutrophil influx and activity has already been 
shown in several animal models of both acute and chronic inflammation 57-59. Additionaly, 
anxA1 and the anxA1 N-terminal peptidomimetic (Ac2-26) are able to reduce neutrophil 
dependent damage to cardiomyocytes within the first few hours of reperfusion 60, 61. We 
investigated whether anxA1 treatment could reduce cardiomyocyte damage 24 hours after 
start of reperfusion and subsequently diminish loss of cardiac function. Our results show 
that treatment with a bolus injection of anxA1 indeed significantly reduced infarcted area 
at 24 hours of reperfusion. This protective effect was less than seen for data published 
at 2 hours of reperfusion 60. Whether multiple injections of anxA1 during the first 24 
hours of reperfusion can improve the protective effect needs to be determined. Moreover, 
we are the first to show that a bolus injection of anxA1 reduces loss of cardiac function 
after 24 hours of reperfusion treatment, both at baseline and in response to dobutamin 
stimulation. Interestingly, the amount of infiltrated neutrophils 24 hours after start of 
reperfusion was equal to untreated controls, suggesting that reduction in damage occurred 
at an earlier time point. There is evidence that neutrophils are required for anxA1 to be 
cardioprotective, even if anxA1 does not reduce the influx of neutrophils in the area at 
risk. However, the exact mechanism remains to be elucidated 62. Ritchie et al. hypothesized 
that Ac2-26 has a direct protective effect on cardiomyocytes 63 and recently proposed that 
this protective effect is caused by enhanced activation of cardioprotective signaling and/
or improved intracellular calcium re-uptake by the sarcoplasmic reticulum 61, 63. Whether 
this cardioprotective effect is FPR-mediated is still subject of discussion, since blocking 
FPR with antagonists partly abolishes the protective effect of anxA1 and its N-terminal 
peptidomimetic 61, 64 whereas FPR gene deletion does not alter the cardioprotective 
effect afforded by the N-terminal peptidomimetic 62. However, it might also be that 
the improvement we have measured in cardiac function is not merely dependent on 
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neutrophils. Nevertheless, our results further support the hypothesis that anxA1 exerts a 
direct protective effect on cardiomyocytes. In addition to a possible direct protection of 
anxA1 on the cardiomyocytes, we have investigated whether AADH treatment would 
reduce histone-mediated cardiomyocyte damage. It has been shown in a murine model of 
sepsis that neutralizing histones with AADH improves survival by decreasing cytotoxicity 53. 
We show that treatment with AADH successfully reduces infarct size, but fails to improve 
cardiac function. The mechanism of protection by AADH remains to be elucidated, but 
may be linked to the reduction heart rate, which decreases the cardiac energy requirement 
and thus oxygen consumption. Since actual damage by neutrophil derived histones may 
take longer than 24 hours, prolonged treatment with AADH possibly leads to improved 
function. This has to be tested in future experiments. 
Structural analysis of anxA1
The structure and availability of cleavage or binding sites is essential for functionality of 
anxA1. Structural analysis of full-length anxA1 thus far has only been performed using 
X-ray crystallography 65. AnxA1 undergoes a conformational change after calcium dependent 
phospholipid binding, exposing a secondary membrane binding site 3, 66. This secondary 
binding site consists of 4 consecutive amino acids and form the basis for the interaction 
between anxA1 and FPR 67. Although structural nuclear magnetic resonance (NMR) 
studies on anxA1 were initiated over 2 decades ago 68, thus far only the first domain has 
been defined 69. This NMR analysis was performed on double isotopically labeled isolated 
anxA1 domain 1. We have produced full-length AnxA1 protein triple isotopically labeled 
and focused on the N-terminal domain (chapter 6). We show that anxA1 has a single 
closed conformation in the absence of calcium, but has two stable open conformations in 
the presence of calcium, in a 2:1 ratio. Even in the absence of a phospholipid membrane 
there is motion of the AnxA1 N-terminus, suggesting that the interaction with the FPR 
might be possible even without a phospholipid surface. Currently we are further defining 
the structure and conformation in presence and absence of phospholipid vesicles and 
with or without competition of the N-terminal peptidomimetic Ac2-26. Future research 
includes NMR measurements in the presence of FPR-transfected cells in order to advance 
knowledge on the interaction between anxA1 and FPR. 
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Clinical implications and future perspectives 
Basic medical science aims to elucidate novel molecular pathways or targets to reveal 
innovative treatments. The search for innovative theranostics and personalized medicine 
will continue in decades to come. Our research on the role of anxA1 and anxA5 in 
cardiovascular disease has identified novel targets for development of innovative new 
medication. The immune system is key in many diseases involving injury/wounding, 
infection, transplantation and auto-immunity. Efferocytosis is unequivocally linked to the 
immune system, and we show important roles for annexins. AnxA5 exhibits inhibitory 
whereas anxA1 has stimulatory properties. Further research should identify whether 
administration of anxA5 or stimulation of anxA5 gene activity is a target in e.g. graft-
versus-host immune responses in order to reduce organ rejection after transplantation. 
Alternatively, inhibition of anxA5 activity by e.g. morpholinos potentially forms a target 
for chronic inflammatory diseases like rheumatoid arthritis or lupus erythematosus. 
For anxA1 similar treatment avenues are paved. Our research has led to the large-scale 
production and augmentation of anxA1, which offers a great opportunity to test and 
further expand this research both in vitro and in vivo.
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Figure 1 – overview of the research chapters in this thesis. After an introductory chapter, current 
molecular imaging modalities of the vulnerable plaque are evaluated in chapter 2. One of the 
targets for molecular imaging is phosphatidylserine (PS) imaging with annexin A5 (anxA5). The 
role of endogenous anxA5 in the development of atherosclerosis is subject of chapter 3. The role 
of anxA5 in the process of efferocytosis is emphasized. Another member of the annexin family, 
annexin A1 (anxA1), is known to have potnent anti-inflammatory properties. Treatment of 
atherosclerosis prone mice with anxA1 is the subject of chapter 4. Without treatment, plaque 
progression continues and may lead to plaque rupture over time. This rupture causes occlusion of 
a blood vessel, which in turn causes ischemia to downstream tissue. Chapter 5 discusses treatment 
of ischemia-reperfusion injury of the heart by inhibition of neutrophil infiltration and neutrophil 
extracellular trap (NET) formation. Finally, nuclear magnetic resonance analysis of isotopically 
labeled anxA1 is discussed in chapter 6.
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Addendum I
Summary
In this thesis main focus was on the role of annexin A1 (anxA1) and annexin A5 (anxA5) 
in cardiovascular disease with emphasis on atherosclerosis and ischemia-reperfusion injury. 
Chapter 1 highlights the importance of cardiovascular disease and potential roles that 
anxA1 and anxA5 may have herein. Atherosclerosis is initiated by dysfunctional endothelial 
cells and consequent leakage of plasma low density lipoprotein (LDL cholesterol) into the 
tunica intima of arteries. Oxidation of LDL activates endothelial cells and subsequently 
leads to the recruitment of inflammatory cells in an attempt to remove the cholesterol. 
Migration of monocytes into the tunica intima and subsequent differentiation into 
macrophages initializes the inflammatory response. Excessive uptake and accumulation 
of cholesterol in combination with ineffective secretion will lead to the formation of 
‘foamy’ cells that lose the ability to egress from the plaque and eventually will die. The 
build-up of apoptotic/necrotic cells in combination with the inflammatory status of the 
plaque is a very good predictor of plaque vulnerability and can therefore form a target 
for molecular imaging as discussed in chapter 2. 
Viable cells retain a phospholipid asymmetry in which they confine their phosphatidylserine 
(PS) predominantly to the inner leaflet of the plasma membrane. Externalization of PS is 
one of the first hallmarks of stressed and dying cells. The two most important ways that 
cells can die are apoptosis and necrosis. Apoptosis is programmed and anti-inflammatory 
while necrosis is accidental and proinflammatory. Both during apoptosis and necrosis PS 
exposure serves as the most pronounced pro-phagocytotic ‘eat-me’ signal. AnxA5 binds 
with high affinity to PS thereby inhibiting phagocytosis, either simply by shielding PS 
from the phagocyte or even complete internalization of PS. In chapter 3 we report the 
impact of anxA5 depletion on atherosclerotic plaque development and progression. We 
found that anxA5 deficient macrophages display increased phagocytotic activity and 
in this way decrease plaque formation. Moreover, plaques of the anxA5 mice had less 
apoptotic cells and no significant necrotic core development. This finding was not caused 
by a difference in cell viability, but rather a difference in cell clearance. The decrease in 
plaque development was more pronounced in the aortic arch than in the brachiocephalic 
artery, possibly due to a difference in developmental speed and/or different developmental 
origin of the vascular cells.  
The previous chapter underlines the importance of proper efferocytosis in atherosclerotic 
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plaque development, so we decided to use this property in the next chapter. AnxA1 is 
known to be an opsonin of apoptotic cells and to facilitate phagocytosis thereby inducing 
an anti-inflammatory response. In addition to the opsonization, anxA1 can directly affect 
leukocytes by outside-in signaling through the receptor for formylated peptides (FPR). 
Treatment of atherosclerosis prone mice with anxA1 is the main focus of chapter 4. We 
found that administration of anxA1 inhibits plaque growth and improves plaque stability. 
Treatment with anxA1 decreased necrotic core growth by inhibiting recruitment of 
neutrophils towards the plaque and/or by increasing phagocytosis of dying and dead cells. 
Eventually, vulnerable plaques may rupture and release their prothrombotic content leading 
to thrombus formation. Occlusion of an artery by this thrombus causes ischemia and 
subsequent cell death. Surrounding tissue senses the ischemic damage and activates the 
immune system. Like in normal wound healing, neutrophils are the first cells to respond 
and migrate towards the infarcted area. In a complex cascade of events, neutrophils release 
reactive oxygen species (ROS), proinflammatory cytokines and chemokines and neutrophil 
extracellular traps (NETs). This results in reperfusion injury and causes enhanced cell 
death. The potential to intervene with neutrophil recruitment and activity using anxA1 
and antithrombin affinity depleted heparin (AADH) is investigated in Chapter 5. AnxA1 
and AADH were successful to reduce the infarct size and attain a trend towards increased 
functionality. This result may be neutrophil independent, since the amount of infiltrated 
neutrophils was unaffected after 24 hours of reperfusion.
In order to further increase the anti-inflammatory potential of anxA1, more knowledge 
about the exact modus operandi is needed. Structural studies using nuclear magnetic 
resonance (NMR) analysis with isotopically labeled proteins provides information about 
the orientation and behavioral properties of the protein in several (sub)physiological 
conditions. Chapter 6 describes different conformations of anxA1 in the presence or absence 
of calcium and a phospholipid surface. While anxA1 has three ‘closed’ conformations 
in the absence of calcium, the addition of calcium changes the conformation towards a 
single stable ‘open’ conformation. This knowledge may lead to the design of augmented 
forms of anxA1 that possess increased functionality. 
Finally, chapter 7 discusses the key findings of this thesis and highlights the possible 
clinical significance in relation to current literature, Addendum I and II summarize the 
thesis in english and dutch and Addendum III reports a short valorization. 
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Addendum II
Samenvatting
In dit proefschrift ligt de focus op de rol van annexine A1 (anxA1) en annexine A5 (anxA5) 
in hart- en vaatziekten en met nadruk op atherosclerose en ischemie-reperfusie schade. 
Hoofdstuk 1 toont het belang aan van het onderzoek en geeft algemene uitleg over 
hart- en vaatziekten en speculeert over de mogelijke bijdrage die deze annexines hierin 
hebben. Atherosclerose wordt geïnitieerd door slecht functionerende endotheelcellen, 
wat als gevolg heeft dat er lekkage optreedt van plasma ‘lage dichtheid lipoproteïne 
cholesterol’ (LDL cholesterol) in de tunica intima van de slagaders. Een oxidatie reactie 
van dit LDL activeert endotheelcellen, die er vervolgens voor zorgen dat ontstekingscellen 
worden aangetrokken in een poging om het geoxideerd LDL te verwijderen. Migratie 
van monocyten en de daaropvolgende specialisatie tot macrofagen is het begin van de 
ontstekingsreactie. Overmatige opname van cholesterol in combinatie met ineffectief 
uitscheiden leidt tot intracellulaire accumulatie en de vorming van zogenaamde ‘schuim’ 
cellen. Deze cellen verliezen het vermogen om uit de plaque te migreren en zullen hier 
uiteindelijk doodgaan. De opstapeling van deze dode cellen in combinatie met de 
ontstekingsreactie in de plaque is een zeer goede voorspeller van de kwetsbaarheid van 
een plaque en vormt daardoor een perfect doel voor moleculaire beeldvorming, zoals 
besproken wordt in hoofdstuk 2.
Levende cellen zorgen voor een asymmetrie van de membraan fosfolipiden, met het 
fosfolipide fosfatidylserine (PS) voornamelijk gelokaliseerd aan de binnenzijde. Het naar 
buiten transporteren van PS is een van de eerste kenmerken van cellen die stress ervaren 
en van cellen die doodgaan. De twee belangrijkste manieren van celdood zijn apoptose en 
necrose. Hierbij is het verschil dat apoptose geprogrammeerd en ontstekingsremmend is, 
terwijl necrose ongepland is en ontsteking opwekt. Zowel bij apoptose als necrose is PS 
beschikbaar en vormt daarmee het meest bekende ‘eet-mij’ signaal voor fagocyten. Het 
eiwit anxA5 bindt met hoge affiniteit aan PS en remt hiermee de opruiming van deze cellen. 
Enerzijds door simpelweg PS af te schermen voor de fagocyt, anderzijds door de PS terug 
naar de binnenkant van de cel te transporteren. In hoofdstuk 3 beschrijven we de functie 
van anxA5-depletie op het ontstaan en de ontwikkeling van atherosclerotische plaques in 
een muismodel voor atherosclerose. We laten zien dat anxA5 deficiënte macrofagen een 
verhoogde fagocytose vertonen en op die manier atherosclerose afremmen. Bovendien 
hadden de plaques van de anxA5 deficiënte muizen minder apoptotische cellen en geen 
grote necrotische kern ontwikkeld. We hebben aangetoond dat dit resultaat niet werd 
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veroorzaakt door een verschil in verminderde gevoeligheid voor apoptose, maar door een 
verschil in verbeterde opruiming van apoptotische cellen door de fagocyten. De afname 
van plaque ontwikkeling was meer uitgesproken in de aortaboog in vergelijking met 
de eerste aftakking (de truncus brachiocephalicus), wat mogelijk een gevolg is van een 
verschillende snelheid van ontwikkeling en/of een verschillende embryonale oorsprong 
van de vasculaire cellen.
In het vorige hoofdstuk is het belang van goede efferocytosis met betrekking tot 
atherosclerotische plaque ontwikkeling benadrukt. We hebben besloten om deze eigenschap 
te gebruiken in het volgende hoofdstuk. AnxA1 speelt een belangrijke stimulerende rol 
bij het opruimen van apoptotische cellen en wekt daarbij een ontstekingsremmende 
respons op. Hiernaast kan anxA1 ook direct invloed uitoefenen op witte bloedcellen 
door zogenaamde “outside-in” signalering via de receptor voor geformyleerde peptiden 
(FPR). De behandeling met anxA1 van muizen die vatbaar zijn voor atherosclerose is 
het onderwerp van hoofdstuk 4. We laten zien dat toediening van anxA1 de plaque 
groei remt en de stabiliteit verbetert. Behandeling met anxA1 resulteert bovendien in 
verminderde groei van de necrotische kern. Enerzijds komt dit door directe remming 
van neutrofiel infiltratie in de plaque en anderzijds door het verbeteren van de fagocytose 
van apoptotische en necrotische cellen.
Uiteindelijk kunnen plaques scheuren waarbij de stollingsgevoelige inhoud vrij komt 
en tot de vorming van een trombus leidt. Verstopping van een bloedvat door dit stolsel 
zorgt voor zuurstoftekort in het onderliggende weefsel met uiteindelijk celdood tot 
gevolg. Omliggend weefsel neemt deze celdood waar en activeert het immuunsysteem. 
Evenals bij normale wondgenezing zijn de neutrofielen de eerste cellen die reageren 
en migreren naar het infarctgebied. Door middel van een complexe cascade zorgen 
neutrofielen voor de uitstoot van reactieve zuurstofradicalen (ROS), pro-inflammatoire 
cytokines en chemokines en neutrofiel extracellulaire vallen (NETs). De combinatie van 
voorgaande factoren zorgt voor de zogenaamde reperfusie schade en verergert de initiële 
schade veroorzaakt door het zuurstoftekort. Behandeling met anxA1 en een aangepaste 
vorm van heparine (AADH) is onderzocht in hoofdstuk 5. Deze behandelingen zijn 
gericht om de neutrofiel infiltratie en toxiciteit te verminderen. AnxA1 en AADH 
zorgen voor vermindering van infarctgrootte en neigen beide de functionaliteit van het 
hart te verbeteren. Dit resultaat is waarschijnlijk neutrofiel onafhankelijk, aangezien de 
hoeveelheid geïnfiltreerde neutrofielen na 24 uur reperfusie overanderd is. 
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Om de ontstekingsremmende activiteit van anxA1 te verhogen is meer kennis nodig over 
de modus operandi. Structurele studies door middel van nucleaire magnetische resonantie 
(NMR) geven informatie over de oriëntatie/conformatie en fysische eigenschappen 
van eiwitten in verschillende (sub)fysiologische condities. Hoofdstuk 6 beschrijft de 
verschillende conformaties van anxA1 in aan- en afwezigheid van calcium en een oppervlak 
van fosfolipiden. Hoewel anxA1 drie verschillende “gesloten” conformaties heeft in 
afwezigheid van calcium, zorgt toevoeging van calcium ervoor dat deze verandert naar één 
enkele stabiele ‘open’ conformatie. Deze kennis kan leiden tot het ontwerp van aangepaste 
vormen van anxA1 die ervoor zorgen dat de ontstekingsremmende functionaliteit van 
het eiwit toeneemt.
Tot slot bediscussieert hoofdstuk 7 de belangrijkste bevindingen van dit proefschrift en 
wijst op mogelijke klinische relevantie in relatie tot de huidige literatuur. Addendum I 
en II geven een Engelse en Nederlandse samenvatting en Addendum III vermeldt kort 
een valorisatie van het onderzoek. 
Addendum III 
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Valorization, to assign a value to this thesis is challenging. Knowledge valorization refers 
to “the process of crafting value from knowledge”, by making knowledge suitable or 
available for social and/or economic use. This definition expects ‘value’ to be expressed 
as a direct impact on society or to be conveyed to a currency. 
In my humble opinion, the primary drive for research should be curiosity rather than 
currency. This curiosity may or may not lead to economic gain, but should foremost 
expand scientific knowledge. Since we are part of a knowledge-based economy in which 
tax money and charities contribute to perform science, society should benefit from 
research one way or another. Increasing knowledge by itself does not directly impact 
society, but has major influence on future innovations. The principal objective of this 
thesis was to improve insights in the role of annexin A1 (anxA1) and annexin A5 (anxA5) 
in cardiovascular disease (CVD), which is the leading cause of death in the developed or 
in other words ”wealthy” countries. It is therefore tempting to suggest that there must 
be both monetary and social ‘value’ somehow. For more information about the socio-
economic impact that molecular imaging of CVD has, I would like to refer to the final 
part of chapter 2. The valorization of my thesis will focus on chapters 3 to 6, which 
contain the actual experimental research. 
Chapter 3 elaborates on the role of endogenous anxA5 in atherosclerosis and identified that 
anxA5 is involved in the clearance of death cells and therefore comprises a potential target 
for treatment. AnxA5 is a proven and widely used agent for in vitro and in vivo imaging 
of apoptosis, and forms the founding upon which MosaMedix BV and PharmaTarget 
BV are build. These companies offer jobs which is presently not a unnecessary luxury. 
Besides offering employment, the products improve diagnosis and treatment of disease. 
On Short-term, there is no economic or social value in this chapter. Additional research 
is needed to transform this target into actual therapy, but one could imagine anxA5 as 
target for mild inflammatory disorders, as is discussed in the clinical relevance part of 
the general discussion of this thesis. 
Chapter 4 and chapter 5 investigate a potential therapeutic role of anxA1. We are the 
first and only group to produce this anti-inflammatory mature protein in sufficient 
amounts to test and validate efficacy in large-scale in vivo experiments. These results 
show great potential for anxA1 in treatment of inflammation related diseases and future 
research should elucidate whether anxA1 is a valuable addition to existing therapies. To 
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express the scientific findings of these chapters in monetary value; the price of purified 
human recombinant anxA1 from Abcam is just below €1500 for 100μg of protein. 
We are able to produce a small multiple of this amount with relatively minute costs in 
commodities and labor. Based on published data and personal correspondence we have 
equal or better purity, stability and efficacy. In addition to anxA1, we have used a very 
innovative approach to reduce the damage of neutrophils. In addition, we have generated 
a novel form of heparin without anticoagulant activity. This therapy aims to reduce the 
cytotoxicity of neutrophils based on its negative charge, and has already proven efficacy 
very recently in an animal model of sepsis. This new form of heparin is patented for the 
treatment of sepsis and would be the only known effective therapy for sepsis for the first 
24 critical hours. Additional research is currently carried out to confirm efficacy and test 
potential use in the clinic. A new company is currently arising from the patent assigned 
to the new heparin.
Chapter 6 focused on structural analysis of anxA1. Increasing the knowledge about 
structural properties of a protein paves avenues for augmentation in order to increase 
functionality. We have produced the protein triple isotopically labeled and analyzed 
the structure by nuclear magnetic resonance. In addition to novel structural insights of 
anxA1, the primary value of this chapter is the optimized strategy for the production 
of this protein. This strategy can be applied by other researchers for other proteins and 
therefore propel structural analysis studies and consequently novel drug development. 
In conclusion, the findings in this thesis are in short term primary of value to other 
researchers, but in long term could be translated into commercially available products 
and/or services.  
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About the author 
Dennis Hubertus Martinus Kusters was born on November 10th, 1984 in Brunssum, 
where graduated from Romboutscollege high school in 2003 completing the Nature & 
Health profile.
After 1 year at the Technical University of Eindhoven (TU/e), he switched to Molecular 
Life Sciences at the University of Maastricht for which he obtained his bachelor’s degree 
in 2007. Directly after completing the bachelor’s program he started with the Research 
Master Cardiovascular Biology & Medicine, a 2 year Master’s program organized by the 
Cardiovascular Research Institute Maastricht (CARIM). He obtained his Master’s degree 
in 2009 after completing an internship of two months at the Department of Cardiology 
from the University of California Irvine (USA) under the supervision of Prof. Dr. Narula 
and six months at the Department of Biochemistry of Maastricht University under the 
supervision of Prof. Dr. Reutelingsperger. 
In 2009 he continued his work at the Department of Biochemistry starting his PhD 
program on the role of annexin A1 and annexin A5 in cardiovascular disease, supervised by 
Prof. Dr. Reutelingsperger. His PhD program was partly funded by the European Union 
through the Intereg IV program of Grensregio Vlaanderen-Nederland. During his PhD 
program he has published his data in peer-reviewed international scientific journals and 
presented his work on international conferences in Amsterdam, London and Kyoto. He 
has always had affection for teaching, which emerged from his role as teaching assistant 
within the Bachelor’s program of Medicine and Biomedical Sciences and supervision of 
Bachelor and Master students during their internship. 
Directly after his PhD he started as research associate of PharmaTarget BV. From March 
2015 on he will continue his career as postdoctoral researcher at the Department of 
Pathology of the University of Michigan (USA) under supervision of Prof. Dr. Nusrat.
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aan de Universiteit van Maastricht, waar hij zijn Bachelor diploma heeft gehaald in 2007. 
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en bij de begeleiding van Bachelor en Master studenten tijdens hun stage.
Na afronding van zijn promotie-traject is hij begonnen als onderzoeksmedewerker bij 
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Aangezien ik een persoon ben van weinig woorden, zal ik het kort houden. Na een intens 
en leerzaam avontuur ben ik nu aangekomen bij het laatste en tevens meest gelezen deel 
van het proefschrift; het dankwoord. Net als iedere promovendus, heb ik veel hulp en 
steun mogen ontvangen van collega’s, vrienden en familie. 
Allereerst bedank ik graag mijn promotieteam. 
Mijn promotor, Prof. Dr. Reutelingsperger, beste Chris, het is nu ongeveer 7 jaar geleden 
dat ik reageerde op een stageplaats in jouw groep. Na succesvolle afronding van deze stage 
bood je mij de mogelijkheid om mijn onderzoek voort te zetten als promovendus, met 
dit proefschrift als resultaat. De drempel van jou kantoor is altijd laag geweest, al wist 
ik je niet altijd te onderscheppen. De naam “Chris-als-hij-er-is” zal jou dan misschien 
ook bekend voorkomen. Jij hebt mij veel geleerd over alle belangrijke zaken die naast de 
wetenschap belangrijk zijn om te slagen binnen de academie. Ik ben enorm dankbaar 
voor de vrijheid en het vertrouwen dat je mij gedurende mijn hele promotieperiode hebt 
gegeven. Hiermee heb je de fundering gelegd voor mijn toekomstige (academische) carrière.
Mijn copromotor, Dr. Schurgers. Beste Leon, het is moeilijk om op papier uit te drukken 
hoe belangrijk jij bent geweest tijdens dit hele traject. Ik was ongeveer 6 maanden aan 
het worstelen met mijn “inteïne-project” toen jij in de groep werd geïntroduceerd. 
Direct tijdens de voorstelronde maakte je grote indruk op me, door het enthousiasme, 
de positiviteit en de rust die je uitstraalde. Ik wist direct dat jij een grote aanvulling 
voor onze groep zou zijn. Jouw deur staat echt altijd open, misschien zelfs wel iets te ver. 
Buiten het werk hebben wij ook een goede klik. We hebben ontelbare uren doorgebracht 
met (on)zinnige (wetenschappelijke) discussies, veelal onder het genot van een biertje. 
Hierbij wil ik ook direct de mogelijkheid aangrijpen om Romy, Juul en Sam te bedanken 
voor de gastvrijheid, als deze discussies weer eens uitliepen tot in de kleine uurtjes en ik 
uiteindelijk de nacht in het stapelbed (of op de bank) door mocht brengen. 
Martijn, onze eerste ontmoeting was in Eindhoven tijdens de studie BMT. Door puur 
toeval zijn wij collega’s geworden op de afdeling Biochemie, waar we ons promotie traject 
gelijktijdig begonnen. Jij hebt ervoor gezorgd dat ik enorm ben gegroeid, als wetenschapper 
en als persoon. Ik heb veel respect voor jouw kennis, gedrevenheid, doorzettingsvermogen 
maar vooral eerlijkheid. Ooit waren we samen studenten, we werden collega’s en zijn nu 
vrienden. De afgelopen 5 jaar zou niet hetzelfde zijn geweest zonder jou. De stap- en 
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quizavonden, niet-nader-te-noemen ‘themadagen’ en het biertje na(/tijdens) werk waardeer 
ik zeer. Te allen tijde ben je mijn steun en toeverlaat geweest, hier wil ik wil je dan ook 
in het bijzonder voor bedanken.
Brecht, jij kwam iets later in onze groep en werd bij twee alfa-mannen op de kamer 
geplaatst. Een korte acclimatisatieperiode en gebroken been verder, groeide je uit tot de 
Brecht die je nu bent. Onze trip naar Japan was een hele ervaring. Naast ontelbare tempels, 
beleefde mensen en lekker eten heeft Japan ook een fantastisch jazz-hostel, mannen 
genaamd Jim Beam die dansen in de Butterfly, de anti-kater burger, overheerlijke ramen 
van opa het Gundam-cafe en zo kan ik nog wel even doorgaan. 
Frauke, naast collega ben jij een van mijn beste vrienden. Wij hebben elkaar leren kennen 
tijdens onze opleiding (>10 jaar geleden) en uiteindelijk promoveren wij in dezelfde 
vakgroep. Onze gezamenlijke verjaardagsfeestjes, vakanties en stapavonden zal ik nooit 
vergeten, in ieder geval de meeste niet... 
Dr. Schutters, beste Kristof, jij hebt mij met annexines in contact gebracht en wetenschap 
leren kennen. Jouw enthousiasme als stagebegeleider ligt aan de basis van dit proefschrift. 
Altijd alleen het goede in mensen zien en jouw uitzonderlijke positieve instelling zijn een 
bijzondere gave. Heel veel geluk met Kelly en jullie dochters. 
Dear Mathias, it was so refreshing having you in our lab. Your unique sense of humor is 
a delight. You have taught me to work towards a goal and not get distracted by side issues. 
Dear Robert, thanks for the pleasant conversations and your usefull input in Chapter 5.
Cecile, Petra, Niko, Liset en Billy, bedankt om het lab draaiend te houden.
Marijke en Matthias, jullie zijn een stralend team en hebben mij enorm geholpen bij 
de biodistributie experimenten.
Dr. Ippel, beste Hans, zonder jou zou dit proefschrift één hoofdstuk minder tellen. Jouw 
NMR expertise en enthousiasme hebben mij overtuigd dit uitdagende project aan te 
nemen. Dit uiteindelijk heeft geleid tot een zeer mooi hoofdstuk en toekomstige publicatie.
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Beste Peter, Jacques, Agnieska en Nicole, hartelijk dank voor alle assistentie en jullie 
uitzonderlijke expertise bij het uitvoeren van zeer complexe dierexperimenten.
Prof. Dr. Biessen, beste Erik, bedankt voor de geweldige discussies tijdens, maar vooral 
na werktijd. Jouw onuitputtelijke specifieke kennis en pragmatisch denken zijn een grote 
bron van inspiratie. Ook wil ik je bedanken om voorzitter van de beoordelingscommissie 
te zijn.
 
I would also like to acknowledge all other members of the assessment committee; Prof. 
Dr. de Windt, Prof. Dr. Mottaghy, Prof. Dr. Frostegård and Prof. Dr. Brachvogel, 
thank you very much for assessing my thesis.
Next I would like to acknowledge my foreign collaborators. Prof. Dr. Solito, Prof. Dr. 
Albano and Prof. Dr. Perretti, thank you for the exquisite cooperation and profound 
discussions at the annexin conferences in Barcelona and London. We will meet again at 
the annexin conference in Maastricht in 2015.
Prof. Dr. Nusrat, dear Asma, we first met at the annexin conference in London, where you 
declined having dinner at the president’s table to eat with me, not knowing of my large 
appetite and that we had to share our food. I would like to thank you for the excellent 
scientific cooperation we had untill now and I look forward to this new chapter ahead 
of us. Your outstanding knowledge and warm personality make me feel confident that 
this will also be very successful. I cannot wait to start!  
Prof. Dr. Narula, dear Jagat, you are one of the smartest people I have ever met. Together 
with Nezam and Artiom you have thought me the importance of accurate and decent 
science. That in case experiments are performed properly, there can merely be discussion 
about interpretation of data, not the data itself. I would like to thank you for your guidance 
and hospitality during my stay in California.
Dit dankwoord zou niet volledige zijn zonder de Baas van Biochemie te bedanken, beste 
Trees, hartelijk dank voor alle hulp en de leuke gesprekken. Ik hoop dat je nog lang 
werkzaam bent bij Biochemie, want ondanks het voortreffelijke werk van Lideweij, zal 
het zonder jou een stuk minder zonnig zijn!
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Prof. Dr. Hackeng, beste Tilman, als vakgroepvoorzitter weet jij als de beste waar het 
om gaat in de wetenschap. Buiten je uitzonderlijke wetenschappelijke kennis, begrijp jij 
dat de sociale activiteiten naast de wetenschap ons creatieve proces voeden en het plezier 
wetenschapper te zijn vergroten.
Joke, Marie-Claire, Rinske, Geert-Jan en Roy, we zullen maar zeggen dat meedoen 
belangrijker is dan winnen. Bitterballen zijn toch ook veel lekkerder dan Whisky.
Nu ik het toch over bitterballen heb; beste Stella, net als in mijn 3 ingediende manuscripten 
verdien jij ook in dit dankwoord een eervolle vermelding. Bedankt voor het uitvoeren 
van de stollingsproeven maar bovenal alle gezelligheid. 
Alle andere (oud) collega’s van Biochemie, bedankt voor alle hulp.
Elke, Thomas, Kosta en Emiel, hartelijk dank voor de samenwerking van de afgelopen 
jaren. Deze samenwerking heeft Biochemie en Pathologie nader to elkaar gebracht, en 
heeft daarbij geleid tot additionele ‘extracurriculaire activiteiten’.
Verder wil ik alle mensen van de CPV bedanken, in het bijzonder: Saskia, Richard, Rik, 
Clarice, Harry, Inger en Anouk. Bedankt voor alle goede zorg voor de dieren en hulp 
bij het papierwerk dat met dierproeven gemoeid gaat.
Beste Guillaume, bedankt voor het maken van de foto’s en al je wijsheden.
Naast alle collega’s zijn er ook veel vrienden die hebben bijgedragen aan de totstandkoming 
van dit proefschrift. De traditie om eenmaal per jaar op ‘mannenweekend’ te gaan zorgde 
voor de nodige ontspanning. Jesper, Loek, Niels, Pascal, Patrick, Pieter, Ralph, Rene 
en Rob, we hebben onze stempel nagelaten in Brussel, Berlijn, Dublin, Krakau en 
Barcelona. Ik ben ervan overtuigd dat we deze traditie ook na alle gezinsuitbreidingen 
gewoon in ere houden. 
Het voetbalteam van SV Brunssum waarmee ik kampioen geworden ben, maar die nog 
beter zijn in de 3e helft: Antoine, Bjorn, Blay, Brian, David, Dean, Denny, Didier, 
Eddie, Ferdie, Gian, Glenn, Martijn, Martijn, Matthijs, Nick, Onno, Patrick, Philip, 
Pieter, Ralph, Remco, Robin, Rocco, Thomas en Timo. “Vriendschap en bier”! 
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Beste Martijn, wij kennen elkaar al sinds de kleuterschool. In mijn woordenboek ben jij 
de definitie van ‘een vriend voor het leven’. Vanwege onze drukke agenda’s zien we elkaar 
niet meer zoveel als vroeger, maar het is altijd vertrouwd als we elkaar zien. Vriendschap 
is kwaliteit, geen kwantiteit. Veel succes en tot ziens in Shanghai. Bij dezen wil ik ook 
direct je ouders en zus bedanken. Prof. Dr. van Uden, beste Rien, beste Gerdie en Cuny, 
enorm bedankt voor alle jaren dat ik bij jullie thuis welkom was en de interesse die jullie 
getoond hebben in mijn opleiding, carrière en leven. 
 
Tante Els, lieve peettante, bedankt voor het mooie schilderij dat aan de basis ligt van de 
omslag van dit proefschrift. Blijf altijd lachen!
Lieve Romy, jij begrijpt mij en het proces van promoveren als geen ander. Ik kan bij 
jou altijd terecht voor een luisterend oor en een goed gesprek. Mede door jou begrip, 
geduld, rust en liefde heb ik deze zeer stressvolle tijd toch als heel prettig ervaren. Zelfs 
in de moeilijkste tijden maak je me aan het lachen, veelal door je onhandigheid. Ich höb 
dich gaer!
Als laatste wil ik de twee personen bedanken aan wie dit proefschrift is opgedragen. Beste 
papa en mama, de afgelopen 30 jaar hebben jullie altijd voor mij klaargestaan, geen 
moeite was te veel. Jullie hebben mij altijd volledig vrij gelaten in al mijn keuzes. Ik 
wil jullie bedanken voor het vertrouwen, de wijsheid en de steun die ik al die jaren heb 
mogen ontvangen. Jullie hebben mij geholpen vanaf het moment dat ik leerde lezen en 
schrijven tot aan het laatste uitroepteken van dit dankwoord. Bedankt!
